Engineering automated systems for pharmaceutical manufacturing: quality, regulations and business performance by Meagher, Diarmuid P.
Engineering Automated systems for Pharmaceutical
f
Manufacturing: Quality, Regulations and Business 
Performance
Thesis submitted for the award of Doctor of Philosophy (PhD) 
Author: Diarmuid P. Meagher Bc(Hons) MEng
School of Mechanical and Manufacturing Engineering 
Dublin City University
Supervisors: Professor M.S.J. Hashmi / Dr. W.G. Tuohey.
Submitted: June 2006.
1
11
D eclaration
I hereby certify that this material, which I now submit for assessment 
on the programme of study leading to the award of Doctor of 
Philosophy is entirely my own work and has not been taken from the 
work of others save and to the extent that such work has been cited 
and acknowledged within the text of my work.
Diarmuid Patrick Meagher
ID No.: 53126785
Date: Z C  £ /£ /
Ac kn ow ledge men ts
I am indebted to my Supervisors, Professor MS.J. Hashmi and Dr. W.G. Tuohey. 
Great gratitude is owed to Professor Hashmi for his assistance throughout my thesis 
compilation and for early guidance. Likewise to Dr.Tuohey for his extremely 
thorough reviews of both the textual and technical material of my research, and for 
helping to make my thesis and papers presentable to a wider audience.
Survey research is made possible by the generous contributions of participants. I 
was charmed to have a group of pre-test participants who were knowledgeable in 
research methodology and in the area under study. Particular mention from this 
group is required for Fernando Cassanova at Labvantage who helped to refine the 
survey instrument and give encouragement to this research effort.
The 122 companies who took the time to carefully respond to the questionnaires 
made this research possible. Most organizations were extremely busy but still took 
time to respond, and oftentimes made contact to make sure that their contribution 
had been received. In these times, surveys are commonplace and it’s easy to refuse 
to participate. This makes their efforts even more remarkable.
This research was conducted part time which had the potential to cause 
considerable strain in the author’s personal life. I am blessed to have had the 
support, encouragement, understanding and love of my (now) wife Pippa. To her I
owe immeasurable gratitude I hope she will fully share in the value and benefits that 
this work will bring
Our 12 week old daughter Catherine Margaret probably knows as much about the 
contents of this work as the rest of my family, but they have all contributed in some 
way to the author’s well being and drive to succeed, so credit and thanks is due to 
them My friends, old and new, have also played a role in the maintenance of my 
sanity, some portion of which was necessary to complete the work herein
This research is firstly dedicated to all people who selflessly commit to and labour for 
the growth of all others, those who work to remove toxic cynicism and begrudgery 
from their hearts and minds, and who inspire people against the odds to see the 
beauty in life over the ugly
Finally this work is dedicated to Pippa and Catherine My successes and heart are 
yours
Abstract
The pharmaceutical sector is very heavily regulated Drug safety regulations form 
one of the pillars of this regulation The manufacture of pharmaceuticals is carried 
out in an environment of onerous regulatory requirements, often from several 
national and international regulatory bodies The quality systems operated by drug 
manufacturers and their regulatory practices have an important impact on product 
quality The quality and regulatory requirements apply not only to handling of the 
medicinal products, but also to the physical and electronic systems used in the 
manufacture of those products, and extend to automated systems used to support 
quality assurance operations Design, development, building and support of such 
systems are ultimately the responsibility of the drug manufacturer The quality and 
regulatory requirements for automated systems are passed down the supply chain to 
suppliers In the last two decades of the 20th century there has been a proliferation in 
the use of computerised and automated systems for use in, or to support 
manufacturing Correspondingly, regulatory requirements have been imposed on the 
manufacturing industry This work used survey research and factor analysis to 
establish relationships between quality and regulatory practices, and between both 
quality and regulatory practices and business performance for suppliers of 
automated systems into the pharmaceutical market A survey instrument and an 
administration strategy were developed from a review of the literature It was 
established empirically that quality practices and regulatory practices were strongly 
related Specific facets of quality practices and regulatory practices were found to 
have had a significant impact on both market share and competitiveness 
expectations and also profit and sales expectations Differences in practices and 
performance were established for various levels of automation complexity and 
criticality, where criticality was a function of the risk the respondent’s system posed 
to the manufacture of their customer’s products
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G lo ssa  ry
CMM The Capability Maturity Model of the Software Engineering Institute of 
Carnegie Melon University in the United States is a standard for software based on 
the principles put forward by Philip Crosby, the purpose of which is to increase 
control over an organization’s software development process.
Construct The operationalising of a concept into a real measure that can be 
determined through an answerable question or ‘item’. Several questionnaire 
constructs may be used to represent a variable. Several constructs may be 
combined into a 'factor' using factor analysis. A variable can be formed by adding 
the construct scores together, where those constructs form part of a factor.
Construct Validity A term that represents the logic of items that are used to capture 
data to represent a given variable. Good construct validity is represented by a series 
of measurable indicators with a sound theoretical basis for representing the parent 
variable.
Content Validity A term that represents how well an item represents the measure it 
claims to. Also called face validity.
Cronbach’s Alpha A measure of internal consistency reliability used to indicate that 
a number of scale items vary together, and hence ultimately measure the same 
feature.
Design Qualification A series of activities concerning the initial user specifications 
of a system combined with the corresponding functional and design specifications, 
the purpose of which is to ensure that the system design is as intended.
EMEA The European Medicines Evaluation Agency is responsible for protection and 
promotion of human and animal health through the evaluation and supervision of 
medicines in European Union member states.
ERES Electronic Records and Signatures as defined by 21 CFR Part 11 and EU 
Volume 4 Annex 11.
Factor A group of constructs/items that share the same underlying variance. A 
factor can be used to produce a single variable representative of all the constructs 
within that factor (See glossary entry for Construct).
FDA Food and Drug Administration of the Unit States Department of Health and 
Human Services that regulates inter alia the testing, approval and manufacture of 
drugs for human use.
GAMP Good Automated Manufacturing Practices as described by the International 
Society of Pharmaceutical Engineering.
GMP Good Manufacturing Practices, the rules as set out by national and 
international bodies for the manufacture of i n t e r  a h a  medicinal products Sometimes 
called Current or cGMPs
ICH The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use are a worldwide body supported by 
the FDA and the European regulatory agencies for provision of global common 
guidelines for the manufacture and control of drugs
ISPE The International Society for Pharmaceutical Engineering, a professional body 
that gives guidance to the pharmaceutical manufacturing world on pharmaceutical 
technology and regulatory compliance Responsible for production of the GAMP 
guide
Part 11 21 Code of Federal Regulations Part 11, is the FDA regulation for using 
electronic records and signatures in a Good Manufacturing Practice environment
PAT Process Analytical Technology is an initiative from the FDA focused on allowing 
manufacturers to use the most advanced measurement and quality system 
techniques for controlling their processes, based on scientific approach and risk 
management
PIC/S The Pharmaceutical Inspection Convention and the Pharmaceutical 
Inspection Co-operation Scheme (jointly referred to as PIC/S) are two bodies that 
include 27 European and Oceanic countries, whose focus is to provide cooperation 
in Good Manufacturing Practice matters
Predicate Rules A mainly American term for the set of Good Manufacturing Practice 
and Quality System regulations relating to a given regulated industry
Principal Components Analysis (PCA) A branch of factor analysis used to find a 
reduced number of underlying factors, or components, out of a large number of 
components
Quality Assurance The set of activities and processes in an organisation that aim 
to ensure that standards of quality are being met
Quality Control An set of activities, usually consisting of inspection of product, 
designed to ensure that specifications have been met
Questionnaire item An item on a questionnaire which can be operationalised 
constructs to represent variables, or can be open qualitative questions
xn
Software Development Life Cycle (SDLC) An approach to software development 
whereby software is specified, built and tested in a continuous iterative system of 
investigation of requirements, analysis, design, testing and continual maintenance 
over the complete life of a software project Several models exist, each of which 
describe a variety of tasks that takes place during the complete lifecycle of a 
software product
System Compliance A characteristic of a system whereby all of its elements and 
functionality conforms to standards which includes regulatory standards
System Qualification I Validation A series of activities aimed at providing objective 
evidence that the system is fit for it’s intended and specified purpose
TQM Total Quality Management is a management philosophy that has total 
involvement of every employee in a company in quality related activities at its core
Validation The set of activities concerned with proving that a system is suitable for 
its intended purpose
Variable A concept that can be measured and assigned a score In survey research, 
this can be derived from constructs (See glossary entry for construct)
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Chapter 1 Introduction
The pharmaceutical industry operates in a climate of onerous governmental 
regulation Regulations concern three main areas, product quality, price and 
marketing The vast majority of pharmaceuticals in the world are produced by an 
oligopolistic group regulated by the Food and Drug Administration (FDA) of the 
United States, or the European Medicines Evaluation Agency (EMEA) of the 
European Union An internationally supported body, the Pharmaceutical Inspection 
Co-operation scheme (PIC/S) produces regulations that are aligned to the EMEA 
regulations [1] It has wide membership from both the European Union members, 
and from non-EU members such as Australia, Canada, Malaysia and Singapore 
The World Health Organization also provide minimum, less onerous directions for 
quality in drug manufacture although these are guidelines rather than legal 
requirements [2] Initiatives such as that of the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) have created common guidelines for worldwide development and 
production of drugs, which draw on both the European and US rules [3]
Manufacturing and related systems are an important factor in drug product quality 
Technological innovation has meant increased emphasis on computerization and 
automation of processes This has resulted in additional concerns for product quality 
and consequently increased regulatory requirements for such systems This work
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focuses on those systems Quality requirements for both manufacturers and system 
developers have increased in line with the complexity of the technology
The design, development and production of automated systems for pharmaceutical 
manufacture must adhere to the regulations imposed upon the drug manufacturer for 
whom those systems are intended These regulations have become increasingly 
rigorous and rigid over time due to a process labelled by some as 'regulatory creep1 
or 'regulatory spiral' [4] - [6] Of course, genuine concern for product quality is the 
main reason for the ever-evolving litany of regulatory requirements [4] Vendors and 
developers providing for any market must be able to meet their customer’s 
requirements Regulatory compliance and high quality are requirements for 
pharmaceutical systems
In biopharmaceutical and pharmaceutical manufacture, validation requirements for 
processes and critical systems that can affect drug quality are substantial [7] The 
regulatory agencies have contributed to additional engineering requirements that 
systems must comply with in order to support validation The requirements for 
manufacturing plants and systems have grown and have pervaded the lifecycle of 
their systems These are mainly in the form of hardware and software design 
requirements and system validation requirements Vendors into these industries 
must be able to support these two requirements, e v i d e n t i a l  design for purpose and 
validation
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For control systems used in manufacture, it is difficult and often impossible to 
delineate between systems that provide management of critical systems and those 
which are non-critical [7] This very often leads to an extension of effort beyond 
known critical systems to ensure that no potentially critical components are missed, 
when deciding where the regulations are applicable The requirement for systems to 
be fully verifiable from their initial specification to retirement means that every aspect 
of their specification, design, development, installation, commissioning, validation, 
and operating phases must be documented in an acceptable manner to both the 
manufacturer and ultimately the regulator
The use of vendors in the compliance process is advocated widely [7] -  [10] Some 
commentators even recommend that manufacturers should consider using suppliers 
that provide full turnkey packages that include all the documentation and validation 
requirements This can be a very efficient means of bringing a new design and build 
project to a swift conclusion, by completely combining the engineering effort with the 
regulatory compliance effort
There is a huge array of automated and computerized systems that are deemed 
either directly or indirectly critical to the quality of the drug being manufactured 
These include measuring systems, information systems and process control 
systems Software can either be embedded in those systems or exist on magnetic 
media on computers or computer infrastructures The quality requirements for such 
software are heavily scrutinized and prescribed by the regulators The scope of this
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research is those automated and computerized systems produced to operate under 
good manufacturing practice regulations set out by the FDA, EMEA and 
consequently by the PIC/S
This research focuses broadly on the manufacture of finished pharmaceuticals and 
biopharmaceuticals for human use as specified in the FDA regulations and the EC 
directives It hence precludes medical devices and bulk pharmaceuticals not 
requiring compliance to these regulations Over 80% of world Pharmaceuticals are 
manufactured in countries covered by FDA or EMEA/PIC/S regulations [4]
Systems supplied to both the pharmaceutical and biopharmaceutical manufacturing 
industries are relevant to this study, and for the purposes of this study 
pharmaceutical can be taken to mean biopharmaceutical also
Substantial evidence exists from the literature of the positive relationship between 
manufacturing quality practice and organizational performance, some of which is 
presented in this work There is apparently no evidence in the literature of whether 
developers, designers and vendors of systems for the pharmaceutical manufacturing 
industry, with its strong regulatory focus and uptake of regulatory related practices, 
have mined a similar vein of business success
This work aims to determine the relationships between regulatory focus and 
practices, general quality focus and practices, and business performance for system
developers of automated and computerized pharmaceutical manufacturing systems 
The literature review looked at the trends in the regulations, specific regulatory 
requirements, quality systems, and the effects of quality system practices in general 
on business performance
A survey instrument was designed and administered to a sampling frame based on 
the P h a r m a c e u t i c a l  T e c h n o l o g y  journal ‘Buyers guide' [11], an internationally 
focused guide purporting to include 80% of all technology suppliers to the 
Pharmaceutical industry P h a r m a c e u t i c a l  T e c h n o l o g y  has both European and US 
editions This claim was validated whilst building the database by using other 
databases and by performing Internet trawls Through following standard accepted 
methodologies for questionnaire design and development, threats to validity were 
avoided in advance Variables were selected and grouped into quality practice 
variables, regulatory practice variables and business performance variables 
Constructs were generated to accurately capture data that reflected the variables 
The instrument used a series of Likert scale items and closed type questions to 
determine data for quality practices, regulatory practices and business performance 
The instrument was administered by electronic mail after receiving permission from 
the respondents and conducting both pre testing and pilot testing Factor analysis 
was used as the basis for establishing reliable summated scales from the data 
Analysis and hypothesis testing was conducted using SPSS software employing 
correlation and difference testing, factor analysis and stepwise regression analysis
[12]
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From a regulatory perspective several things were considered The FDA and EMEA 
pharmaceutical regulations themselves were important Focus and adherence to 
regulations were determined from survey results The Good Automated 
Manufacturing Practice guide (GAMP) from the International Society of 
Pharmaceutical Engineering (ISPE) [13] has now become a d e - f a c t o  standard for 
selection and production of automated equipment for pharmaceuticals and pervades 
both the European and FDA requirements It was assessed whether there was a 
relationship between business success and regulatory activities such as the 
application of this guidance by providers An important regulatory support 
requirement is the provision of adequate design documentation and validation 
support for end user verification that the systems delivered meet their intended 
purpose Relationships between the extent of this practice by suppliers and business 
performance were also determined
Total Quality Management (TQM), the ISO 9000 quality series, and the Software 
Engineering Institutes Capability Maturity Model (SEI CMM) [14] for software quality 
are important systems for establishment and improvement of quality performance in 
software development environments It has to be recognized that although suppliers 
may not subscribe to formal systems or guidelines such as ISO, the CMM, GAMP 
and TQM they may still be engaging in such bespoke practices as to be at least 
functioning in a manner equivalent to those systems To this end, it was important to 
derive a set of fundamental quality constructs common to all these systems In this
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research, those constructs were derived from a literature review and analysis of the 
core criteria specified in the literature, ISO, CMM, GAMP, TQM, the US Malcolm 
Baldrige National Quality Award (MBNQA) [15] and the European Quality Award 
(EQA) [16] Business performance constructs were selected from a review of the 
MBNQA criteria for performance measurement and from a review of the wider 
literature on performance measurement While recognizing that quality or regulatory 
practices are not static, it was possible to examine multivariate relationships 
between current practices and business performance, and to establish cross- 
sectional deductions using empirical and analytical methodologies
This study is intended to be useful in several respects It provides guidance to 
developers of computerized and automated systems for use in pharmaceutical 
manufacture as to best (or optimal) quality and regulatory practices It could also 
give manufacturers, regulators and professional industry bodies indications as to 
how well developers perform with respect to quality system practices and regulatory 
compliance To the wider quality profession, it would provide insight into the extent 
to which commonly held relationships apply within this specialised sector
At the time of writing, the author has spent 8 years working in the pharmaceutical 
and medical device industries as a Process Engineer, Validation Engineer, Quality 
Engineer and an engineering compliance Consultant Over this time sea changes in 
regulatory and quality practices have been observed Categorizing the business 
effects of revolutionised practices was a motivation for this research
7
The remainder of this introduction summarises the study background, quality 
management systems, pharmaceutical regulations, the aims and hypotheses of the 
research, and the methods used to acquire data pertaining to, and for testing the 
hypotheses
1 1 B ackg round
Product safety regulations affect the physical manufacture of drugs more than the 
other two regulatory factors (marketing or price) [4]
Fundamental to all product quality regulations are the employment of Good 
Manufacturing Practices (GMPs) and ‘current’ Good Manufacturing Practices 
(cGMPs) It is within these that the requirements are laid out for the production of 
medicines for human consumption The GMPs of both the US and Europe provide 
basic requirements for equipment and computerized systems used for 
pharmaceutical manufacture Whilst the requirements for cleanability and 
maintenance of physical equipment are easily understood and applied, those for the 
automation of processes are more complex Systems must comply with those 
requirements to allow their employment in medicinal manufacture and hence 
developers must adapt to them and their application
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Automation and computerization of processes results in significant process 
advantages and economies and if designed correctly can serve to enhance GMPs 
[17]
It is acknowledged that quality must not only be built into the drug but must also be 
built into any system associated with the product [18] Validation is the means by 
which the manufacturer must verify suitability for purpose, and the system design 
must be implemented in a way that it can be validated The systems should be 
designed so that validation does not show up any inherent GMP weaknesses and 
that it is hence suitable for its intended purpose Qualified or validated equipment is 
a fundamental component in GMP In order for validation to be successful, validation 
features need to be built into equipment GMP design problems, and validation 
activities to ensure that those problems have been eliminated, should be identified at 
design evaluation [19][20]
When regulatory compliance requirements are considered for implementation into a 
system for use in a GMP environment, the level of detail and complexity rises This 
can cause a substantial increase in the time taken to select, design, acquire, build 
and install the system The complexity of equipment for use in GMP environments 
can vary greatly from that used in non-GMP environments for a given purpose [21]
The level of detail of documentation required by differing manufacturers from 
vendors varies So do vendor attitudes (and costs) towards providing documentation
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to the extent required by the industry There are often disputes between vendors and 
manufacturers over provision of validation documentation This can result in further 
unanticipated demands for payment from the system vendors, and other conflicts in 
expectations A greater emphasis on regulatory issues results in better and more 
complete equipment, which will be better understood by everyone involved and 
produces fewer misunderstandings between vendors and manufacturers [21]
Quality is important for both the drug manufacturer and the manufacturing system 
developer It is desirable for the developer to produce high quality goods in an 
efficient and competitive environment This must be demonstrable to the drug 
manufacturer Hence, it is postulated in this thesis that quality practices, and practice 
directly linked to regulatory requirements or guidelines, enhance business 
performance It is also put forward that quality and regulatory practices are mutually 
dependent in an organization producing automated goods for the pharmaceutical 
market
Adherence to the regulations by both manufacturers and system developers is 
achieved mainly through quality management systems Sharp [5] argues that there 
is a ‘spiral staircase’ effect evident in the relationships between medicine 
manufacturers and the regulators He explains that on quality issues it is sometimes 
the regulators who lead and other times it is the manufacturers When the regulator 
leads, the manufacturer interprets the regulations more tightly than required to 
ensure compliance and hence takes over the lead, as their position becomes the
10
expected position The regulator responds by tightening the regulations to match 
industry practice and expectations, taking over the lead, again Manufacturers often 
then take the lead by introducing new technologies which the regulator must make 
rules for (as in the case of Process Analytical Technology [22] and 21 CFR Part 11 
[23]), and so on The net effect of this is an overall spiralling and tightening of the 
regulatory and hence quality requirements with time for the manufacture of goods
Sharp [5] says that quality assurance consists of all those activities that involve GMP 
and Quality Control In discussing the functions within a pharmaceutical 
manufacturing environment, he says that engineers need to be fully appraised of the 
special requirements for medicines manufacture A test of validity for any quality 
effort in pharmaceuticals is that if that effort does not ultimately contribute to patient 
well being then it is unnecessary expense Deciding on what does or does not 
contribute to wellbeing can be a difficult job for engineers, particularly when the 
manufacturer themselves are unclear However, when software is used to support 
GMP activities, then the GMP quality assurance requirements apply to the software 
Standard Software quality assurance philosophies and methods can be invoked to 
help fulfil the regulatory requirements for software quality
I
With time, vendors and manufacturers have been developing better partnerships 
when designing systems for regulated environments Validation and documentation 
are seen by some vendors as necessary, fundamental components of the products
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they are selling Examples also exist of systems that have been developed for 
industry by several manufacturers in conjunction with several vendors [24]
The onerous requirements that suppliers must adhere to if they wish to be 
competitive in the industry have resulted in quality requirements for software 
vendors far beyond what is normal in software engineering [25] An example of this 
is where requests for complete documentation of the software development life cycle 
from manufacturers are made of the vendors, vendors have to spend much time 
preparing documentation to a standard determined by the customer, and must 
deliver it together with the software product The increased involvement by the 
regulators in software quality assurance is seen as both a complicating factor and a 
positive influence on the development of software for the pharmaceutical industry 
This research is heavily concerned with those software quality assurance practices 
employed by developers, as software quality is fundamental to the quality of 
automated and computerized systems
The gaps that may exist in regulatory awareness by developers may be due in part 
to lack of training in educational institutions for engineers designing systems for use 
in GMP environments Engineers should have greater access to training on 
pharmaceutical issues [26] including regulatory matters [27]
In this work, quality and regulatory practices and business performance were 
measured The additional element of regulatory focus in a quality system for
1 2
developers of automated systems for the pharmaceutical industry could be seen as 
making quality a more important business factor for that industry than for other 
industries This would become clear from the survey analysis The effects of the 
additional regulatory element in supplier practices were determined and compared 
with the established relationships between quality practices and performance in the 
literature for other sectors [28]-[31]
The differences in the nature of the questions asked in this work from those in the 
literature are reflected in the survey design Criteria and questions from the literature 
are developed regarding quality practice and business performance for application in 
an automated system / software vendor setting Criteria representing regulatory 
factors were deduced from the themes and considerations in the literature, although 
no evidence exists of survey research that uses regulatory constructs relevant to this 
work The literature on regulatory influences on business performance tends to look 
at performance of companies subject to regulation (such as electricity companies), 
rather than looking at their actual regulatory practices
1 2 Quality Management
The importance of quality management system implementation is well documented 
Quality management exists in many forms The most common and influential 
systems of quality management include systems for Total Quality Management 
(TQM), the ISO 9000 series of quality management systems and for software the
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Capability Maturity Model (CMM) [14] These systems are discussed later, and their 
fundamental features were used to develop constructs for quality practice measures
Customers of engineering companies want evidence that product quality is being 
improved, whilst at the same time requiring competitive product prices [29] This 
means that quality management efforts must improve both processes efficiencies 
and the end product itself Engineering firms are expected by their clients to be 
taken along with the tide of the quality revolution the same as any other firm Many 
firms see the advantages of having high quality management standards and there 
has been an increase in the percentage of small companies going for quality awards 
such as the Malcolm Baldridge National Quality Award (MBNQA) [15] in the United 
States and the EQA [16] in Europe
1 3 Pharmaceutical Regulation
Many regulatory requirements may be met by excellent quality management 
practices on the system developer’s side Essentially, regulatory requirements 
consist of a set of instructions to manufacturers regarding their quality systems and 
processes Evaluation of both quality management and regulatory factors provides a 
balanced assessment of the overall quality effort actively exercised
Applying the principles of quality management to the design of automated systems 
makes sound business sense as well as assisting with regulatory compliance [32] It
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allows the full potential of those systems to be realised, as it is universally realised 
that better business performance is related to quality However, no relationship 
seems to have been established in the literature between regulatory compliance and 
business performance, or between quality practices and regulatory compliance This 
is the case for the sector being studied (and could be applied to other sectors)
The US regulators are generally seen as rule-makers when it comes to regulation 
whereas the EU are considered more consensus based when resolving regulatory 
matters [4], making much less use of courtrooms to solve disputes or for taking 
punitive action 'Regulatory clout’ holds for both regions though It is recognised that 
regulatory change can arise from changes in competitive structures and markets, 
rather than just from product safety or economic events Hancher [4] sees 
competitive factors as being greater than drug safety factors in the strength and 
flexibility of drug regulation The concept of regulatory conservatism is often the 
result of fear of wrong decisions being made, leading to increasingly onerous 
requirements for product safety and hence equipment design and validation
Validation costs have increased in part due to uncertainty about regulatory 
requirements [33] The trend for validation of processes in pharmaceutical 
manufacture has been to validate right back from the front end (finished product 
end) of the process to the facility support utilities, such as water and air conditioning 
systems
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Christoffersen and Jespersen [34] point out the importance of QA in all aspects of 
pharmaceutical projects from conception to completion Particular importance is 
given to the acquisition and management of documentation throughout the project to 
ensure that both customer and regulatory requirements are met This has both cost 
and organizational consequences for the system developer as they must be able to 
provide documentation that reflects the specification, design and testing of their 
systems
Andrews [35] says that the challenge that the pharmaceutical industry must meet is 
maintaining the balance between increased use of automation to reduce business 
costs and maintaining regulatory compliance, which is costly Failure to adequately 
validate has resulted in many “observations” and warning letters to manufacturers by 
the FDA The FDA has acknowledged that computers and their validation are 
compliance risks and that rises in non-compliance as a result of increased 
computerization have accrued [36]
Certain regulations have had substantial impact on the requirements for systems 
used for pharmaceutical manufacture, not least the FDA’s 21 CFR part 11 [23] 
(known as ‘Part 11’ in the industry), and EU volume 4 annex 11 [37] These rules set 
out requirements for computerized systems and in particular for electronic record 
keeping Good engineering practices supplemented by guidance from the regulators 
and industry bodies such as the Good Automated Manufacturing Practice (GAMP)
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[13] initiative has evolved to support regulatory compliance These specific 
regulations, guidance and their effects are discussed in the literature review
1 4 Aims and Hypotheses
The aims of the study were to assess the relationships between quality practices 
and regulatory related practices, between quality practices and business 
performance and between regulatory practices and business performance for 
developers of computerized and automated systems for use in pharmaceutical 
manufacture through survey research Research questions focus mainly on the 
quality and regulatory features of the aforementioned computerization and 
automation Hence this distinguishes between other regulatory related factors such 
as cleanability or product contact material concerns The regulatory focus is thus 
constrained to those hardware and software automation elements that make up a 
system for use in pharmaceutical manufacture
This research aimed to use the results obtained from the survey questionnaire to 
evaluate the relationships between practice and performance for the defined 
variables, which are obtained from the literature or introduced for the purposes of the 
study It aims to address a current gap in the literature regarding the quantitative 
empirical evaluation of the relationships between regulatory practices, quality 
management practices and business performance for system developers supplying 
the pharmaceutical manufacturing industry
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The following hypotheses were tested
H1 High levels of quality systems implementation for developers of automated and 
computerized systems for pharmaceutical manufacture result in better business 
performance
H2 Firms with higher general quality implementation levels have a better regulatory 
focus
H3 High levels of regulatory practice results in improved business performance
The relationships established for H1 have been established for many other sectors 
and are widely accepted as valid across other industries, but have not been 
established for suppliers of automated solutions to the pharmaceutical industry Due 
to the hypothesised interactions between regulatory practices and quality practices, 
it was postulated that this relationship needed to be established for the 
pharmaceutical sector, as the regulations could be seen as a complicating factor 
This might have meant that the generally accepted relationship between quality and 
business performance may not have held here There was no evidence in the 
literature concerning the relationships H2 or H3
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1 5 M ethodology
System developers selected from the other major pharmaceutical engineering 
industrial journal from the International Society of Pharmaceutical Engineering 
(ISPE), P h a r m a c e u t i c a l  E n g i n e e r i n g  [38] were used to validate the ‘Buyer's guide’ 
selection [11] Questionnaire constructs were developed in accordance with the
/
literature on survey research
The data was tested for reliability using accepted standard methodology Factor 
analysis was used to establish reliable scales and multiple regression models were 
used to test for relationships and hence to try to disprove the research hypotheses 
SPSS software [12] was used to handle the raw survey data and produce useful 
statistical results
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1 6  Sum m ary of In troduction
System developers producing for the pharmaceutical manufacturing industry must 
be capable of producing high quality automated and computerized products that 
comply with strict regulatory requirements The quality and regulatory practices 
employed by those developers may have an influence on business performance, 
and on each other This study set out to empirically evaluate these relationships and 
hence address a gap in the literature An overview of quality systems, regulations 
and their effects, and the research methodology has been provided The research 
hypotheses have been presented
2 0
Chapter 2 Literature review and derivation of study variables.
2 1  Development of computerized and automated pharmaceutical
manufacturing systems
Uzzaman [39] states that compliance with Computer Systems Validation (CSV) 
regulations should be a by-product of good systems engineering practices designed 
to optimise return in investment Therefore, by adopting good engineering practices, 
it should be possible to achieve two objectives, regulatory compliance and an 
efficiently produced quality product A good quality approach aimed at best practice 
can go a long way to achieving compliance However, good engineering practice on 
its own is unlikely to result in compliance Developers should be mindful of the 
specific regulations in existence such as 21 CFR Part 11 [23] from the FDA
Margetts [40] says that attention must be given to the following 13 points when 
considering the suitability of computerized systems for use in pharmaceutical 
manufacturing These points ultimately lead to high quality systems and regulatory 
compliance
1 Validation
2 System description
3 Staff qualifications
4 Quality system under which software is developed
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5 Study of the installation environment
6 Security
7 Built in checks for critical data entries and control over alteration
8 Input and output accuracy tests
9 Structural testing of the software
10 Functional testing of structurally sound software
11 Change control procedures
12 Data backup and restore procedures
13 Contract procedures for use of external personnel
Margetts does not mention provision of documentation as one of his 13 points, which 
is generally a crucial requirement
Standards such as the Capability Maturity Model (CMM) [14] and both IEEE 1074 
[41] and ISO 12207 [42] software development life cycle standards should be 
considered when adopting best practices in a design environment [39] The quality 
requirements for pharmaceutical manufacturing Computer Systems Validation (CSV) 
exceed those provided by ISO 9000 and ‘TicklT’ [43] accreditation according to 
Wingate [44] Other industrial engineering standards should be considered when 
designing systems with validation for use in a pharmaceutical environment in mind 
such as the SP88 model, which is a pre-cursor to the Instrumentation Society of 
America’s (ISA’s) S88 model [45][46]
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In the last 25 years (pre 2000) there have been significant changes in the design of 
equipment for pharmaceutical manufacture [5] Primarily there has been a move 
away from borrowing from other industries such as food towards a position where 
bespoke systems are manufactured with GMP principles considered Anyone who is 
involved with the development of a computer system for use in a GMP environment 
is responsible for its validation and regulatory compliance [8][25][47]
In the 1970’s the concept and initial regulatory rulings on validation of processes and 
manufacturing systems including automated systems was introduced [48] Further 
concerns over the increasing use of computers in all areas of pharmaceuticals 
through the 1980s and 1990s led to further validation guides and pressure being 
applied to the FDA to make increased and definitive ruling on the subject They did 
so in the form of 21 CFR Part 11
Carrier [9] recognizes a trend with suppliers in that they have made considerable 
investment into trying to understand the 21 CFR Part 11 rule for electronic records, 
and that they are building their product functionality based on the rule It is 
suggested that this is done to become compliant and to create a competitive 
advantage through product differentiation over competitors Carrier does not 
consider though, that the supplier might create an impression that compliance is 
r e q u i r e d  for their product, when it may not be within the intended scope of 21 CFR 
Part 11
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Often, systems that are used for other industries cannot be used in a GMP 
environment due to compliance requirements [49] Direct investment in the rule can 
thus benefit both the industry and suppliers so that suppliers should be able to 
knowledgably discuss the rule with manufacturers One requirement of developing 
Part 11 compliant systems is to ensure that adequate documentation is available 
from the vendor explaining all the design permutations and revisions of any software 
involved This requirement of the rule may have the effect of putting more onerous 
documentation practice expectations on developers than they were used to prior to 
the ruling, or when developing systems for other industries This would require 
quality system inputs for the maintenance of development and revision records, 
which are auditable by manufacturers
The increased amount of automation in pharmaceutical manufacturing, storage and 
distribution has increased the potential nsk to the medicinal product [50], as well as 
mitigating the risks associated with human error This has led to the proliferation of 
rules and industry guidance on the use of such systems Automation can be built as 
a modular system at the developer’s site or be part of the production plant's 
distributed automation solution Either way, external system developers may be 
used in building the systems The quality and regulatory practices for each of these 
developer categories are relevant
Wingate [48] states that regulator’s expectations have increased in line with 
manufacturer capabilities This is not strictly accurate in the case of 21 CFR Part 11,
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where manufacturers did not necessarily have the capability to comply These 
expectations are then passed on to suppliers A problem with this is that the GMPs 
can be interpreted differently and do not provide detailed guidance, which naturally 
leads to differences in compliance strategies
Validation has existed in the software engineering world in a different sense to that 
required by the pharmaceutical industry [51] In many software projects, outside of 
safety or mission critical contexts, validation has often meant checking that software 
works after it has been developed The validation required by regulators is broader 
in scope, and starts much earlier in the design and development process, at the 
specification stage It also extends forward into the operation of the system by the 
end user
Best practices in design, development and validation as viewed by pharmaceutical 
manufacturers have not always been followed traditionally by software vendors 
Although in software terms, the requirements from manufacturers are not much 
different from other industries, the interpretation and integration of the GMPs into the 
software product is novel The difficulties associated with applying the GMPs to 
software makes assuring compliance onerous
The demands placed on developers by the pharmaceutical industry are no different 
than what is expected by any industry, in that software should work as specified and 
should be proven to do so The expectations of the FDA are not that far removed
from what is required in normal industry for established good software engineering 
practices The FDA has stated in the past that they do not intend to establish new 
standards for development of software and have pointed to industry standards such 
as ANSI and IEEE [51]
With regard to computer system regulatory compliance, computer hardware needs 
to be considered as well as software According to the FDA’s compliance policy 
guide 7132a 11 [52], when computers are used to fulfil GMP related functionality 
hardware is viewed as equipment as defined in the GMPs This equipment will 
hence require the same level of controls applied as for other equipment under the 
remit of the regulations
The involvement of vendors in the software development life cycle can be intense 
The vendor must be able to fit into the manufacturer’s life cycle model and provide 
all the documentation and design features necessary to support it Each aspect of 
the software firm’s design process must be verified by both the firm itself and by the 
manufacturer Some of this verification occurs through factory testing and verification 
and some as site acceptance and final testing at the pharmaceutical manufacturer’s 
site
Design Qualification (DQ) is the process of building a set of requirements and 
specifications for a system to be developed for a pharmaceutical manufacturer In 
response to the design requirements of the manufacturer, the vendor will produce a
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set of detailed design specifications The combination of these reviewed 
specifications and the original requirements make up the DQ It requires that the 
design is in compliance with GMPs and this should be demonstrable as stated by 
Annex 15 of the EC working party on Control of Medicines and Inspections [53] The 
ICH Q7A guide [3] says that design review should be used to ensure that the 
systems are suitable for their intended purpose In practice the design review and 
DQ are carried out by the system purchaser, acting on behalf of the eventual end 
user As this determines the eventual suitability of systems for implementation based 
on i n t e r  a h a  their compliance to GMPs, then there is pressure on the 
developer/vendor to ensure compliance Ultimately compliance is up to the 
manufacturer, so the interface between developers and the manufacturers is an 
important one
It may be possible to attain a similar or better standard than adherence to GAMP 
produces by following other established industry development guidelines such as the 
Capability Maturity Model (CMM) [14] from the Software Engineering Institute 
according to Foote [54] However, the requirements for working to the CMM differ 
from those required by GAMP so it is not obvious that they produce comparable 
performance when each is adhered to independently Use of industry established 
industry standards as suggested by Foote may not result in full compliance In 
particular, suppliers would not be used to the language used by the regulators, or 
the expectations from regulators for documentation standards, if the CMM is relied 
on solely
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Suppliers can often lose out on opportunities because they are unaware of 
requirements for the software they produce in terms of validation and regulations, 
although they are capable of meeting those requirements within their current 
organisational structures Similarly, manufacturers may lose out, as they may not 
necessarily be choosing the best software developers, merely the more regulatory 
aware ones
2 11 Food and Drug Administration regulations
The FDA guidelines on process validation [55] are not legal requirements (unlike the 
regulations themselves) but the FDA deems its principles acceptable for 
pharmaceutical manufacture and fit to aid compliance with the regulations Process 
validation includes verifying that equipment is suitable for its intended purpose The 
guidelines define the basic principles of quality assurance in terms of medicinal 
manufacture as follows
1 Quality, safety, and effectiveness must be designed and built into the medicinal 
product
2 Quality cannot be inspected or tested into the medicinal product
3 Each step of the manufacturing process must be controlled to maximise the 
probability that the finished medicinal product meets all quality and design 
specifications
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The term medicinal is used here to differentiate between the drug product and the 
software product Systems have a role in meeting these requirements and must be 
capable of supporting them The process design and validation is important for 
achieving these quality assurance aims In determining validation requirements the 
FDA urges manufacturers to consider any factors that might affect product quality 
including equipment functions Validation should examine the design of equipment 
used in, or in support of the process The process validation guidance tells 
manufacturers not to rely solely on vendors when choosing equipment, which means 
scrutinising the vendors design and quality practices
If a computer related system is performing a cGMP related function then software is 
deemed to be a record and hardware falls under the ‘equipment’ tag in the 
regulations [53] Software that falls under this category includes applications that 
perform process control, laboratory analyses, and acquisition, storage and 
processing of data required by the GMPs
The instructions, procedures and specifications stored as programme source code 
used in computer applications with cGMP impact are deemed to be equivalent to 
their paper equivalents in a manual system The FDA requires that source code is 
made available for review and approval by the manufacturers [56] This puts an onus 
on the designer for that code to be readable In fact, the FDA considers source code 
and its supporting documentation for systems used in process control to be part of
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the master production and control records This code must hence adhere to the 
same requirements for master production records as outlined in the predicate rules 
for control of manual records
In the US, the responsibilities of vendors of software applications to the 
pharmaceutical industry mean that they may be liable to prosecution if their product 
leads to adulterated or misbranded drugs finding their way on to the market as a 
result of vendor negligence [57]
FDA 21 CFR Parts 210 [58] and 211 [59] give the requirements for Good 
Manufacturing Practice (GMP) for finished pharmaceuticals Part 210 gives general 
requirements for the manufacture of drugs whilst Part 211 is specific to the 
manufacture of finished pharmaceuticals Part 210 gives the legal standpoint, 
applicability and definitions used by the FDA in the GMP regulations Part 211 
details the requirements for automatic, mechanical and electronic equipment These 
equipment requirements can be summarised as follows
(a) Such equipment including computer related systems should perform functions 
satisfactorily It should be calibrated routinely, inspected and checked regularly 
according to a written plan for doing so
(b) For computer related systems, adequate controls should exist to ensure that 
only authorised persons institute changes to batch records Inputs, outputs and
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algorithms should be checked for accuracy Backup data should be maintained 
for data and programs
The inputs and outputs from a computer system should be regularly checked for 
accuracy and the expected responses verified [59] This means that they must be 
designed in such a manner as to allow this to happen Built in controls may be used 
to determine the frequency and extent of such testing
2 1 1 1  FDA rule 21 CFR Part 11 -  Electronic Records and Signatures
One of the most crucial regulatory changes with regard to electronic systems and 
computers has been the introduction of 21 CFR Part 11 [23] in 1997 It was not
enforced until 2000/2001 It makes up a substantial part of the regulations that must
be adhered to by developers of systems into the pharmaceutical industry The rule 
has been interpreted in various ways and it has never been clear whether the more 
rigid interpretations have been propagated by vendors looking for a competitive 
edge, by using scare tactics regarding the scope of the rule 21 CFR Part 11 is the 
FDA regulation concerning the equivalence of Electronic Records and Electronic 
Signatures to paper records in the pharmaceutical industry Its scope is i n t e r  a h a  
pharmaceutical manufacture The purpose of Part 11 is to allow the use of electronic 
records in lieu of paper records and electronic signatures in lieu of written 
signatures, as long as the requirements of the predicate GMP rules are still met The 
regulation applies to electronic records that are created, modified, maintained,
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archived, retrieved or transmitted, should those records be required under those 
same predicate rules The regulation means that all computer hardware, software 
and associated documentation must be available for inspection by the agency where 
the related system handles records required by the predicate rules
Part 11 requires system controls and procedures which must ensure that
(a) Systems are validated to ensure ‘accuracy, reliability, consistent intended 
performance, and the ability to discern invalid or altered records’
(b) The controls and procedures should allow records to be generated which are 
human readable and are fully representative of the record that was initially 
created
(c) Records are protected for a sufficient timeframe dictated by the predicate rules 
to allow their retrieval for inspection
(d) Access is limited to authorised personnel
(e) Audit trails should be built in to track all changes and the history of records
(f) Checks are carried out to ensure that only authorised people can access and 
use the system at the level assigned to them (e g to sign, approve, or to initiate 
automated sequences in a process)
(g) Checks are carried out to ensure validity of data at the point of entry
(h) Personnel are trained appropriately
(i) People accept the accountability of their signatures in the same way as they 
accept the integrity of a written signature
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0) Appropriate documentation handling procedures such as revision change 
control, distribution and access control for any documentation involved
The controls required to ensure the security and integrity of electronic signatures are 
detailed In summary they are
(a) Password and identification codes should be unique combinations
(b) Passwords and identification codes should be revised periodically
(c) Procedures should exist for lost, stolen or otherwise compromised passwords 
and for identification code generation devices
The introduction of Part 11 resulted in many reservations, difficulties and complaints 
from industry as to the cost and complexity of compliance [60][61], even with 
published guidance from the FDA and industry bodies aimed at helping developers 
to comply [62]
The use of clear requirements specifications by the manufacturer when acquiring 
technology is of paramount importance and should include requirements for 
compliance with Part 11 This compliance may be assessed in the form of vendor 
audits or questionnaires, so it is clearly in the supplier’s interest to be ahead of the 
game
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The ISPE guide for complying with the rule details 19 technological requirements 
that are supplier responsibilities (in that supplier involvement is required in order to 
ensure compliance with those requirements) [62] The remainder of the 
requirements of the rule can be met by procedural means at the manufacturer's site 
or through on site validation One procedural requirement for suppliers is that they 
must be able to demonstrate that personnel involved in the development of 
compliant systems have appropriate education, training and experience [23]
The array of technological features required for compliance with Part 11 is hence 
produced in table 2 1 1 1 1
Table 2 1 1 1 1  Technological requirements of 21 CFR Part 11 -  Supplier 
responsibilities [62]_____ ________________________________________________
Requirement
number
Related 
clause in 
21 CFR 
Part 11
Requirement
1 11 10(a) Systems must be able to detect invalid or altered 
records Systems must have a searchable audit trail 
which can track alterations to records
2 11 10(b) It should be possible to access electronic records and 
present them in human readable form
3 11 10(b) It should be possible to electronically export records 
and associated data (such as audit trails) from the 
system of interest
4 11 10(c) Systems should be able to maintain electronic records 
and associated data over the period that paper records 
would be required, despite upgrades to that system or 
its operating environment
5 11 10(d) System access should be restricted in accordance with 
pre-determined rules
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Requirement
number
Related 
clause in 
21 CFR 
Part 11
Requirement
6 11 10(e) Systems should be capable of recording all record 
create, update and delete operations Updates should 
not write over previous data Data must be stamped 
with the time, data, and originator of the creation, 
update or deletion Alteration of the records should only 
be possible by authorised personnel
7 11 10(f) Where sequential operations are required, the system 
should only allow authorised sequences to be 
performed
8 11 10(g) The use of defined functions and features should be 
restricted to authorised personnel in accordance with 
configurable rules Changes to restrictions should be 
captured by the system
9 11 10(h) Where devices are required to act as data or command 
sources, the system should enforce this requirement
10 11 10 (k) Where the documentation for the system is electronic 
and can be changed by the manufacturer, changes 
must be captured in the audit trail
11 11 50 Where electronic signatures are used they should 
contain at a minimum, the name of the signer, date and 
time of signature, and the meaning of the signature 
(e g approve, review) The components of an 
electronic signature are subject to the same controls as 
other electronic records
12 11 70 The system must provide a method for linking 
signatures to records in a way that prevents the 
signature from being removed, copied or changed for 
use with any other record
13 11 100 
(a)
The system should enforce uniqueness of the 
electronic signature and prevent reuse in any form It 
should not be possible to delete information relating to 
a signature from a system
14 11 200
(a) (1)
Non-biometric signatures should have at least two 
distinct components
15 11 200 
(a) (1)
If system usage sessions are not continuous (if the 
system is left alone for a defined period), then rules 
should exist for re-entry that requires two components 
of identification (e g user name and password)
16 11 200 
(a) (1)
The system should ensure that two identifying 
components are used on first signing in to the system 
and after a break in a usage session
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Requirement
number
Related 
clause in 
21 CFR 
Part 11
Requirement
17 11 200 
(a) (3)
Electronic signature information should not be 
accessible by ordinary means (i e by any reasonable 
means)
18 11 300 
(b)
Systems should require passwords to be changed 
periodically although it is recognised that for some 
embedded or PLC based systems this may not be 
possible and procedural controls may be used
19 11 300 
(d)
Systems should log attempts for unauthorised access 
and should take action if continuous failed attempts are 
made (such as locking itself out)
It is important to understand the origins of Part 11 in order to be fully able to evaluate
its effects, application, and the upheaval it has caused in system development
The rules on record keeping and the use of signatures in pharmaceutical
manufacturing are detailed in the predicate rules Records are required to be
maintained for a variety of functions in pharmaceutical manufacture 21 CFR 211
[59] details the record requirements Specifically these are
1 Equipment cleaning, use and maintenance records (Calibration records and
inspection records are required to be maintained)
2 Component, drug product container, closure and labelling records
3 Master production and control records (batch to batch monitoring of products)
including the instructions and specifications necessary to manufacture
4 Batch (specific) production and control records including process measurements
5 Laboratory Records including methods and result data and analysis
I
I
I
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6 Distribution Records
7 Customer complaints
Other requirements for maintaining records are included in Part 211 and are implicit 
in other criteria For example, validation data for automatic, mechanical and 
electronic equipment and program backups are required to be maintained Many 
technologies are employed in the industry, which use computers to store and handle 
records for all the items above Many of the records, such as customer complaints 
and distribution records are often managed on manufacturer designed and built 
applications However, many of the control and acquisition records are stored on 
vendor-developed systems outside of the manufacturer's direct environment Typical 
of these might be chromatography data systems for laboratories which usually use 
off the shelf software packages, or PLC controlled vendor packaged systems such 
as packaging machines, clean water generators and so on
So that more advanced technologies could be used to replace record keeping 
functions that were traditionally carried out on paper, the industry pressed the FDA 
for many years to get them to produce rules and guidelines on the use of electronic 
records and electronic signatures The FDA set up a task force and issued notice of 
its intent to issue a new rule The regulators needed to look at the key areas of 
regulatory acceptance, enforcement integrity, security, validation, existing industry 
standards for digital signing and freedom of information before making rules
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Comments and information for building rules were solicited from industry After a 
period of collaboration with industry, the final 21 CFR Part 11 rule was published in 
March 1997 Most of the blame for the problems later to be discovered by the rule 
was generally laid at the doorstep of the FDA However it would seem that industry 
had sufficient time to work with the regulator to produce a more refined rule The 
FDA does say in the 1992 Federal Register entry that the issues to be faced with 
electronic records and signatures are complex and often beyond the scope of GMP 
This early reluctance to fully clarify scope was obvious throughout early guidance 
from the industry as to the implementation of the rule and led to problems later on 
with interpretation
The FDA, when considering making their ruling had targeted direct impact systems 
This did not mean that other systems with much smaller scope and with less 
potential product quality impact escaped from the requirements of the rule in the 
eyes of cautious manufacturers In fact, there seems to have been very few systems 
that fell outside the scope due to regulatory conservatism in the rule’s interpretation
Farrell and Cooper [63] put the causes of the gap between perceived and actual 
intent of the rule down to three mam factors, confusion between records required for 
predicate rule and other records, the imprecise terminology in use in the computing 
industry (i e anything on a computer can be termed to be a record), and the desire 
in the pharmaceutical industry to have definite direction and guidance for all its 
regulatory requirements They do not consider that a main cause of the gap might be
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the reluctance of manufacturer's to employ risk based assessments of applicability, 
or the role suppliers might have played in ‘pushing’ a Part 11 agenda for competitive 
purposes
The objectives of Part 11 were to enhance production efficiency whilst maintaining 
predicate rule requirements for records and ensuring the integrity and security of 
those records [64] Although it was effective in 1997, the rule was not enforced until 
1999 to allow the industry to get over its ‘year 2000’ [65] issues
The requirement placed constraints on the use of electronic rules and signatures 
Although their use was optional, manual methods had to be used where compliance 
with Part 11 was not demonstrable Woodrum [66] highlights interpretation issues 
with the rule One of her points is that although the rule was not meant to interfere 
with systems producing paper records in the traditional style, systems which use 
electronic records to produce the paper ones must be compliant with the rule The 
regulators guidelines in 1997 did not preclude legacy (already in use) systems from 
their scope
The interpretive issues with the rule led to what was somewhat of a backlash from 
the industry This provoked the FDA into withdrawing their guidance, replacing it with 
new guidance which had a narrower scope, allowed the use of risk assessments 
when determining the applicability of systems and stated that the FDA would 
exercise enforcement discretion on certain features of the rule [63][65][67][68]
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However some reservations still remain about interpretation and abuse of the 
discretionary elements of the revised guidance [65][67]
Although the rule has requirements that are quite specific, they are not 
technologically new and industry standards for software development exist that 
contain many of the requirements of Part 11 [69] Nevertheless, the impact of the 
rule has been dramatic
2 12  European rules for drug manufacture
Directive 2001 /83/EC [70] from the European Union says that pharmaceutical 
manufacturers must have suitable and sufficient technical equipment GMP 
equipment must be designed to suit their intended applications Where electronic 
systems are used in lieu of paper systems, the manufacturer must have validated 
systems proving that the data will be stored appropriately Electronic data should be 
protected appropriately against loss or damage
Validation studies should be used to enforce GMPs according to European rules 
That is, the testing should verify that the equipment is suitable for its intended 
purpose Any changes that affect the manufacturing process should be validated 
The European guidance requires that critical process should be validated Again, 
criticality is often subjective and must be determined by the manufacturer
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As with the FDA rules, the European Commission requires that computer systems 
used in controlling or monitoring drug manufacturing processes should be validated 
Annex 11 of the European rules states that
“Where a computerised system replaces a manual operation, there should be no 
resultant decrease in product quality or quality assurance" [37]
There should be appropriate expertise available for the design and validation of 
systems Annex 11 of the EC rules also requires a life cycle approach for computer 
systems [37] The life cycle should include planning, specification, programming, 
testing, commissioning, documentation, operation, modifying and monitoring Many 
of these phases involve external developers
Software should be produced in accordance with a quality assurance system, should 
be thoroughly tested, and should include internal checks of correct entries and data 
processing Consideration should be given to building audit trails into software to 
capture all changes to data and use of the system For auditing purposes it should 
be possible to obtain print outs of the electronically stored data
Annex 11 requires that when outside agencies are used to provide computer 
services, then the responsibilities of the outside agencies should be clearly defined 
The developer falls into this category
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Annex 15 of the EC rules says that the compliance of the design of systems with 
GMP should be demonstrated and documented and that they should be validated 
[70] The requirements from the European regulators for computerised systems are 
relatively sparse and less prescribed than those put forward by the FDA
2 1 2  Good Automated Manufacturing Practice (GAMP)
Trill [71] points out that much of the guidance for support of new technology is taken 
from industry bodies such as the ISPE, GAMP forum, PDA, Pharmaceutical Quality 
Group (PQG), and the ISO This guidance is usually well received by the regulators 
to the point that they are often quoted in regulatory literature and may eventually 
evolve as annexes to current regulations
Trill [71] speaks in particular of the evolution of GAMP into an industry standard He 
claims that a desire for better understanding of computerized solutions by the 
industry, together with a requirement for best practice and regulatory compliance in 
the late eighties resulted in its conception Negative inspection findings within the 
industry with regard to computerized systems were also a driving force for GAMP
[13]
The Good Automated Manufacturing Practice (GAMP) forum is a sub-committee of 
the International Society of Pharmaceutical Engineering (ISPE) and the GAMP 
initiative has been endorsed by the FDA and the EMEA Its purpose is to aid m t e r -
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a l i a  pharmaceutical manufacturers in providing validated and GMP compliant 
automated systems The GAMP guide [13] is directed both at suppliers engaged in 
systems development and manufacturers for assessing those systems At the time 
of writing, the latest version of the guide is GAMP 4 It has d e  f a c t o  standard status 
in the industry
An outcome of the GAMP Forum project was the realization that in order to ensure 
quality of both software and ultimately the product, quality would be required to be 
demonstrably built in to the system code Suppliers were hence encouraged and 
pressurized into attaining greater regulatory compliance understanding when 
developing their systems In 2002, suppliers, developers and vendors were 
'positively enthused’ at this prospect of ‘building quality into systems’ [71]
The GAMP guide speaks of automated systems as being
‘A broad range of systems, including automated manufacturing equipment, control 
systems, automated laboratory systems, manufacturing execution systems and 
computers running laboratory or manufacturing database systems The automated 
system consists of the hardware and software components, together with the 
controlled functions and associated documentation Automated systems are 
sometimes referred to as computerized systems, in this Guide the two terms are 
synonymous’ [13]
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This assertion is used in this research That is, automated and computerized 
systems shall be deemed equivalent
Automated systems can affect product quality either directly, or indirectly Quality 
must be built into the software to a sufficient degree to support the regulations The 
Medicines Controls Agency in the UK had discovered in their inspections in Europe 
and the US that there was a deficiency in understanding of technology and 
terminology related to software quality and validation [72] They observed that many 
companies were engaging in retrospective validation of a completed automated 
system based on the overall functionality rather than testing to verify the structural 
integrity of systems and their building blocks This was found to be a more 
expensive approach and did not meet with regulatory expectations
A 1988 report [73] to the UK government indicated that, in general, software was 
traditionally of poor quality, and required retrospective modification Another report to 
the same government department [74] recommended software quality standards be 
harmonised through ISO 9000
GMPs are targeted at the drug manufacturers rather than suppliers of equipment 
into that industry The GAMP guidelines serve to provide an accepted interpretation 
of the European and US GMPs and it provides specific guidance for suppliers
The development of guidelines by bodies such as the ISPE has been driven in part 
by the increased regulatory interest in computerised systems during inspections [75] 
The development of GAMP involved collaboration between suppliers and the 
pharmaceutical industry Its aim was to produce a standardised interpretation of the 
regulations
Automated systems consist of hardware, software and networked components A 
benefit quoted in the GAMP guide is that it offers a convergence of existing industry 
standards including ISO and IEEE standards and has relevance to both software 
and hardware
The fundamental framework behind GAMP is the ‘V-model’ This is a life-cycle 
compliant model that maps testing onto the specifications The model maps 
validation onto development to provide assurance that systems meet their design 
intent and to ensure that all aspects of design are tested The life-cycle model 
suggested by GAMP addresses the quality requirements of an automated entity, 
from conception to retirement The responsibilities in the ‘V-model’ section of the life 
cycle are split between the manufacturer and the developer, with ultimate 
responsibility lying with the manufacturer The 'V-model' is depicted in figure 2 12  1
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Figure 2 1 2 1  The GAMP 4 ‘V-model’ for automated systems development
for the Pharmaceutical industry
In figure 2 12 1, the solid arrows represent the sequential order of events and
actions The dashed arrows represent verification relationships That is, PQ verifies
the URS, OQ verifies the FS and DS and the IQ verifies the DS Each step deserves
separate explanation, as their importance for pharmaceutical systems in
pharmaceutical manufacturing environment is huge System developers whose
products are used in pharmaceutical manufacture are expected to know and
understand all the features of the GAMP model, even if they do not use or know the
GAMP guide itself
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The following is a summary of the important features of the GAMP V-Model
1 User Requirements Specification
The User Requirement Specification (URS) is the user’s detailed specification of 
what the system should do It is a statement of the objectives and deliverables 
required for the automated system The URS tells suppliers what the user wants
2 Functional Specification
The Functional Specification (FS) is prepared by the supplier and tells the user how 
they can meet the user's needs It details the functionality they can offer to meet the 
user requirements
3 Detailed Design Specifications
The Detailed Design Specifications (DDS) are the supplier’s detailed specifications
for building the system DS includes hardware and software specifications necessary 
to ensure that a reliable system will be produced that will meet the user 
requirements
4 System design, development and build
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This involves the design, design review, hardware and software building, software 
review and supplier testing of the automated system
5 Installation Qualification
The Installation Qualification (IQ) verifies that the supplied installation is as required 
on the target system and that basic functionality operates It involves inspection of 
drawings, design documents, instrument calibration certification and software 
version recording and verification The IQ documentation may be prepared by the 
vendor I developer of the system or can be produced by the manufacturer The 
same is true for the OQ
6 Operational Qualification
The Operational Qualification (OQ) tests the functionality of the system It verifies 
the FS It verifies normal and realistically abnormal operational conditions to ensure 
that the system can handle those conditions
7 Performance Qualification
In Performance Qualification (PQ) the system is operated in its intended operational 
environment The testing is mapped to the URS The system must do what it was
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intended to do at the outset of the project and within pre-determmed specification 
limits
The combined IQ, OQ and PQ constitute the system qualification or validation The 
system is released for operational use on successful completion of the PQ 
Validation however may continue into full system operation to ensure that the global 
process performs as intended during drug manufacture The developer can be 
involved in each of the phases on the ‘V-model’ from carrying out the associated 
tasks completely within a phase to providing supporting design and testing 
documentation to the manufacturer
Although the vendor - supplier relationship is still important in the operational phase 
or while the system is in its ‘validated state’ for the purposes of technical service and 
system modifications, it is in the V-model phases of the life cycle that the vendor's 
involvement is greatest
Treatment is given by the GAMP guide to categories of automated systems such as 
information systems, embedded control systems, process control and stand-alone 
systems The fundamentals of the life cycle and V-model apply whatever the 
automated entity
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The contents of a user quality plan are suggested by GAMP and reinforce the 
supplier’s responsibilities The suggested contents of a user quality plan are
1 Specification management
2 Design reviews
3 Programming standards and code reviews
4 Testing
5 Installation
6 Data migration
7 Factory and user site acceptance testing
8 Document management
9 Change control
10 Configuration management
11 Non-conformance and risk management
12 Project training
13 Handover to support organisations
ISO 9000-3 [76] and the TickIT [43] guide for software quality were used in the 
creation of GAMP [13] It was hence influenced by contemporary industry standards 
for software
Many things are taken into consideration when a manufacturer is selecting a vendor 
Among these are the vendor's quality commitments and approvals, their financial
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stability (likelihood of survival), and ability to support end users [77] Biographies, 
references, and audits are tools that can be used to assess suitability GAMP 4 
gives guidelines for conducting vendor audits and for audit preparation by vendors 
In addition to this, stringent controls are expected for software developers In 
accordance with GAMP and good software engineering expectations, criteria that 
may be used to establish best practice by developers include assessments of tools 
used by the developer, their general level of experience, and references from other 
pharmaceutical users of the software, change management system, and source 
code availability to the end user
2 2 Quality Systems
2 2 1 Quality Management and its effects
The influences that quality has on business performance are well documented in the 
literature The relationship between GMP and quality however is not so well covered 
Much work exists in the literature looking at the contribution to quality management 
by ‘gurus’ of quality such as Crosby, Deming, Juran and Feigenbaum (see [28],[30] 
and [31] for example) This work was not repeated here Of those gurus, the work of 
Philip Crosby was deemed most pertinent to this work because of his focus on 
Quality Management rather than techniques and because of his influence on 
software development systems such as the CMM
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Sharp states that GMP is required for product quality, and ultimately for patient 
safety [5] He says that in a draft of the orange guide (early British guidance on 
GMP) that ‘any so called GMP measure which does not contribute directly or 
indirectly to those ends is an irrelevance’ The problem lies with defining what is 
meant by direct or indirect This has usually led to all activities being considered to at 
least having an indirect effect on GMP He puts the increased requirements for 
quality assurance in the manufacture of medicines down to the potential hazards 
that could accrue in environments where there is less than one hundred percent 
testing of all final drug products, which is not a practical possibility in most cases, as 
testing would be detrimental to the product Three important factors are identified by 
Sharp [5] justifying the heightened assurance requirements
1 Limitations on the testing of end products
2 The hazard that would result from even a small number of product defects
3 The low probability of detection (before consumption) of any defects by the 
drug recipient
Thus, the additional levels of quality assurance are passed onto system suppliers for 
the same reasons
The suggestion that quality is free and that there can never be too much quality in an 
organisation is much espoused by the quality guru Philip Crosby [78] He argues that 
quality has the ability to make a firm first among equals in a competitive environment
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and that it is often the difference between success and failure Crosby identifies four 
fundamental ‘pillars of quality’ that lead to total quality success 
These are
1 Management participation and attitude towards quality
2 Professional quality management within the organisation
3 Original quality programs
4 Recognition, both of internal quality and by external sources
Another recognized quality guru, Deming [79] claimed that quality reduces costs and 
increases market share In fact the rise of the quality professional has been 
attributed to increases in global competition, loss of market share, national quality 
award scheme and the ISO 9000 series of standards
Although quality can help to expand market share, cut costs, improve productivity 
and increase profits, quality alone will not suffice, activities such as marketing, 
product and process design and engineering amongst other factors, including the 
market itself all play roles [80] Positive relationships between quality, market share, 
and profitability are evident from the literature [28][30][31][80] consistent with the 
theories put forward by the quality gurus [78][79][81] The general finding from the 
literature across many sectors was of a weak to moderate positive relationship 
between quality practices and business performance Some work [80][82][83] used 
technical measures relating to the manufacturing process, whereas others used 
quality management measures to ascertain quality practice scores [28][30][84]-[86]
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Customer focus, according to Dale [87], is the greatest motivator for quality 
improvement, followed by the need to keep costs down Competition can drive 
quality improvement programmes directly
Quality assurance, as distinct from quality control, should have features designed to 
p r e v e n t  quality failures, rather than just consist of a series of checks to verify that no 
failures have occurred Three factors that can influence developers not to 
incorporate a distinct quality management structure into their m o d u s  o p e r a n d i  are 
perceptions that there is no added value from quality, that they ‘do it anyway’, and 
that it is a luxury rather than a requirement [88] These are naive and erroneous 
positions though as quality management is basically just a formal system of doing 
things right, or to use TQM vocabulary, doing the right things right
Quality should be embedded into every business process and there should be a 
balance between technical skills and quality skills for those who are involved with 
QA [89] Research indicates that organisations committed to quality management 
are more likely to have top management support, good communication on quality 
matters, and a high emphasis on customer service, yielding better business 
performance [30]
Although there are indications in the literature that formal structures such as TQM, 
ISO, and the SEI CMM can result in better quality and business performances,
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informal structures, which rely on the same principles espoused by formal systems, 
can yield good results also TQM encapsulates a series of approaches, which 
involve customer focus, top-down quality leadership, statistical thinking, continuous 
improvement and teamwork [30][79]
Hamid [90] concluded in his research based on a NASA software project that there 
was an optimal QA input to a development project of around 15% of the total man 
hours spent on the project, and that the law of diminishing returns is invoked beyond 
this, meaning that the cost of the project increases with less returns on error 
detection during development The example analysed was very specific though, and 
differing interpretations of what is meant by quality would yield differing results In a 
TQM environment for instance, many more functions than fault detection, design 
reviews and walkthroughs comprise quality assurance Applying a rule of thumb for 
an optimal level of quality would contribute to losing sight of why quality is important 
at all, to make sure that everything is done the way it should be
Software quality assurance in general requires the same conditions to prevail as for 
general quality assurance in order for it to be successful For example as with ISO 
and TQM, top management have an important role in making software quality 
assurance successful Organisational structure is more important to successful 
quality performance than the selection and use of piecemeal quality practices [91]
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A firm’s performance at any point may be related to their progress on the quality 
journey In this work it was possible to determine progress based on a quality score 
derived from the established core quality practice criteria
Fundamental to any system is a set of key criteria, the achievement of which can 
ultimately improve quality and business performance A set of criteria derived from 
the literature is presented later in this work This was for two purposes Firstly it 
established that any organisation surveyed that claimed to have a formal quality 
system in operation had the fundamental criteria firmly established Secondly it 
allowed assessment of organisations without formal structures
In order to determine the overall picture of quality in an organisation, it was 
necessary to determine quality effectiveness as well as practices [92] Through the 
survey, data pertaining to quality effectiveness were obtained through the quality 
practice criteria
2 2 2 ISO quality systems
ISO 9001 2000 [93] lays out the general requirements for quality management 
systems for any organisation compliant with that standard ISO 9000-3 2004 [76] 
then maps those requirements onto a computer-engineering organisation It 
advocates the use of a life-cycle model for the production of software where testing 
is directly mapped onto requirements and quality begins at project conception and
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ends at system retirement The central quality requirements for the general case and 
the software case are hence identical and can be seen summarised in table 2 2 2 1
Table 2 2 21 ISO 9000 2001 and ISO 9000-3 2004 requirements for quality 
____________________________ systems__________ _______ __________
ISO 9000 2001 and ISO 9000-3 2004 requirements for quality systems
1 Process approach
2 Documentation and record management
3 Quality manual
4 Management commitment and policy
5 Customer focus
6 Quality policy
7 Planning
8 Assigned responsibility
9 Communication
10 Management review
11 Resource management
12 Human resource management
13 Training
14 Infrastructure
15 Product realisation (customer interaction and planning)
16 Requirements review
17 Design and development planning, review and validation
18 Design change control
19 Purchasing management
20 Service provision
21 Measurement, analysis and improvement
22 Audits
23 Non-conformance resolution
ISO 9000 influences better quality performance [94] and can provide a useful first 
step or framework for a developing TQM organisation [28] [95] [96]
ISO 9000 is customer and performance focused but applies to the quality 
management system, not the product or service offered by the firm Advantages of 
being accredited to such a standard include companies having more precise 
specifications, ultimately a better quality product, effective systems for dealing with
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customer feedback, general increases in workmanship and an improved reputation 
ISO 9000 companies tend to notice increased sales [92]
The ISO series of standards are limited however Braa and Ogrim [97] criticise them 
on the basis that they are too static By virtue of the standard requiring fixed 
specifications, being completely documentation driven, and not involving the end- 
users enough in the software development they do not necessarily ensure high 
quality This can lead to low quality performance if a company's internal 
requirements are of low quality That is, the standard provides a framework to 
organisations to prove that they can meet their own internal requirements, 
regardless of the requirements However, there is nothing in the ISO standard that 
means that software specifications cannot be revised as the need arises, as long as 
the revisions are controlled Hence the interpretation of the standard by Braa and 
Ogrim with regards to fixed specifications may be seen as rigid
The problem with fixed requirements is that they can prohibit the advantages 
brought about by cyclical or incremental development and basing all decisions on 
pre-determined documentation can lead to compliance to something that is not 
always in the best interest of the end user Braa and Ogrim [97] recommend a 
circumspective application of the ISO standards They also warn of ‘symbolic’ or 
valueless application in order to improve competitiveness through aesthetic 
certification
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Andrews says that IS09000 / 9001 are not targeted to software design [35] and 
validation and that whereas IS09000-3 does go some way, it does not go far 
enough to meet GMP requirements However, as ISO offers a quality management 
framework, it is up the supplier to ensure that the elements of the ISO standards are 
effective for their processes, the ISO standards can be applicable to a software 
environment with careful application
2 2 3 Total Quality Management
TQM is defined by the IS08402 standard as
“A management philosophy embracing all activities through which the needs and 
expectations of the customer and the community, and the objectives of the 
organisation are satisfied in the most efficient and cost effective way by maximising 
the potential of all employees in a continuing drive for improvement” [98]
TQM is claimed by Dale [87] to have been a major contributing factor in the rise of 
the Japanese manufacturing sector The basic premise of TQM is that all members 
of an organisation are actively involved in the quality structure and the improvement 
processes The key elements of TQM as defined by Kan and Basili [99] are
1 Focus on customer satisfaction
2 Process improvement (both product and business processes)
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3 Company wide quality culture
4 Measurement and analysis
TQM gurus are united in their view that customer focus is a primary feature of TQM 
[99] Total Quality Management (TQM) involves complete interaction between all 
internal and external customers, suppliers, stakeholders and greater society for a 
given organisation [92] It requires effective and efficient management of all 
processes TQM involves long-term quality improvements and commitments
The BS7850 TQM standard [100] says that every person in an organisation must be 
used to his or her fullest potential if the goal of total quality is to be achieved 
Customer satisfaction, investment in people and training are three major features of 
the standard It defines a process in an organisation as being any activity that 
accepts inputs, adds value to these inputs for customers, and produces outputs for 
these customers TQM involves maximising efficiency and effectiveness for all 
processes that an organisation engages in It gives examples of quality losses and 
mentions i n t e r  a l i a  loss of customer satisfaction and loss of opportunity to add more 
value to the customer, the organisation and society as being losses This is an 
indicator of the totality of the approach Functions within a company that would 
normally be away from the production coalface such as administration, accounts, IT 
departments and so on should be fully included in quality management and 
improvement processes
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Chou et al [101] equate the plan -  do -check -  act phases associated with TQM to 
the quality elements of a software life cycle stages as follows ‘Planning’ is when the 
requirements are being analysed, ‘doing’ is the system development, ‘checking’ is 
the testing or validation phase and ‘acting’ is the implementation and maintenance 
phase of the life-cycle
According to Chou et al [101] the key elements of TQM include customer focus, 
obsession with quality, scientific approach to quality, long term commitment, 
teamwork, continuous improvement, education and training, freedom to change 
through control, unity of purpose, and employee involvement and empowerment
Ismail and Hashmi [28] said that about three-quarters of TQM implementations are 
in companies with less than 250 staff (based on an Irish survey) However 
performance is only enhanced through TQM for manufacturers who have more than 
50 employees A marginal increase in performance was observed from their survey 
analysis for ISO registered firms adopting TQM Substantial performance differences 
did exist in Ismail and Hashmi [28] between the performances of these firms and 
firms without TQM or ISO
The permanency of TQM in an organisation is related to the level of TQM adoption 
Dale [87] identifies six levels of adoption or practice of TQM
1 Uncommitted to TQM (no formal TQM process)
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2 Drifters (Short-term view TQM aware, but not convinced of its value)
3 Tool-Pushers (Lots of quality tools such as Statistical Process Control Award 
focused Tools not appropriately used or linked to a 'total' strategy Pre­
occupied with numbers)
4 Improvers (Good quality infrastructure although doesn’t pervade the entire 
organisation)
5 Award Winners (Can compete for top quality awards, Quality is ‘total’)
6 World class (Total quality works to ‘delight’ the customer Never-ending 
pursuit of improvement and complete customer satisfaction)
Dale [87] says that permanency of TQM is strong only for improvers, award winners 
and world-class practitioners
Quantitative assessment is fundamental to ensuring TQM [102] and cost of quality is 
a central measurement feature Quality costs typically range from 5% to 25% of 
sales turnovers in manufacturing organisations, Cost effective quality management 
systems can reduce cost of quality by two thirds [87] according to Dale However 
this is a theoretical assertion and generalizations may be invalid
Cost of Quality (COQ) measurements are important as they help to focus 
organisational improvement and categorise that improvement Through careful 
definition of measures within an organization including cost of failure, COQ can be 
ascertained
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Morse [103] says that cost of quality can have four uses
1 To promote product and service quality
2 To give rise to performance measures
3 Provides means for budgeting for and controlling COQ
4 Motivators
It is also a performance indicator that can be used in vendor approval
Cost of Quality (COQ) measurement is useful to determine actual costs and to drive 
improvement measures at management levels Costs include costs of both 
conformance and non-conformance, and TQM should aim to minimise both Cost of 
conformance as defined by BS6143-1 1992 is
“The intrinsic cost of providing products or services to declared standards by a 
given, specified process in a fully effective manner” [104]
In the same standard, cost of non-conformance is
“The cost of wasted time, materials and capacity (resources) associated with a 
process in the receipt, production, despatch and correction of unsatisfactory goods 
and services" [104]
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Process cost elements should include people, equipment, materials and the relevant 
environment Costs can be further subdivided into prevention costs, appraisal costs, 
internal failure costs such as waste and poor productivity, and external costs such as 
loss in sales and growth [104] Increased quality awareness and improvement 
serves to reduce all such costs The total cost of quality can typically be expressed 
as a percentage of sales revenue for reporting purposes
Krishnan [105] established that costs of development and support for software 
products increased in line with quality He challenges the application of Crosby’s 
much-cited hypothesis that quality is free to the area of software development [78] 
Crosby’s philosophy is taken out of context Crosby says that by adding quality, 
which does have a finite cost, defects can be lowered and profits increased, thus 
paying for quality In order to realistically challenge this, an empirical assessment 
would be required that compared pay-offs against absolute quality costs Krishnan 
[105] ultimately asserts in conclusion that Crosby [78] is upheld in that by excluding 
other factors, higher quality reduces costs The effects that increased quality inputs 
have on profit or business performance are not ascertained in the study, which are 
fundamental to Crosby’s theories The sampling frame in this study was restricted to 
27 projects from the same software development company This may be seen as a 
significantly biased study in the sense that it may not be feasible to generalise based 
on the practices of a single firm’s quality management practices
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Krishnan’s study (105] indicated that for more complex software projects, cost 
decreases with quality inputs by a greater amount than for less complex software.
The use of tools in a quality environment does not ensure success, as effectiveness 
is not guaranteed. However their use can be an indication of a mature quality 
system. Dale [87] lists a series of tools and techniques that are best known in TQM 
as shown in Table 2.2.3.1.
Table 2.2.3.1 Series of tools and techniques that are best known in TQM 
according to Dale [87].
Tool Main features
Checklists Prompts for checking key features of processes, equipment, 
systems, products or services.
Flow charts Process maps for operations, systems and functions.
Histograms Graphical representation of event occurrence based on frequency 
of occurrence.
Graphs Used to convey key data.
Pareto diagrams Statistical diagram used to prioritise factors in a given global 
measure.
Cause and effect 
diagrams
Used to determine main causes of a given event.
Scatter diagrams Used to plot data for the purposes of determining relationships 
between variables.
Control charts Used to collect data about a given process and determine whether 
it is operating inside pre-determined limits.
Quality costing Ascertaining the cost of quality
Statistical Process 
control
Control of the process through use of statistics.
Failure mode and 
effects analysis
A risk assessment method for improving design of products and 
processes by analysing all likely failures and mitigating against 
their occurrence.
Fault tree analysis Analysis of possible causes of a fault starting at the system level 
and working down through each sub-system, equipment, materials 
etc. looking at all possible causes.
Design of 
experiments
Mathematical techniques used to define process parameters.
Quality function 
deployment
A system for mapping customer requirements into organisational 
structure and processes.
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Tool Main features
Affinity diagrams Used to collect verbal data in complex situations and link 
statements together to produce order and analysis
Relations diagrams Used to identify, understand and clarify complex cause and effect 
relationships
Systematic (tree) 
diagrams
Evolving diagram used to produce a hierarchy of tasks to solve a 
given problem
Matrix diagrams Table used to assess the relationship between results and causes 
or between objectives and methods
Matrix data analysis Used to order and analyse matrix diagrams
Process decision 
chart and arrow 
diagrams
Used to select the best process from a choice of processes to 
solve a given problem
Departmental 
purpose analysis
Assessment technique for improving departmental purpose
Mistake proofing Uses detailed analysis of the source of defects to prevent their 
recurrence
Benchmarking Benchmarking practices and performance against competitors or 
best in class organisations for the purposes of improvement
2 2 4 Software Quality
Software defects are common and tolerated with most applications, but should be 
eliminated for critical applications Rodford [106] claims that design inspection, code 
inspection, quality assurance and testing used throughout the development life cycle 
can produce median defect removal rates of 99% from software
Concerns about software quality are well documented [107] - [109] Unfortunately 
there has been acceptance by the wider software market of the trade off between 
low quality and better features speedily delivered [108] As software processes 
mature, there are increasing numbers of companies focusing on both reliable quality 
and enhanced functionality Today, as in the past, QA knowledge by software
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developers spans a large range, from those who are barely familiar to those totally 
adept or willing to become so [110]
There is genuine reason for manufacturers and regulators to be concerned about 
software quality Hayes [109] reported from a survey of user businesses on software
quality that only 45% of those questioned reported satisfaction about the commercial
>
software they had purchased 76% of the respondents said that quality was a 
significant consideration when choosing a software vendor
Evidence exists of some vendors pricing their software products based on key 
quality factors [111] That is, price is linked to customer satisfaction giving a very 
visible reflection to the customer of the vendor’s quality performance and a huge 
incentive for vendors to maximise total quality
)
Quality management and software quality monitoring should be given rigorous 
treatment and should be approached scientifically [112] There are many features 
that must be planned into software design, which cannot be retrospectively 
integrated successfully For example, building security into critical software is a 
fundamental design requirement Software should be built around a security frame 
and it should not be added on as an afterthought [113] Quality planning can ensure 
such requirements are managed
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In any software project, documentation management makes up a vital element in 
ensuring that the actual product matches the intended product [114] This is 
extremely important in software quality assurance due to the difficulties with 
assessing the finished product, owing to the hidden nature of the code Research 
indicates that there has been significant dissatisfaction with software quality by 
users, particularly for bespoke software Poor documentation has often been cited 
as been a source of user dissatisfaction [115]
Software Quality Assurance (SQA) began in the 1960s with IBM’s final product 
testing [116] SQA can often occur too late in the software cycle to add real value 
Software quality for regulated industries in general means adhering to requirements 
approved by the regulators, amongst the litany of requirements laid down by non 
industry-specific standards
There is evidence in the literature that increasing investment in SQA is required 
amongst system developers Of 100 Malaysian companies surveyed by Ow and 
Yaacob [117], most reported low investments in SQA and also acknowledged the 
need for higher investment Commercial companies reported the highest 
investments on average In general it is not wise for developers solely to review and 
inspect their own systems as this can lead to lower than desired product quality 
That is, the development company should employ independent quality assurance 
personnel to verify design work, to supplement the development engineering team's 
own reviews
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Ow and Yaacob [117] recognise ISO and CMM as being two of the most important 
quality frameworks relevant to software development in Malaysia
The primary goals of SQA are to monitor the software development, ensure 
compliance with standards and procedures, and to highlight improvement 
requirements to management It should do this through independent observations 
Runeson [118] suggests an appropriate SQA organizational structure consisting of a 
separate SQA function with auditing relationships with the project staff and project 
manager, and a reporting function to the senior manager
SQA includes the technical methods and tools that aid in the design and 
construction of high quality software ISO 9000, the SEI CMM and TQM can be used 
as methods to achieve SQA [101] CMM involves an SQA function However, SQA 
within CMM is not solely responsible for quality, this lies with all the elements of the 
development project team SQA involves reviews of project literature, audits to 
check adherence and measurements to determine compliance to processes and to 
ascertain progress information SQA essentially monitors the controls developed by 
quality management, both functions being fundamental to the quality effort required 
by CMM
The selection of an appropriate software quality assurance programme is a vital 
project management step in software development [119] Software produced under
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an accredited quality assurance scheme can improve buyer confidence, especially 
when the developer is accredited by national bodies [115]
Standards are tools for showing compliance with regulations, policies and guidance 
according to Herrmann [120] When there are overlapping or conflicting standards 
there can be difficulty following and implementing standards No single standard can 
be followed which can yield the desired quality of a software product for use in a 
regulated activity, rather a series of appropriate standards should be used for the 
purpose [121]
Other models exist for software quality such as the ‘TickIT’ initiative [43] but are not 
advocated widely in the literature [121] with regards to achieving regulatory 
compliance
Many models such as GAMP are built on industry standards such as the ISO 
standards already described and standards developed by the IEEE For example, 
the IEEE standard 730-1998 [122] provides the requirements for quality assurance 
plans for critical software Critical software in this case is said to be i n t e r - a l i a  any 
where failure can have safety implications The standard contains many features 
familiar to other standards and guides such as GAMP, the IS09000 series and the 
CMM [14] Its scope equates firmware to software The minimum requirements for a 
SQA plan are presented in order to give developers a baseline against which to
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assess their own SQA plan against Table 2 2 4 1  shows the key features of IEEE 
730-1998 [122] for software quality assurance plans
Table 2 2 41 Key features of software quality assurance plans fo r critical 
 ______________software according to ISO 730-1998 [122]_______________
Required sections Key Features o f plan section
Purpose Specifics on scope of plan including software details
Reference Documents All documents referenced in plan
Management Description of the organisational structure and how it affects 
quality, responsibilities, reference to the software life cycle phase 
developed under the plan, tasks to be carried out under the plan, 
sequence of tasks in the project with emphasis on quality related 
tasks
Documentation Identify all design, verification, and operation and maintenance 
documentation Design documentation should include 
requirements specifications, design description Verification 
documentation should include a validation plan and report There 
should be a plan to deal with configuration management for 
configurable software
Standards, practices, 
conventions and 
metrics
Identification of standards and practices to be used and how 
compliance to them will be handled Detailed design standards for 
logic structure, coding, testing and metrics
Reviews and audits Definition and logistics of technical and management audit 
requirements At a minimum these must include software 
requirements reviews, preliminary design reviews (management 
overview), critical design reviews (or detailed design review), 
verification and validation plan review, functional audit before 
software delivery to ensure all software requirements have been 
met, physical audit of pre-delivery software and documentation, in- 
process audits to ensure continuous adherence to standards and 
requirements during design, managerial reviews of the SQA plan, 
configuration management plan review, and post-project post­
mortem reviews
Test Test sections excluded from the verification and validation plan
Problem reporting and 
corrective action
Mechanisms for resolving problems and issues
Tools, techniques and 
methodologies
Identification of special tools and techniques used to implement the 
SQA plan
Code control Methods for software code storage and control
Media control Physical media requirements for the software product
Supplier control Requirements for supplier’s software Suppliers must also have an 
SQA plan
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Required sections Key Features o f plan section
Records collection, 
maintenance and 
retention
SQA documents to be retained including their retention duration
Training Training requirements to meet the SQA plan
Risk management Methodology used to assess risk during the life-cycle phase
The IEEE/EIA 12207 0 [42] standard, which is also ISO/IEC 12207 1995, is a 
standard for software life cycle processes for Information Technology and was 
influenced by IEEE 1074 [41] It applies to the software portion of firmware as much 
as to computer based software It provides a framework for lifecycles, but does not 
give details as to implementation techniques The life cycles used by developers 
must be mapped onto the IEEE 12207 0 standards requirements in order to prove 
compliance It divides the life cycle process into 3 blocks, Primary life cycle 
processes, supporting life cycle processes and organisational life cycle processes as 
follows
1 Primary Life cycle processes consisting of acquisition, supply, operation, 
development and maintenance
2 Supporting Life cycle processes consisting of documentation, configuration 
management, quality assurance, verification, validation, joint review, audits and 
problem resolution
3 Organisational life cycle processes consisting of management, infrastructure, 
improvement and training
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The development process consists of thirteen activities Table 2 2 4 2 outlines those 
activities and details their primary features Documentation of all activities is required 
by the standard
Table 2 2 4 2 Development activities and primary features o f the IEEE/EIA 
_______________________ 12207 0 standard [42]________________________
Development
A ctiv ity
Primary features
Process
implementation
Define a lifecycle to be used Document all project outputs Place 
outputs under configuration management Document and resolve 
problems and non-conformances Choose and document standards 
and programming languages Develop project plans that include all 
the requirements of the standard
System
requirements
analysis
Document the specific intended use of the system Define functions, 
capabilities, and all system requirements
System
architectural design
Build a top-level architecture of the system identifying all 
configurable items
Software
requirements
analysis
Establish and document software requirements including quality 
characteristics
Software
architectural design
Transform requirements into an architecture Develop preliminary 
user documentation, top-level design and test requirements
Software detailed 
design
Develop design into smaller units that can be coded
Software coding 
and testing
Develop each software unit Develop test plans and carry out testing
Software
integration
Develop a plan to integrate coded units Integrate and test unit 
integration
Software
qualification testing
Evaluate and test the software
System integration The software and hardware should be integrated and configuration 
managed The integration should be tested
System
qualification testing
Testing should take place that maps the requirements to the 
completed system
Software
installation
Install software according to a plan The installation should be 
verified against requirements and basic operation checked and 
documented
Software
acceptance support
Support the end users acceptance review and testing of the product 
Provide continued training and support
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2 2 41  The Capability Maturity Model
The Capability Maturity Model (CMM) from the Software Engineering Institute (SEI) 
of Carnegie Mellon University in Pennsylvania [14], USA, uses a 5 stage maturity 
framework to allow growth in capability with the objectives of improving software 
development processes and improving software quality The model is centred on the 
principles of sustained continuous process improvement and sound quality 
practices The model used derives many of its principles from the recognised quality 
gurus like Crosby, Deming and Juran It defines a maturity level as
“A well-defined evolutionary plateau toward achieving a mature software process"
[14]
The CMM [14] was developed in the USA with military sponsorship It was intended 
for evaluating US Department of Defence software contractors but has been 
adopted by civilian software developers worldwide [123] It consists of five levels of 
organisational software process maturity levels CMM organisations must pass 
through each level
Each level is focused on moving to the next level The final level requires 
continuously improving beyond the requirements of that level Although CMM does 
not tell how to get to the next level, it gives high-level guidance on where an 
organisation needs to be to have achieved it There are a series of ‘Key Process
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Areas' or KPAs that must be established for any given level to be seen as complete 
The maturity levels, and the KPAs associated with them are detailed in table 
2 2 4  1 1
Table 2 2 41 1 The maturity levels and the Kej
associated w ith the CMA
f  Process Areas (KPAs)
Maturity Level Characteristics o f maturity level Key process areas
1 Initial Ad hoc, chaotic processes Success 
based on individual effort
None
2 Repeatable Basic project management 
processes for finance, schedule and 
functionality Can be repeated for 
instances of similar projects
Software configuration 
management
Software quality assurance 
Software subcontract 
management
Software project tracking and 
oversight
Software project planning 
Requirements management
3 Defined A single defined organisational 
software process approach in use 
that pervades management and 
engineering functions
Peer reviews 
Inter-group coordination 
Software product 
engineering 
Integrated software 
management 
Training program 
Organization process 
definition
Organizational process focus
4 Managed The defined process and product 
quality are measured, controlled and 
understood
Software quality 
management 
Quantitative process 
management
5 Optimizing The process is continually approved 
through use of quantitative feedback 
and innovative techniques
Process change 
management 
Technology change 
management 
Defect prevention
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The CMM identifies five common features of the key process areas These are
1 Commitment to perform including establishing policies and senior management 
sponsorship
2 Ability to perform, including training and organisational structure
3 Activities performed, including procedures and tracking
4 Measurement and analysis
5 Verifying implementation, typically through audits and software quality assurance 
initiatives
The CMM has become a d e - f a c t o  standard for software processes and for assessing 
organisational capability maturity, it is probably in wider use in the US than the ISO 
9000/9001 series of standards for quality and software development [118][124]
The SEI CMM can be used as a framework to support the process improvement 
aspects of TQM for software developers [99] TQM can be seen as the integration of 
project, process and quality management for software development Measurement 
and analysis is important as a means of quantifying current performance trends and 
making improvements in software quality
Because of the complexity of software and the invisible nature of the building blocks 
of the finished product, structure is required in software design and testing A quality 
system can fulfil this role and CMM can be used for this purpose
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Software Quality Engineering (SQE) within the CMM involves quality development 
elements, which are prospective in order to achieve quality in the software product, 
as well as Quality Assurance (QA) to assure that the required quality is achieved 
Activities in development include tasks such as requirements engineering, system 
and software design and implementation of the software Activities in QA include 
SQA, general quality management and testing SQA is said to be all those activities 
that provide independent assurance that prescribed processes and procedures are 
adhered to These processes and procedures are defined through the quality 
management effort within a CMM environment
2 3 Comparisons between quality management systems and the development
of primary practice criteria
Some of the review work for this thesis involved near exhaustive trawls of the 
literature on quality management in order to develop sets of criteria and measures 
reflective of effective quality practices This section extracts from and expands on 
that work but does not aim to repeat it This work aimed to limit the number of 
constructs required for the survey to a manageable, practical level Appendix D 
outlines all the literature reviewed and the corresponding criteria deemed important 
by the respective literature reference The main findings from the review of these 
criteria are discussed below in section 2 3 1 The criteria that were for further 
consideration in this work are summarised in section 2 3 2
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2 3 1 Overview of collated quality practice criteria
Adam et al [31] used average percent items defective, cost of quality and customer 
satisfaction to measure quality performance Rao, Ragu and Solis [94] identified 
seven general factors that underlie quality practices
1 Leadership
2 Information and analysis
3 Strategic quality planning
4 Human resource development
5 Quality assurance system
6 Supplier relationships
7 Customer orientation
The European Quality Award (EQA) [16] from the European Foundation for Quality 
Management (EFQA) used two sets of criteria for establishing levels of 
organisational excellence These could be broken into ‘enabler’ criteria and ‘results’ 
criteria Specific parameters for performance measurement were not provided 
Applicants must submit information on how they assess the criteria within their 
organisations together with any results and targets Information about competitor’s 
performances and ‘best in class’ performance was also required (where available) in 
the model The five ‘Enabler’ criteria and four ‘Results’ criteria were each given a 
50% weighting of the total score Each main criterion was also given an even
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weighting within their criteria type For example, ‘Leadership’ and ‘Processes’ each 
had a 10% weighting of the total score ‘People results’ and ‘Society Results’ each 
had a 12 5% weighting
The criteria used to assess EQA applicants together with their weighting, is 
produced in table 2 3 1 1  below
Table 2 3 11 The criteria used to assess EQA [16] applicants together with 
 i________  their weightings_____________ ____________
Criteria
Number
Type Criteria / Sub Criteria Name W eighting o f sub- 
criteria (as a 
percentage o f 
criteria)
1 Enabler L e a d e r s h i p
a Leaders develop the mission, vision, value and 
ethics and are role models of an excellence 
culture
20%
b Leaders are personally involved in ensuring 
the organisation’s management system is 
developed, implemented and continuously 
improved
20%
c Leaders interact with customers, partners and 
representatives of society
20%
d Leaders reinforce a culture of excellence 20%
e Leaders identify and champion change 20%
2 Enabler P o l i c y  a n d  S t r a t e g y
a Policy and strategy is based on the present 
and future needs and expectations of 
stakeholders
25%
b Policy and strategy are based on information 
from performance measurement, research, 
learning and external related activities
25%
c Policy and strategy are developed, reviewed 
and updated
25%
d Policy and strategy are communicated and 
deployed through a framework of key 
processes
25%
3 Enabler P e o p l e
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Criteria
Number
Type Criteria / Sub Criteria Name W eighting o f sub- 
criteria (as a 
percentage o f 
criteria)
a People resources are planned, managed and 
improved
20%
b People’s knowledge and competencies are 
identified, developed and sustained
20%
c People are involved and empowered 20%
d People and the organisation have a dialogue 20%
e People are rewarded, recognised and cared 
for
20%
4 Enabler P a r t n e r s h i p s  a n d  R e s o u r c e s
a External partnerships are managed 20%
b Finances are managed 20%
c Buildings, equipment and materials are 
managed
20%
d Technology is managed 20%
e Information and knowledge are managed 20%
5 Enabler P r o c e s s e s
a Processes are systematically designed and 
managed
25%
b Processes are improved, as needed, using 
innovation in order to fully satisfy and generate 
increasing value for customers and other 
stakeholders
25%
c Products and services are designed and 
developed based on customer needs and 
expectation
25%
d Products and services are produced, delivered 
and serviced
25%
6 Results C u s t o m e r  R e s u l t s
a Perception Measures 75%
b Performance Indicators 25%
7 Results P e o p l e  R e s u l t s
a Perception Measures 75%
b Performance Indicators 25%
8 Results S o c i e t y  R e s u l t s
a Perception Measures 25%
b Performance Indicators 75%
9 Results K e y  P e r f o r m a n c e  R e s u l t s
a Perception Measures 50%
b Performance Indicators 50%
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The Malcolm Baldnge National Quality Award (MBNQA) provided criteria for quality 
and business performance measurement used extensively in both the literature and 
in business [15] The American NIST (National Institute of Standards and 
Technology) sponsors the award scheme The criteria were developed and based 
on a set of defined core values and concepts These values and concepts were
1 Leadership
2 Customer driven excellence
3 Organisational and personal learning
4 Valuing employees and partners
5 Agility (capacity for rapid change and flexibility)
6 Focus on the future
7 Managing for innovation
8 Management by fact (using measurement and performance analysis)
9 Social responsibility
10 Focus on results and creating value, and a systems perspective
Seven criteria were detailed for performance measurement by the system They 
were scored according to the following table 2 3 12 based on a maximum score of 
1000
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Table 2 3 1 2  Criteria and scoring system fo r the MBNiQA
Criteria Score Total
1 L e a d e r s h i p 1 2 0
1 1 Organisational Leadership 70
1 2 Social responsibility 50
2 S t r a t e g i c  p l a n n i n g 8 5
2 1 Strategy development 40
2 2 Strategy deployment 45
3  C u s t o m e r  a n d  m a r k e t  f o c u s 8 5
3 1 Customer and market knowledge 40
3 2 Customer relationships and satisfaction 45
4  M e a s u r e m e n t ,  A n a l y s i s  a n d  k n o w l e d g e  m a n a g e m e n t 9 0
4 1 Measurement and analysis of organisational 
performance
45
4 2 Information and knowledge management 45
5  H u m a n  r e s o u r c e  f o c u s 8 5
5 1 Work systems 35
5 2 Employee learning and motivation 25
5 3 Employee well-being and satisfaction 25
6  P r o c e s s  M a n a g e m e n t 8 5
6 1 Value creation processes 50
6 2 Support processes 35
7  B u s i n e s s  r e s u l t s 4 5 0
7 1 Customer focused results 75
7 2 Product and service results 75
7 3 Financial and market results 75
7 4 Human resource results 75
7 5 Organisational effectiveness results 75
7 6 Governance and social responsibility results 75
Aziz, Chan and Metcalfe [125] surveyed the use of a series of quality techniques 
when comparing quality practices in UK and Malaysian manufacturing These 
techniques were specific to each area of the production process and to employees 
of the company They are summarised in table 2 3 13
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Table 2 3 1 3  Quality techniques used in UK and Malaysian manufacturing
[125]
Operations Quality Technique
Goods In 100% inspection
Sample inspection
No-inspection -  rework at own expense
No-inspection -  rework at supplier’s 
expense
No inspection -  supplier’s QA reliable
JIT
Manufacturing 100% inspection
Sample inspection
Control charts on process variables
Control charts on results of 100% or 
sample inspection
Process capability studies
Failure mode and effects analysis
Goods out 100% inspection
Sample inspection
Product audits
Design Market research
Quality planning
Failure mode and effects analysis
Process capability studies
Statistically designed experiments
Taguchi experiments
Employees Written quality policy
Quality awareness campaigns
Quality training programmes
Customer surveys
Quality costs
Written work procedures
Inter-departmental quality improvement 
teams
Intra-departmental improvement teams
Quality facilitators
Employee suggestion schemes
‘Seven basic tools for QC’
Deming cycle
‘Seven management tools for QC’
ISQ9000 registration
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Crosby [78] defined the cost of quality as the expense of doing things wrong He 
developed a 5-stage maturity model for organisational quality management Level 1 
is ‘Uncertainty’ meaning that quality is thought of at the low levels in a company, 
there is measurement of Cost of Quality (COQ) and that management are in denial 
of the need for better quality management Level 2 is ‘Awakening’ Here firms 
recognise that quality management can help and there is inspection and testing 
earlier in the process than for an 'Uncertainty' firm There is a reluctance to allocate 
resources, improvements are near sighted and the quality system is disorganised 
Level 3 is ‘Enlightenment’ Here a formal quality improvement structure exists, an 
organised quality unit, a no blame culture and cost of quality is measured in some 
way Level 4 is ‘Wisdom’ which encounters very few or no quality problems When 
they occur, they disappear quickly Accurate and realistic quality costs are obtained 
People wonder why the quality department exists Level 5 of Crosby’s maturity scale 
is ‘Certainty’ In a Certainty firm the Quality Manager is considered vital and is on the 
board of directors There is dynamic and continuous restructuring of the quality 
improvement teams
Crosby [78] offers a self-administered tool for firms to establish their quality 
management maturity level The criteria therein was modified and included in this 
study when determining the quality maturity of firms being surveyed Several 
statements were made in Crosby’s tool about quality practices that relate to each 
level of maturity The respondent then selects one statement that most closely
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describes their practice A set of statements for each level of maturity is presented 
for seven categories
1 Management understanding and attitude
2 Quality organisational status
3 Problem handling
4 Cost of quality as a percentage of sales
5 Quality improvement actions
6 Summation of company quality posture
A problem with the tool is that the statements are made in a table where the heading 
is the level of maturity Hence, a respondent who sees their employer as having a 
'Certainty' culture might mark the certainty column statements regardless of their 
accurate quality management posture It was necessary therefore when determining 
maturity levels from a survey to separate the statements so that the respondent 
does not know the implications of selecting a particular statement as being the 
closest description of their practices
In obtaining quality practice scores by survey, very few of the standard quality 
measures considered vital in other research were considered by Lee et al [82] 
although the MBNQA [15] criteria are referred to in their work Omissions include 
process improvement and management commitment
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The paper by Ismail and Hashmi [28] identified six main elements, for use in a 
survey, as being critical to quality commitment determination These were 
management commitment, education and training, feedback measurement, total 
employee involvement, technological factors and continuous improvement The 
MBNQA [15] criteria were used heavily in the derivation of these criteria
From a trawl of the TQM literature by Yee Tsang and Antony [126], several factors 
were identified as being critical success factors for TQM The factors were classified 
as
1 Customer focus
2 Teamwork and employee involvement
3 Continuous improvement
4 Top management commitment and recognition
5 Training and development
6 Quality system and development
7 Supervisory leadership
8 Communication within the company
9 Supplier partnership and supplier management
10 Measurement and feedback
11 Cultural change
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In their survey, Yee Tsang and Antony [126] found that 'Customer focus', 
‘Continuous improvement’ and ‘Top management commitment and recognition’ were 
the most critical success factors in the UK service industry This is deemed to be 
consistent with the general consensus for manufacturing industries
If the TQM programme is not implemented correctly, then business performance 
may not be positively affected [127] Hackman and Wageman [127] listed seven 
change principles and five practices that should be in place for an organisation's 
quality management to be considered total
Hackman and Wageman’s [127] Change principles
1 Focus on work in progress
2 Analyse variability
3 Manage by fact
4 Commitment to learning and continuous improvement
5 Knowledge of customer requirements as a test for evaluating change
processes
6 Supplier partnerships to ensure that materials entering the organisation are of
acceptable quality
7 Cross-functional teams for decision making on system wide problems
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Hackman and Wageman’s [127] Key practices indicative of total quality
1 Formation of short-term problem solving teams
2 Training
3 Top down implementation
4 Developed supplier relationships
5 Obtain data about customers
McAdam and Bannister [128] used these principles and practices as a measuring 
framework for business performance and change management within TQM 
Customer focus was again deemed to be a major factor in any quality practice 
measurement survey
The case study carried out into quality performance within a TQM company by 
McAdam and Bannister [128] used measures that were categorised under the 
headings of
1 Leadership and management commitment
2 Policy and strategy
3 Processes
4 Employee resource
5 Business results
6 Customer satisfaction
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7 Teamwork
8 Employee motivation
Parzmger and Nath [129] identified eight TQM implementation factors that positively 
affected software quality based on survey data from software development houses 
and the literature
1 Employee empowerment
2 Quality measures and tools
3 Executive commitment
4 General Training
5 Customer needs assessment
6 Process evaluation
7 Quality training
8 Cycle time reduction
These eight criteria were compared against both the MBNQA [15] criteria, and also a 
selection of research works from the literature on TQM The comparison matrix in 
Parzinger and Nath [129] showed that all eight factors covered all the MBNQA 
criteria and the criteria derived from the five research papers considered Employee 
empowerment, customer needs assessment and specific skills training were 
deduced to be the three most important implementation factors In addition to TQM,
89
customer satisfaction was found to have positive association with the CMM maturity 
level attained by a firm [129]
In terms of the measurement criteria used in software environments, it has to be 
understood that there are broad similarities between CMM SQA criteria and ISO 
9001(118] and a short analysis is necessary to deduce criteria Although they both 
require internal auditing of quality systems compliance, the methodology employed 
by each is different SQA reports audit results directly to the source of the findings as 
well as to management, whereas ISO 9001 generally involves reporting to quality 
management and up to senior management
The ISO 9000-3 [76] standard compares with the SEI CMM [14] model in that they 
both require defined and formalized software processes, standard objective 
evaluations by independent assessors and continuous internal audits with a view to 
product and process improvement [130] The ISO standard is not as detailed or 
formalised as the CMM standard, but it has a greater organisational reach, starting 
at top management The CMM standard is more relevant to sub-projects within a 
greater organisation
Ghosh [123] recognises that the CMM and the ISO 9000 series have much in 
common Ten major commonalities are summarised, and seven fundamental 
differences in his paper Also, four process elements are identified as unique to each 
system The commonalities and differences are identified in table 2 3 14
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Table 2 3 1 4  Commonalities and differences between ISO 9000 software 
____________standards and the CMM based on Ghosh [1 2 3 ]___________
Commonality Difference Process elements 
unique to ISO 
9000
Process elements 
unique to CMM
Both aim at consistent 
delivery of quality
CMM is specifically for 
software development 
ISO is for all industries
Contract
management
Project tracking
Both include quality 
improvement of the 
product
ISO has a corporate 
focus CMM is software 
engineering focused 
only
Purchase and 
customer supplied 
components
Process and 
technology change 
management
Both require quality to 
be planned
ISO is more concerned 
with what to do than 
how to do it CMM has 
more ‘how’ information
Personnel issues 
(other than training)
Inter-group 
coordination to meet 
customer 
requirements
Both require high level 
commitment and formal 
quality statements
CMM is technically 
detailed ISO is not
Packaging, delivery 
and installation
Organisation wide 
process focus, 
process development 
and integrated 
management
Both emphasise 
prevention over 
correction of faults
ISO has a pass/fail 
certification structure 
CMM has levels of 
maturity
Both require formally 
documented processes
CMM has a stepwise 
sequence for 
compliance ISO has 
no sequence
Both require adherence 
and monitoring of 
processes
There are unique 
process elements 
exclusive to each 
system
Both require that 
process outcomes be 
documented
Both require 
management review of 
processes
Both require continuous 
process improvement
Both models have product quality, process focus, use of quantitative evaluation, and 
review and improvement as central requirements
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There was general recognition in the literature that good software quality is not the 
norm Radding [131] identified seven steps for success for software quality These 
were
1 Management commitment
2 Creation of a common quality language
3 Quality as a design function
4 Building testability into development
5 A measuring quality system
6 Management and measuring of testing trends
7 Investment is automated software quality solutions
Rubey and Brewer [132] compare nine SQA standards all of which evolved from US 
military standards including ANSI/IEEE STD 730 [122], NATO standards, Australian 
and Canadian SQA standards They deduce that the degree of commonality 
between the various standards means that a single model can be used to comply 
with all the standards A summary of the requirements for an all-encompassing 
model derived by Rubey and Brewer [132] is produced below
1 Organization details
2 Quality assurance plans
3 Standards, practices, procedures and conventions
4 Requirements evaluation
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5 Design evaluation
6 Test evaluation
7 Reviews and audits
8 Evaluation of software development processes
9 Library control
10 Configuration management
11 Subcontractor control
12 Non-developmental, non-deliverable and customer supplied items evaluation
13 Problem reporting and corrective action
14 Preparation for delivery/approval for release
15 Quality records
16 Audit of SQA
17 Rights and responsibilities of customer or contracting organisation 
2 3 2 Summary of quality assessment criteria
It is important to stress that the criteria noted are taken from specific measuring 
tools, appraisal systems and research conclusions within the literature reported on It 
is not suggested that other factors are not deemed important by the referenced 
authors For example, although the CMM does not explicitly require a lifecycle 
approach, this does not mean that such an approach is unimportant to achieving 
improved CMM maturity levels Likewise, Crosby’s maturity test does not explicitly
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mention customer satisfaction, although Crosby [78] espouses the importance of this 
readily
The quality practices criteria in Appendix D were then summarised and reduced 
(table 2 3 2  1), each “sub criterion” of the appendix being either equivalent to or 
implicit in the main criteria stated in the table
Table 2 3 2 1 Collated and summarised quality assessment criteria
No Main Criteria Incorporated sub criteria from Appendix D
1 Training and 
development
Information and knowledge management
Training and employee development
Organizational and personal learning
2 Defect
management Average percent items defective
Defect prevention
3 Cost of quality Cost of quality
4 Customer focus 
and feedback Customer focus and satisfaction
Stated rights and responsibilities of customer and 
contracting organization
Obtain data about customers
Customer feedback driven improvement
5
Problem handling
Problem reporting and corrective action
Formation of short term problem solving teams
6 Quality system 
infrastructure
Sound quality system infrastructure
Infrastructure
Financial, building and equipment management
7 Leadership The role of supervisory leadership
Top management leadership, commitment and 
recognition of quality
8 Communication Communication within the company
Creation of a common quality language
9 Quality planning Strategic quality planning
Quality assurance plans
10 Supplier Supplier partnership and supplier management
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No. Main Criteria Incorporated sub criteria from Appendix D
management
Subcontractor control
Non-developmental, non-deliverable and customer 
supplied items evaluation
11 Software lifecycle 
approach Lifecycle approach
12 Measurement Measurement and feedback
13 Documented quality 
policies and 
responsibilities Explicit organizationally linked policies
Defined roles and responsibilities
Quality manual
14 Use of standards, 
practices, 
procedures and 
conventions
Use of standards, practices, procedures and 
conventions
15 Requirements 
management and 
evaluation Requirements evaluation
Requirements management
16 Reviews and audits Management review of processes
Evaluation of software development processes
Audit of SQA
Quality reviews and audits
Design evaluation
17 Software control Software library control
Configuration management
Change management and control
18 Testing
management Test evaluation
Validation and testing plans
Building testability into development
19 Cultural change Cultural change
20 Quality as a design 
function Quality as a design function
21 Automated software 
quality products Automated software quality products
22 Teamwork, human 
resource
management and 
employee 
involvement / 
motivation
Teamwork, human resource management and 
employee involvement / motivation
Continuous quality improvement
95
No Mam Criteria Incorporated sub criteria from Appendix D
23 Quality driven
documented
processes Documented and systematic processes
Quality records
24 Use of quality tools Use of quality tools
25 Cycle time 
reduction Cycle time reduction
26 Preparation for 
delivery / approval 
for release and 
product realization
Preparation for delivery / approval for release and 
product realization
27 Capacity for rapid 
change and 
flexibility Capacity for rapid change and flexibility
28 Focus on the future Focus on the future
29 Managing for 
innovation Managing for innovation
30 Social responsibility Social responsibility
31 Service provision Service provision
32 Project 
management 
tracking and 
oversight Project management tracking and oversight
33 Risk management Risk management
The above 33 criteria were used as a starting point to evaluate the effectiveness of a 
quality management effort for developers and manufacturers of automated and 
computerized systems However, many of these 33 criteria overlapped and could be 
further summarised into 21 criteria as presented below
Thus, finally, the criteria used to assess quality practices were
1 Training and development
2 Cost of quality
3 Customer focus and feedback
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4 Quality system infrastructure
5 Leadership
6 Communication
7 Quality planning
8 Supplier Management
9 Software lifecycle approach
10 Measurement
11 Documented quality policies and responsibilities
12 Use of standards, practices and procedures
13 Requirements management and evaluation
14 Reviews and audits
15 Software control
16 Testing management
17 Teamwork, human resource management and employee involvement 
motivation
18 Quality driven documented processes
19 Preparation for delivery / approval for release and product realization
20 Service provision
21 Risk management
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2 4 Regulatory Practice Measurement
Derivation of regulatory related constructs was not straightforward as there was no 
existing literature from which to extract constructs Therefore a new set of variables 
had to be constructed based on themes derived from industrial literature and trade 
journals, elaborated on in section 2 1 of the literature review [8][9][13][40][49][50] 
Several factors emerged as being important for suppliers of systems in order to 
achieve compliance as discussed It was important for suppliers to have knowledge 
of the GMP regulations, and the ability to apply them to the development and 
delivery of their products The extent of use of the GAMP guide is also a good 
indicator of the compliance level of a company, although it is not suggested that 
compliance cannot be achieved without it The regulations apply to the lifecycle of 
any given automated system and require objective evidence of validation and the 
design approach Hence, availability of design and validation documentation from 
the supplier is essential Many validation features are also required to be built into 
systems, as it may not be impossible to test for aspects of system behaviour without 
these features An extremely important aspect of regulatory compliance since 1997 
has been the emergence of the Part 11 This regulation has had a huge impact on 
the compliance requirements for suppliers of computerised systems in terms of 
requirements for built in capability to ensure electronic record and signature integrity 
A further requirement for compliance with US regulations is that the suppliers make 
some provision to make source code available to manufacturers, either directly or
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through third party agreements Finally, the use of regulatory design reviews for 
software is a feature that would indicate involvement in regulatory activities These 
regulatory criteria were used to evaluate the extent of regulatory practices by 
respondents and are detailed in table 2 4 1
Table 2 41 Literature derived variables considered critical to regulatory
___________________________ practices____________________________
Regulatory Variable
Extent of direct use of GMPs in design
Extent of provision of design documentation
Extent of provision of validation documentation
Extent to which validation features are designed into products
Extent to which other regulatory requirements are designed into the software
Extent of use of the GAMP guidelines
Extent of regulatory training for system developers
Knowledge and application of rules for electronic records and electronic
Availability of source code to manufacturers
Extent of planning of regulatory activities into design
Extent of regulatory design reviews
2 5 Business performance measurement
A review of the literature revealed a number of common measures for determining 
business performance in survey research The requirements for this study were a 
set of simple common measures to all companies that were likely to be revealed by 
survey respondents This section first looks at the measures used in the literature, 
then collates them It then briefly discusses those criteria in terms of study 
usefulness
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Rather than evaluate respondents own performance measures, which can often be 
misguided, global ‘hard’ business performance measures must be obtained 
according to some [133] There were a variety of performance measures in use by 
businesses which vary between soft internal measures such as flexibility and quality 
performance to hard measures such as productivity and profit and cost measures 
[134]
Financial measures alone may not necessarily be relied on as sole performance 
measures There are shortcomings with relying solely on these measures for 
business performance measurement particularly as they do not assess internal soft 
measures such as resource utilisation, flexibility, innovation and so on [135] 
Although not a true reflection of performance in the global sense, competitiveness 
and financial measures are results, which can be measured and used to determine 
an organisation's general performance from an external viewpoint
To follow the advice of Leandri [136], simplicity is the key to performance 
measurement There were salient themes found in the literature regarding how to 
measure hard and soft business performance
Adam et al [31] used net profit as per cent of sales, past year return on assets, and 
average past 3 years sales growth as business performance indicators
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The dependent business performance variables used by Forker [80] were after tax 
return on assets, return on investment after tax, growth in return on investment, 
sales growth, market share, growth in market share, return of sales, and growth in 
return of sales These were assessed objectively by Forker [80] in a survey by 
asking respondents for actual figures, and also assessed subjectively by using 
seven point rating scales Only one third of respondents studied were willing to 
release actual figures
Mole and Worrall [137] used seven business performance indicators in their 
research Sales growth, profit growth, order book growth, export growth, workforce 
growth, training expenditure and business confidence were all used
McAdam and Bannister's [128] research showed that TQM could impact positively 
on ‘hard’ business performance measures although the business measures were 
mostly related to internal efficiency The case study research showed increase in 
production orders and the product range on offer over the longitudinal study 
timeframe These were two significant 'hard' business performance measures that 
could potentially have been used in a study
Lee et al [82] used net profit as a percentage of sales and annual employee turnover 
rate to measure operating performance and last year’s return on assets, last three 
year's return on assets, and past three years sales growth to measure performance, 
in their study of the effects of quality systems in Hong Kong industry
I
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Suggestions were given in the MBNQA award criteria booklet for possible financial 
measures of performance [15] These were
1 Revenue
2 Profits
3 Market position
4 Cash-to-cash cycle time
5 Earnings per share
6 Returns
For marketplace performance, the following indicators were suggested
1 Market share
2 Measures of business growth
3 New products and markets entered
4 Percentage of sales from new products
It is primarily these four MBNQA performance indicators which were used as the 
primary business performance criteria for this study as they can encompass many 
other measures
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A collation of the e n t i r e  list of business performance indicators denved from the 
literature is produced in table 2 5 1
Table 2 51 A collation o f the hard business performance indicators 
discovered in the literature review
Performance Indicator
1 Net Profit as a percent of sales
2 Profit growth
3 Past year return on assets
4 Past 3 years return on assets
5 After tax return on assets
6 Return in investment after tax
7 Growth in return in investment
8 Sales growth
9 Average last 3 years sales growth
10 Market share
11 Growth in market share
12 Return of sales
13 Growth in return of sales
14 Order book growth
15 Export growth
16 New markets
17 Percent of sales from new products
18 Increase in product range
19 Business confidence
20 Training expenditure
21 Annual employee turnover rate
Applying sets of these indicators to the widely used MBNQA criteria gives the 
derived criteria in table 2 5 2 By mapping some of the measures in table 2 5 1 onto 
the MBNQA indicators, a focused set of measurement criteria was acquired, which 
was used to form the basis for the questionnaire constructs
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Table 2 5 2 MBNQA [15] suggested indicators of business performance and
iterature derived proposed measures for assessing the indicators
No MBNQA Indicator Proposed Measure
1 Market Share Market share
2 Growth i n  market share
3 Measures of business growth Net profit as a percent of 
sales
4 Profit growth
5 Sales growth
6 Average past 3 years sales 
growth
7 Order book growth
8 Workforce growth
9 New products Increase in product range
10 Percent sales from new products Percent sales from new 
products
This left a total of ten simple hard measures of business performance, which were 
used to develop the business criteria for the questionnaire It is not suggested that 
the remaining measures in table 2 5 1 are trivial, only that the above ten measures 
were adequate to get a realistic and attainable picture of the business performance 
of a system developer
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2 6 Summary of literature review and derivation of study variables
The literature review looked at the pharmaceutical regulations as they pertained to 
automated and computerised systems and how the development of such systems 
must proceed in the regulated environment It looked at the area of quality 
management and its effectiveness, entailing a comparison and selection of a set of 
quality criteria that can be used to evaluate quality effectiveness in organisations 
involved with the development of the systems under study A set of regulatory 
criteria was extracted from themes in the literature Literature on business 
performance indicators was reviewed and a set of criteria determined to establish 
such performance from a survey instrument
i
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Chapter 3: Methodology
Bell, McBride and Wilson [92] recommend the use of surveys in obtaining accurate 
snapshots of organisational and quality status It was important though not to end up 
with an attitude survey rather than a representative quality, regulatory and business 
snapshot Questionnaire wording and variable selection were critical in ensuring this 
The design of the instrument and derivation of meaningful variables was essential to 
a successful survey
3 1 The survey instrument
This research used an e-mail questionnaire in conjunction with a web based survey 
and an option for postal submission by respondents The use of such survey 
methodology has been addressed in the literature It must be said however that as 
time goes on, e-mail usage and familiarity increases in all sectors of life Thus some 
of the earlier research findings in the literature may no longer be entirely transferable 
to contemporary settings
There is evidence from the literature of an increase in the use of e-mail in survey 
research [138] The advantages associated with e-mail surveys are its capacity to 
allow processing of large amounts of information and to increase interaction
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between researchers and respondents [139] However, there are limitations in terms 
of response rates, which ranged from 1% to 6% [139]-[142]
The target audience is very important in survey research, particularly so in e-mail 
surveys, as the requirement for routine and established Internet and e-mail usage by 
the respondents is vital By selecting a group (as is the case in this work) that uses 
e-mail as a core part of its business then higher response rates should be expected
The important factors attributed to low response rates by Ranchhod and Zhou [139] 
were
1 The inherent lack of anonymity by using e-mail
2 The lack of formality that may be attributed by some to e-mail
3 No incentives offered to the respondents such as prizes or research results
4 The layout of the e-mail in terms of its aesthetics and flexibility of use
Schaefer and Dillman [143] reported on the response rates achieved in various 
research surveys In most cases postal survey response rates were larger than for 
e-mail surveys They collate the published factors attributed to the low response 
rates and formulate a standard methodology This methodology however involves 
inserting the actual questionnaire into the text of the mail message rather than the 
more favoured method of using the e-mail to point to a web site as described by 
Klasson and Jacobs [144] The speed of e-mail fared better than for postal mail in all
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cases where this was reported The number of times that a respondent was 
contacted also had a positive bearing on ultimate response rates The main features 
of the standard method suggested and used by Schaeffer and Dillman [143] were
1 Pre-notification of intent to survey
2 Personalisation (using the persons name rather than a ‘dear sir’)
3 Thank you mails and reminders
4 Provision of replacement questionnaires
5 Careful design of the page to reduce cognitive effort on behalf of the 
respondents
6 Users must simply send a reply to the researcher and populate the response 
email with X’s and answers to open ended questions
7 Option to return by post
8 Repeat contact
9 Non-use of the Carbon Copy or Blind Copy functions of e-mails to ensure mail 
is not perceived as spam mail
Their experiment using this methodology yielded much i m p r o v e d  response rates 
from that in previous literature as reported in their paper Response rates between 
8% and 73% have been reported dependent on the target population Average rates 
were reported from the literature as 23 5% for single contacts and 41% for two 
contacts, and even greater again for three contacts Mixed mode studies using a
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combination of both email and postal questionnaires could also help boost response 
rates [145]
The use of new technologies in survey research has the potential to introduce 
respondent bias In e-mail surveys these may be related to the computer literacy of 
the target sample, the availability of e-mail of target respondents or company policy 
for responding to e-mail [144] Access to web based technology and available 
resources for completing questionnaires may favour larger firms E-mail 
questionnaires offer advantages in terms of turnaround speed and international 
access It may also be possible to carry out censuses of entire international 
populations in ways that would not be practical for postal surveys On the 
assumption that e-mail and Internet access is freely available to the researcher, the 
cost advantage over postal surveys is important Ease of follow up and the ability to 
thank respondents are also advantageous [144] E-mail can be used in three ways 
Firstly, by inserting the questionnaire into the e-mail text, secondly by attaching a 
questionnaire to a mail, and thirdly by providing a web link on the e-mail which 
hyperlinks onto a web survey page When using attachments, consideration must be 
given to the file format of the document Several types should be considered Using 
web software makes collection of data easy A disadvantage though is that 
unintended respondents can access the web and fill in the questionnaire Web 
based surveys are likely to succumb to the same ‘survey fatigue’ as other types of 
survey, leading to reduced response rates [146]
109
Trust, cost and rewards are three critical considerations when designing the 
instrument The trust of the potential respondents must be obtained Costs to the 
respondents (in the form of time and resources) should be consciously minimised 
and some form of reward or incentive should exist to encourage respondents This 
may be in the form of an offer of the results of the research findings Advanced 
contact and follow-ups both assist in achieving a worthwhile response rate Some 
research suggests [140] [147] that e - m a i l  response rates were not as good as for 
paper based postal surveys However the use of self-selected groups or 
convenience samples [143] [148] can enhance response rates Klasson and Jacobs 
[144] suggest therefore that sending questionnaires to a random sample may not be 
beneficial However, care has always to be taken to ensure that a convenience 
sample is a representative one which will not introduce bias
From reviewing the literature it was clear that electronic administration of a 
questionnaire was an acceptable means of survey research, particularly when an 
international reach was required The guidelines and methodologies suggested by 
Schaeffer and Dillman [143] and Ranchhod and Zhou [139] were adhered to as 
much as possible so as to maximize coverage and respondents, hence attempting to 
avoid non-response bias It was hoped that familiarity in computing technology by 
respondents would be advantageous and would yield higher response rates than 
forecasted by the literature
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3 2 Sampling strategy
The sampling frame consisted of the selection of suppliers of automated and 
computerized systems found in the P h a r m a c e u t i c a l  T e c h n o l o g y ’s  B u y e r s  G u i d e  [11] 
The guide represented almost two thousand suppliers of all sizes and relevant 
product types from which a qualified survey population was selected consisting of 
original equipment manufacturers and system developers Suppliers from all sectors 
including materials, contract analysis and laboratory services were included in the 
guide and were not relevant to this work
The buyers guide had an international reach and claimed to have 80% coverage of 
worldwide suppliers to the pharmaceutical industry This figure is statistically based 
as stated by Pharmaceutical Technology [149] There is no evidence either way to 
suggest that the remaining 20% of suppliers have characteristics any different from 
the proportion of the population included in the guide Therefore it was assumed that 
the 80% of suppliers would adequately represent the population
E-mail addresses were acquired from the Internet for every potential respondent and 
a database was compiled consisting of these addresses and the supplier's names 
No distinction was made between large or small companies or the types of products 
produced, once each supplier could be placed in the category ‘develops automated 
or computerised systems for use in pharmaceutical manufacture'
i l l
Suppliers from the other major journal, P h a r m a c e u t i c a l  E n g i n e e r i n g  [38] were used 
both to validate the 80% claim of P h a r m a c e u t i c a l  T e c h n o l o g y  [11] and also to top up 
the list of available respondents
The entire sampling frame was then considered to be applicable to the study and all 
were used to create the database of potential respondents for the survey
3 3 Questionnaire administration strategy
The survey questionnaire was pre-tested by university staff and by selected 
suppliers to the pharmaceutical industry, and then piloted to a group of randomly 
selected respondents after modifications based on the pre-test The returned 
questionnaires were then used to adjust the questionnaire template for the mam 
study This was then administered to the complete sampling frame The 
methodology and guidance provided by Schaeffer and Dillman [143] and Ranchhod 
and Zhou [139] was followed This resulted in the following administration strategy
1 Pre notification of intent to survey by targeting rather than sending to a large 
group of collected e-mails
2 Where possible, acquisition of names of agreed respondents
3 Provision of an attached MS word questionnaire
4 Option to post the responses by paper mail
5 Option of using an instant link to a web survey
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6 Offer to release the survey findings to the respondents on completion of the 
research, which would have competitive advantages
7 Repeated contact
8 Provision of replacement questionnaires when requested
9 Thank you mails and reminders
10 Complete anonymity for respondents This would mean that it would not be 
possible to link suppliers to their survey responses This was assured by 
using the web-based survey host and by extracting data from questionnaires 
returned by e-mail Hence associations between respondents and data was 
not possible once the data was entered into SPSS Assurances of anonymity 
were provided on all e-mail correspondence, the questionnaire instructions 
and on the questionnaire itself
Targeting can help to improve e-mail survey response rates but care should be 
taken not to introduce bias to the survey [150] Targeting involves individual 
communications to potential respondents as distinct from sending mails to a list, 
which can be interpreted by targeted organizations as spam and treated as such A 
form of targeting was used here using carefully constructed emails, an identical mail 
being sent to each potential respondent individually
The questionnaire was carefully designed to ease completion and reduce effort 
whilst maximising the probability of response Guarantees of anonymity were
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provided throughout on all e-mails and the questionnaires The university e-mail 
system was used to assure respondents of the credibility of the study
3 4 Building the Database
The aim of building the database was to produce an international list of potential 
respondents, including contact details Firstly it was thought that a single database 
(Pharmaceutical Technology’s (PT) Buyers guide [11]) would result in a sufficiently 
large and thorough study frame However through validating this with the 
Pharmaceutical Engineering (PE) suppliers listings (from the ISPE) [38], it was found 
that only seventy percent of the test list from PE were found in the PT database The 
test list was made up of all advertising listings in PE over a three-year period from 
2002 to 2004 inclusive
Also, the PT database yielded just 452 potential respondents Adding the qualifying 
companies from PE and those found from other online databases [151]-[153] 
increased the number of potential respondents up to 647 A very small percentage 
(not measured) of the companies included in the databases searched had no 
Internet site or e-mail address These were rare however and deemed small enough 
in number that their exclusion from the study would not introduce any significant 
non-response bias It was hoped that over 100 responses would be obtained leading 
to a response rate of 15% which would be high for an e-mail survey and would 
require an aggressive and well managed survey administration
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Each respondent’s website was searched to ensure that they produced systems for 
use in a pharmaceutical manufacturing market, or that it was quite feasible that the 
products on offer could be used as such (this was supported by the fact that they 
were sourced from a pharmaceutical database) A second criterion was that the 
products had some level of automation This was generally very obvious but in some 
cases the product specifications were assessed or occasionally, the manufacturer 
was contacted The website address and the e-mail addresses were entered into the 
database
Where it was found that companies were part of some global family of companies 
under a single umbrella company, a determination was made as to the 
independence of the sub-companies (usually evident through independent websites 
or independent premises) The sub-companies whose independence was clearly 
determinable were included as separate entries in the database (Where 
independence was not determined, only the parent company was included in the 
database)
All available e-mail addresses were input to the database In many cases the 
addresses were sales addresses The administration procedure used ensured that 
many of the addresses were used for first-contact purposes and as conduits to the 
preferred targets, Quality managers Many of the sites did not provide e-mail
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addresses but online forms instead Again, these could be used as conduits to 
obtaining access to the target questionnaire completion personnel
Once the database was compiled, the potential respondents were contacted by e- 
mail The purpose of the first contact e-mail was to get agreement from respondents 
as to their participation in the study A standard e-mail template was used and a 
series of response e-mail templates were also employed (Appendix A 1) Also, a 
mail template was utilised for non-response follow-ups (Appendix A 2) That is, 
where no response was obtained a follow-up was sent approximately two weeks 
after the first enquiry Once responses were obtained from the follow-ups, the 
original first contact template mail was again employed to inform respondents as to 
the nature of the study
The first contact mail gave an overview of the study, stressed the importance of 
getting a high number of respondents and asked the addressee of the mail to 
participate No carbon copying or broadcast e-mailing was used This would ensure 
that mails were not mistaken for ‘spam’ or nuisance mail The central philosophy of 
the database-building phase was to try and build relationships with respondents by 
e-mail so as to attempt to maximise the likelihood of receiving completed 
questionnaires
The e-mails were sent over two different time frames This had two purposes Firstly 
it meant that response mails could be managed easier allowing more involved
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contact with each respondent Secondly it would help ensure that there were no 
temporal underlying factors affecting the response rates The first batch of mails 
involved 375 entrants A total response rate of 52% was (eventually, see below) 
achieved Of these, 142 or 38% agreed to participate Agreements varied from those 
who wholeheartedly wished to participate to those who would ‘have a look' at the 
questionnaire and make a decision afterwards All respondents were thanked Those 
who agreed to respond were s e n t  another mail to let them know that they would be 
contacted again regarding the questionnaire, once the instrument had been pre­
tested
It was found that very few responses were returned after the initial mailing The 
second mailing, which stated that there had been no response to the first mailing, 
yielded a much higher response rate Third and final mailings (a repeat of the first 
mailing) yielded some success too It was decided that as a rate of 38% (achieved 
after the initial mailing, a reminder and a repeat of the initial mailing) considerably 
exceeded the overall requirement of 15%, and as responses were unlikely from 
those who had not made any contact at all, no further mailings would be sent It is 
hence a finding of this study that adequate response rates using e-mail surveys 
could be achieved using a starting mail and two follow ups It should be said 
however that in the pharmaceutical industry, suppliers are used to receiving 
assessments (which often take the form of a questionnaire) by e-mail This might 
account for the high initial response rate relative to that reported in the literature as 
being typical for e-mail responses
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There were no apparent response patterns from the first mailing lot The 
respondents appeared varied in terms of regulatory environment, organizational size 
and end product type From this there was no evidence or reason to believe that any 
bias was present However, background information gathered from the questionnaire 
would be necessary to clarify and assess respondent characteristics The sampling 
frame itself, as derived from the database, was almost a census frame for the 
defined respondent profile Therefore as there was an equal chance of each 
respondent replying (all were contacted), and no clustering or stratification took 
place, the sampling could be considered to approximate simple random sampling 
As such, no obvious bias was present in sampling and hence no obvious threats 
existed to the external validity of the study
3 5 Questionnaire design
3 5 1  M ethodology
The questionnaire was developed through a number of phases Initially a set of 
questions was drafted which linked to the study variables and to required 
background information In the main, the questions were new to this study The 
questions were designed so as to ensure that they were clearly representative of the 
measure which they purported to represent, thus giving maximum assurance of 
content (face) validity
118
After carrying out an initial reduction of the instrument (from a large number of 
possible questionnaire items, to a smaller number of representative items), a pre­
test was carried out The pre-test was carried out by contacting 5 potential 
respondents from the study database to form a focus group Some of the pre-test 
participants were those who had expressed an interest in the proposed survey 
methodology or in the outcome of the study when compiling the respondent 
database initially Once agreement was achieved a set of instructions was prepared 
(see appendix A 3) for the pre-test The instructions for the pre-test prompted the 
respondent to critically appraise the questionnaire in terms of content, appearance, 
difficulty and validity The quality, regulatory and business performance variables 
identified in Chapter 2 as well as the background variables identified in section 3 5 3 
were also listed as an appendix to the pre-test instructions
A spreadsheet was created using all the variables from the study Every variable 
was then considered separately Constructs were introduced to represent the 
variables based on constructs extracted from the literature or new questions were 
proposed that had a strong relationship with the variable Some of these questions 
(constructs) had to be created anew whereas others were based on themes from the 
literature For example, in the case of the Human resources variable, the literature in 
general states (or merely intimates) that the existence of goals and objectives is a 
consideration that contributes to the strength of human resource management 
Hence this consideration was translated into a question that could be used to assess
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the variable That is, where there are no obvious constructs available, they were 
derived or extrapolated from the general body of literature All questions were later 
evaluated for their relevance and value to the variable that they would represent 
Groups of questions were assessed as to their comprehensiveness towards 
covering all that would be required to get a realistic picture of how the respondents 
performed with respect to each variable Questions were then added or deleted as 
required
The questions themselves were left sufficiently open (linguistically and 
methodologically) so as to be relevant to as many respondents as possible That is, 
specifics were avoided where not required so as to not to preclude differences in 
respondents approaches to each variable This might have an equally beneficial 
effect and become masked were too much direct and specific questioning posed 
Vagueness and ambiguity was reduced through retrospective analysis of each 
construct so as to improve the instrument's reliability A relational analysis was 
carried out between constructs to reduce the amount of questions asked by 
comparing the intent of the questions, and combining them or removing them 
depending on their determined exclusivity Supporting questions were added or 
questions revised where possible ambiguities were perceived Finally a set of 
questions were produced relevant to each variable which were deemed to be of 
sufficient value and independence to warrant inclusion in the questionnaire to be 
pre-tested ‘Nice to have’ questions were eliminated and only required ones were 
used so as not to have a questionnaire that was too large and cumbersome It was
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important to have an instrument that was accessible and did not overburden 
respondents This would have been detrimental to the volume and quality of 
respondent data received
A checklist was prepared before pre-testing which assessed the questionnaire item 
by item The checklist was based on several texts on preparing questions and 
questionnaires for use in survey research [154]-[157] The questions for acquiring 
factual type information usually used four to five point ordinal multiple-choice 
questions whereupon ascending answers on an ordinal list would indicate the 
respondent’s strengths in a particular area For opinion or belief type questions 
Likert-scale related items were used to assess the respondent’s position Odd and 
even ordinal-scaled items were used to avoid potential central tendencies in some 
cases (even) and to allow neutral options in some cases (odd) The use of open- 
ended questions was minimized (only one appeared in the final questionnaire, which 
went largely ignored by respondents)
The checklist was used to assess the general appearance of the questionnaire, its 
length, user friendliness and layout Each individual question was then assessed 
under several headings as derived from the survey research methodology literature
1 Is the question simple?
2 Is the question clear?
3 Is the question manageable or does it involve burdensome tasks?
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4 Does the question contain concepts or nomenclature that may not be in common 
use?
5 Does the question have any ambiguities or does it use any potentially shared 
definitions?
6 Is the question specific enough?
7 Is the question stand-alone? Would any definitions or assumptions be required?
8 Does the question help to exhaustively assess its related variable?
9 Is there any order interference (that is, will the answer to a question be 
influenced by the answer to the previous question) associated with the question 
or could it potentially introduce any order interference?
10 Is the question leading? Does it allow for swings in opinion I position and does it 
allow for any potential neutrality?
11 Could the question be combined with another?
12 Are there sufficient residual ‘others’ available to the respondent?
13 What is the real value of the question? What if it were deleted?
Considerable work was then carried out to the appearance of the questionnaire and 
the instrument was prepared for pre-testing At this stage the instrument consisted of 
134 items and was 10 pages long after considerable attempts at reduction without 
causing excessive bunching of questions The questionnaire was prepared in 
Microsoft Word™ format only Several drafts were produced until a satisfactory final 
pre-test draft was produced
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3 5 2 Structure
The questionnaire was laid out so as to be clear as to what each section was 
attempting to do It was titled ‘Survey of quality practices, regulatory practices and 
business performance for developers of automated systems for use in 
pharmaceutical manufacturing’ The title was so worded as to immediately indicate 
the full scope to the respondent, attempting to ensure that they would not respond if 
their activities were not inside the scope (which was clarified later in questionnaire 
instructions and in the e-mail correspondence with respondents in any case) A 
header was then presented emphasizing the value of returning the completed 
questionnaire due to the limited population of potential respondents, and assurances 
of confidentiality Supplementary to this, the value of the findings of the study to 
respondents was outlined, and instructions for obtaining the results were provided A 
statement was initially included which informed the respondent that input from more 
than one organizational department was likely to be required
The following sections were used in the questionnaire
I Background and qualifying questions
II Organizational Management
III Quality Management Systems
IV Regulatory related practices
V Software quality related practices
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VI Business performance
Section one originally consisted of mostly open-ended background questions used 
to qualify or support the quality, regulatory and business data In general, these 
questions were not related to variables but could be used to understand findings 
Questions included those which attempted to assess company size, complexity of 
code, perceived criticality of products in terms of drug quality and so on as 
discussed in section 3 5 3 Sections II to VI asked questions with direct association 
to one of the study’s variables They, with the exception of section V, were all 
originally 6 point Likert-scale questions preceded by the statement ‘to what extent 
can it be said of your company that ’ Most of these questions had distinctive closed 
ordinal options relating to the variable rather than Likert-type 'strength of opinion' 
items This was to ensure that factual, more objective information was obtained 
where possible rather than the more subjective attitudinal type responses 
characteristic of Likert scale related items Section VI on the other hand asked for 
estimates relating to business performance No absolute figures were required in 
this section originally, just percentages An emphasis was presented on provision of 
comments, and initially it was requested of respondents that they would provide 
alternative hard financial data, where the requested options on the questionnaire for 
business performance were not relevant This was because it was expected (and 
evident from the literature) that business performance measures would differ 
considerably between respondents, which may be due to many factors, of which 
geography (in terms of what market the respondents supply) was likely to be one At
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the header for each section a description was given of what was meant by each 
possible selection on the Likert scale related items This ranged from 0 = 'Not at all’ 
to 5 = To  a great extent’ An explanation of the purpose of the section was also 
provided in the header For each option, instructions were provided which instructed 
the respondent to place an ‘x’ in the box Alternate questions were highlighted in 
grey to provide clear visual delineation between questions, hence avoiding errors 
and aiding clarity
3 5 3 Background Variables
In order to avoid threats to external validity, it was important to establish the context 
in which the respondent’s data was set In order to do this, background variables 
needed to be measured in the questionnaire The length of time a company is in 
business may potentially have an impact on the scores obtained from respondents 
It was not sufficient just to look at time in business, as it was possible that a 
company in business for many years may be recent entrants to the pharmaceutical 
market Hence, it was also necessary to determine how long an organization had 
been active in the pharmaceutical market Similarly, it was necessary to establish 
company size, which could have had an influence on scores
The regulatory and quality environments that respondents operate had to be 
determined, in order to ascertain whether differences existed between respondents 
in differing environments, and whether generalisations could be made The same 
applied to the complexity level of the software used in the respondent’s product, and
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how critical that software was to the end user’s drug quality That is, more complex 
or critical software may lead to more stringent controls and practices by suppliers 
As complexity of software is a difficult thing for respondents to categorise, the time 
taken to develop software was used as an indicator for measuring complexity, where 
low complexity software was that which took in the order of a few months to develop, 
and high complexity software took many months or even years to develop
It was initially anticipated (but removed after pre-testing), that it would be useful to 
determine the effect that regulatory and quality changes had on the end prices of 
products However, these variables were not consistent with the objectives of the 
survey
Many companies develop software at the manufacturer's site and use the in-house 
quality system to do so Hence it was asked whether the developer fell into this 
category, and to what extent they used an independent quality system It was also 
initially suggested that it would be necessary to determine whether the company 
wide quality system applied to the software development environment This was 
eventually removed from the questionnaire, as it was clarified in the survey 
instructions that the questionnaire applied to the software development environment
Finally (post pre-study) two additional background variables were added The focus 
of these was to determine if there were differences in scores between companies 
who had experience with audits by their pharmaceutical customers, or whether those
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customers asked for quality plans. This direct involvement with the pharmaceutical 
industry may have driven supplier behaviour and practices.
The final background variables considered are hence detailed below.
1. Length of time in business
2. Length of time serving pharmaceutical industry
3. Company size
4. Complexity of automation used in products
5. Regulatory environment
6. Extent to which supplier is subjected to customer audits.
7. Extent to which supplier is asked for a quality plan from customers.
8. Criticality of product to drug quality.
9. Organisation type.
10. Quality system independence from client.
11. Quality management environment.
Note that the international focus was not ascertained through looking at the country 
of origin of the respondent, but rather at the market they were supplying. Hence the 
questionnaire asked about whether companies sold into FDA, EMEA, PIC/S, WHO 
or other markets. The reason for this is that it was felt it was not the country of origin 
of the supplier, but the country of drug manufacture (regulatory environment) which 
makes the difference in terms of supplier practices. This has been observed in 
practice by the author with pharmaceutical suppliers.
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3 5 4 Initial reduction and justification of questionnaire items
In order to ensure that each question added independent value to the study, that 
sufficient constructs existed to allow evaluation of the variable represented, and that 
questions were worded clearly and unambiguously, an initial analysis was earned 
out of the survey instrument A phased approach was taken whereby a relational 
diagram was produced showing all constructs representing a given variable 
contained in individual bubbles The relationships between the constructs were 
drawn Relationships to other constructs relating to other variables than the variable 
under analysis were also constructed Reduction then took place by means of a 
qualitative evaluation of the independent value of each construct (that is, what 
unique contribution it would offer) and of the commonality between constructs After 
reducing the list of constructs to those that added high value to the variable, an 
assessment was made as to how thoroughly the variable was served by the 
remaining questions In some cases, supplementary or clarification constructs were 
added to support the variable or another construct In the end the number of 
questions to be asked was only slightly reduced Figure 3 5 41  (for illustration only) 
below shows an example of a relational diagram and the qualitative evaluations 
used to reduce the amount of questions and to assess the thoroughness of the 
construct set
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Variable Quality system infrastructure
ANALYSIS
Question 1 is related to Question 4 As a certified QMS is an indication 
of the use of an established QMS, then Question 4 can be considered to 
add little value to the variable as they essentially ask the same thing 
Therefore Question 4 will not be used
Question 3 is similar to question 5 for the variable 'use of standards and 
procedures’ It is much more closely tied to that variable and will not be 
asked for the infrastructure question
The combination of questions (1, 2, ) provided adequate
coverage for the variable
Figure 3 5 41 Illustrative example of how relational and coverage analysis 
was earned out
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For the open type questions in section I, relational analysis was not used (except for 
those cases where the question was linked to a variable) However, a qualitative 
assessment was carried out which examined the structure of the questions This 
caused improvements in clarity and form In general this resulted in a move to more 
closed type items
3 5 5 The Pre-test
The next stage of reduction was the pre-testing Five respondents who had agreed 
to complete the questionnaire were selected based on their unsolicited stated 
interest in survey research Although these five had many of the characteristics of a 
focus group they did not contact each other at any stage They remained 
anonymous from each other Independent assessments of the questionnaire were 
also sought from two people who had no experience in survey research or the focus 
of the study This was to get non-expert opinion as to the appearance and user- 
friendliness of the questionnaire Appendix A 3 shows the pre-test instructions sent 
out with the draft questionnaires A set of questionnaire completion instructions was 
also sent to the pre-testers The pre-test instructions asked the respondents to feel 
free to criticize, enhance or make suggestions to improve the instrument in whatever 
way they chose It stated the purpose of the questionnaire clearly and asked the 
respondents opinions as to whether they believed that the questionnaire addressed 
what it was supposed to (i e the questionnaire was internally valid) The study 
variables and background variables were presented as an aid to the pre-tester in
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determining the suitability of the questions The respondents were asked to appraise 
both the questionnaire and the instructions Prompts were provided in the form of 9 
questions addressing the simplicity, clarity, difficulty, ambiguity / specificity, burden, 
accessibility, relevance to study questions and variables, and the feelings of the 
respondent regarding the completion of the business performance questions This 
was asked because concerns existed over the intrusiveness and confidentiality of 
proprietary financial information It was important that business performance data 
was acquired in order to answer the research questions
The pre-test resulted in the following findings
1 The questionnaire was too long 10 pages and 134 items were thought to be 
excessive and unlikely to result in obtaining sufficient data
2 The questionnaire looked unprofessional Recommendations were put forward 
for comparing the instrument presentation with some professional surveys used 
for marketing purposes, credit card companies and other such bodies
3 The use of an online survey option was highly recommended to improve 
response rate and accessibility (at this point, only the MS Word version was 
known to respondents)
4 More ‘neutral’ and ‘residual other1 type options were required in general and in 
some specific cases That is, some of the questions forced a leaning in a certain 
direction, where a neutral question would have given respondents an opportunity 
not to lean in either direction The addition residual other questions would allow
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respondents to opt out of an answer, where the question had no relevance to 
their business
5 The business performance section of the questionnaire was intrusive and difficult 
to answer, and unlikely to encourage a high response rate
6 The questions in some cases were unfairly predisposed to a particular direction 
This was particularly the case for the business performance section where 
questions were asked relating to how much certain facets have increased or 
grown with a lean towards growth rather than decay or neutrality
7 To assess the respondent’s 21 CFR Part 11 scores, it was pointed out that the 
questionnaire did not adequately address the underlying features of part 11
Each of the main comments was addressed in some way and led to an overhaul of 
the questionnaire Through vigorous application of the literature-derived checklist in 
section 3 5 1 , and a variable reduction phase, the number of questions was reduced 
from 134 to 84 This resulted in a 7-page instrument An affordable online web- 
survey host [158] was located and the questionnaire was built and launched as an 
online form Considerable work was done to the appearance of the MS Word™ 
questionnaire to improve the flow and aesthetic features Comparisons were made 
with various postal surveys received through junk mail and on the Internet Neutral 
and residual other options were provided where suggested and the other questions 
assessed as to whether such options were required The Part 11 variable would be 
assessed with a more m depth set of constructs These would measure the
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respondent’s practices with regard to the actual requirements of Part 11 electronic 
signatures and records, security, access and audit trails
In order to aggressively reduce the number of questions to a manageable but still 
useful number, the study variables for quality practices were evaluated as they were 
the most numerous (21) The purpose of this exercise was not to dimmish the 
importance of the variables derived during the initial literature evaluation but to see if 
a variable could be measured as subsets of other variables A table was created 
with all the variables present together with the literary references for each variable 
presented in columns A ‘literary importance' score was again produced based on 
the amount of times the particular variable was deemed to be important in the 
reviewed body of work That is, if a variable was stated as being important in 6 
different papers (reviewed as part of this work), then the variable received a literary 
importance score of 6 A series of questions was then produced as an evaluative 
tool, which looked at each variable
1 What is the literary importance score for the variable?
2 Could the variable be considered a sub-category of another variable?
3 How independent does the variable seem from the other variables?
4 Could the main score (quality practice / regulatory practice / business 
performance) stand up without the inclusion of this variable (i e would the 
combined set of items provide a valid score without the variable?)
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5 Write some general comments on the value of the variable in light of questions 1 
to 4 and on omission of the variable
6 Make a decision on whether to retain or remove the variable from the study or 
whether to subsume the variable into another variable
Table 3 5 51 shows the resultant evaluation for the set of quality practices study 
variables that were eliminated at this point and the decisions made
Table 3 5 51  Quality variables removed for the purposes of instrument 
_________   reduction during pre-testing_____________________
Variable
name
Literary
score
Number of 
associated 
questions in 
original 
questionnaire
Rationale for removal
Testing
management
4 (30%) 3 Testing management can be considered 
a work practice and can be assessed as 
part of the variables that assess whether 
work processes are well documented 
and followed The literary score was low
Cost of 
quality
2(14% ) 2 The low literary score was the main 
reason for exclusion As only 14% of the 
literature surveyed indicated COQ to be 
amongst the most important criteria in 
quality success, then it was reasonable 
to propose that the remaining variables 
would provide an adequate indication of 
the quality practice strengths of the 
respondents
Preparation 
for delivery / 
approval for 
release and 
product 
realization
2 (14%) 1 Same rationale as for COQ
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Variable
name
Literary
score
Number of 
associated 
questions in 
original 
questionnaire
Rationale for removal
Risk
management
2 (14%) 1 Same rationale as for COQ
The regulatory variables were also looked at in the same way as the quality 
variables with the exception of the use of the literary score technique This was 
because the regulatory variables were derived from professional literature that was 
not generally research based and the constructs were developed from a summation 
of the literature rather than a cross examination The eleven regulatory variables 
were reduced to nine Table 3 5 5 2 below shows the decisions for removal of two 
regulatory variables from the study
Table 3 5 5 2 Regulatory variables removed for the purposes of instrument 
___________ reduction during pre-testing_______________________
Variable
name
Number of 
associated 
questions in 
original 
questionnaire
Rationale for removal
Extent to 
which other 
regulatory 
requirements 
are built into 
the software
1 It was sufficient to measure whether GMP (and 
hence all regulatory requirements) is built into the 
respondent’s products This could be more than 
adequately addressed by the ‘Extent of direct use of 
GMPs’ variable
Extent of 
planning 
regulatory 
activities into 
design
1 It was really the end goal that was important with 
this variable, i e that regulatory activities are part of 
design The planning should be the means by which 
it was achieved but for the purposes of the study it 
was sufficient to measure the end goal
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The most fundamental changes to the questionnaire as a result of the pre-testing 
were in the business performance section The literature was consulted extensively 
and new measures and constructs were produced which were more likely to provide 
business performance data through a questionnaire The questions were adapted 
from the work of Luk [159], Kannan and Tan [160], Greenley and Foxall [161] and 
Rozenwig [162] although they were tailored to suit the focus on the pharmaceutical 
industry for the purpose of this study The measures were mainly consistent with the 
business performance criteria derived during the initial literature survey, although the 
means of acquiring the data differed substantially The remaining measures as used 
by previous studies to determine business performance were
1 Change in market share over 5 years in the pharmaceutical industry
2 Overall profit levels for products sold into pharmaceuticals over 5 years
3 Overall sales volumes into the Pharmaceutical industry over 5 years
4 Overall percentage sales from new products (pharmaceutical) in last year
5 Competitive strength relative to competitors
For the first 4 variables subjective closed measures were used asking the 
respondent to select on a 5-point scale whether their results were considerably 
below expectations, below expectations, met expectations, exceeded expectations 
or considerably exceeded expectations For the relative competitive strength 
variable, a 2-item Likert scale was employed
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The use of measures that may be deemed to be partially subjective, to accurately 
reflect objective realities, is supported by the literature [159] - [162] Although not as 
effective as acquiring objective data, strong correlations were found in the literature 
between subjective and objective measures making the use of subjective measures 
acceptable [163] - [165] From the pre-test it was evident that getting objective 
proprietary data would be a barrier to high response rates
As these measures were found to produce valid results in other studies, which used 
questionnaires to measure business performance, they were deemed adequate for 
use in this study Although fewer variables were employed than initially set out from 
the initial literature review, the main elements of the original variables (Market share, 
Profit and profit growth, sales and sales growth, and new product sales) were 
covered in the five variables selected above, with the exception of ‘Workforce 
growth’, which was not assessed
After completion of the pre-test remedial work the questionnaire was reconstructed 
both in the MS Word format and on the online version The pre-test respondents 
were again contacted and presented with the new questionnaires Some minor 
adjustments were made and the pre-testers were satisfied with the revised 
instrument The questionnaire was then ‘locked down' as a single controlled soft 
copy in preparation for Pilot testing
137
The resultant and final questions were those presented on the questionnaire in 
Appendix B 1
3 5 6 Pilot testing the instrum ent
The questionnaire was sent out to twenty respondents who had agreed to take part 
in the study (as determined by the database building) The respondents chosen 
were the first 20 in alphabetical order in the database Therefore, no particular 
respondent characteristics were chosen In addition to these 20, a further 21 
respondents, who had made contact after several reminders had been sent, were 
also given the questionnaire to complete From the 41 sent, 29 questionnaires (71%) 
were either returned or completed online The e-mail instructions (appendix B 2) 
were sent together with the final questionnaire (appendix B 1) and a web link (URL) 
The instructions stated that the questionnaire was focused on the respondents 
software / automated system development environment and provided 3 ways to 
complete the questionnaire, online, by completing the MS Word™ document and 
returning by e-mail or by printing out and completing the MS Word™ by hand, 
returning by normal mail The instructions also contained statements of 
confidentiality, anonymity and non-disclosure The respondents were not made 
aware that the questionnaire was being pilot tested but were asked for comments on 
the questionnaire
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In general, the questionnaire was well received and comments were mostly positive 
with regards to presentation and ease of completion Some suggestions were made 
regarding removing forced choices on the online questionnaire to allow respondents 
to choose whether or not to answer certain questions This was taken into account 
and the online questionnaire was modified accordingly Some other minor 
modifications such as adding residual others also took place but in general the 
questionnaire remained unchanged This also meant that the 29 valuable 
respondent data sets could be used in the full study
The most important finding from the pilot study was that some of the respondents 
who had agreed to participate in the study initially had forgotten Therefore when 
they were sent the questionnaires they did not respond and needed to be reminded 
about it The lesson from this was that in the main study, ‘memory jogging’ mails 
would be sent out first and agreement re-established before sending the 
questionnaire and instructions
The pilot response rate of 71% was higher than expected and much higher than 
what the literature pointed to as being a reasonable expectation This was the case 
even though the same best administration practices from the literature, which 
reported much lower response rates, were followed As a total of approximately 
N=100 would be required to make the study meaningful and representative 
(externally valid) and would allow analytical tools such as factor analysis to be 
applied with confidence, the administration strategy was retained for the main study
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The high response rate was probably attributable to the use of that strategy 
combined with the high emphasis on repeated personal informal communication with 
respondents and also to the fact that respondents seemed used to answering 
questionnaires This was possibly because many of them had participated in 
supplier assessments, which often use questionnaires to evaluate supplier quality 
practices in the pharmaceutical industry
3 5 7 Analysis o f  the pilot study data
The pilot data (with N=29) was analyzed using various SPSS statistical procedures 
The data was mostly ordinal and where possible non-parametric tests were 
employed which did not make any assumptions of normality or continuity In some 
cases though parametric testing was used in order to harness the power of such 
tests to determine differences or relationships between ordinal variables It has been 
widely argued in the literature that the use of parametric testing for ordinal data is 
acceptable [166][167] The main study variables certainly had the characteristics of 
continuous normally distributed interval variables as the high number of intervals 
present in the data made it very close to continuous even though the variables were 
derived from ordinal sources (see below) Visual checks using SPSS plots and tests 
for skewness and kurtosis for the main variables confirmed normality for the three 
variables Quality, Regulatory and Business (Table 3 5 7 1) Kurtosis and skewness 
values of less than +/-1 indicate acceptable normality, with zero representing perfect
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normal distribution This allowed use of parametric testing, for the purposes of the 
pilot study, to evaluate relationships between these three variables
Table 3 5 71 Normality statistics produced for the three study variables 
_________________showing normal distribution_________________
Quality Regulatory Business
N Valid 29 28 29
M issing 0 1 0
Skewness 033 -4 2 3 002
Std Error o f  Skewness 434 441 434
Kurtosis - 147 569 -2 0 6
Std Error o f  Kurtosis 845 858 845
The individual scores from each question were all standardized to give equal 
weighting to the sub-variable it was designed to represent They were then summed 
to form a scaled sub-variable The reliability of the questionnaire items within the 
scale was then checked using Cronbach’s Alpha The coefficient alpha values for 
the pilot study data sub-variables and their corresponding questionnaire items are 
presented in appendix C 1 Some items had to be removed (only for the pilot study) 
to ensure reliable scales were being employed In the main however, reliability was 
confirmed Ideally alpha values of greater than 0 7 are acceptable For the pilot 
study this was mostly achieved however some scales were accepted with coefficient 
alphas below the recommended 0 7 threshold This is a regular occurrence in the 
literature [159][161 ][167] It would have been detrimental from an information- 
gathering point of view to remove some indicators where reliability was not ideal but 
still adequate The decision was hence made to retain some less than ideal scales 
for the pilot study
141
The sub-variables were related to the three mam study variables of quality practices 
(Quality), regulatory practices (Regulatory) and business performance (Business) 
Two approaches were taken to reducing the number of variables to a more 
representative sub-group of main study variables Ideally, factor analysis would be 
used This was attempted but the small N meant that very low communalities were 
noticed and the number of factors extracted using principal components analysis 
which would even reasonably explain the variance, and hence represent the sub- 
variables adequately, approached the number of sub-variables themselves So the 
factor analysis was not used here
The second technique was to use simple summated scales (See appendix C 1) 
Here, a set of sub-variables would be scaled to produce a score for quality, 
regulatory and business performance Firstly, the reliability of the items making up 
the sub-variables had to be ascertained Each sub-variable was represented by a 
number of questionnaire items Cronbach’s alpha was used to determine if the items 
‘varied together’ and could be used to form a sub variable Items were removed until 
a reliable scale was achieved Appendix C 1 shows what items were removed to 
form the sub-variables These items were then summed to produce a sub-variable 
score The sub-variables (which consisted of sub-variables that had a single 
questionnaire item and those which were analysed in appendix C 1) were then 
assessed as to whether they varied together to form a scale, which could be used to 
represent the main variables The sub-variable scores could then be summed to 
produce a single score for quality, regulatory and business performance The
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reliability of the sub-variables scaled was tested using Cronbach’s alpha and in the 
case of the set of Quality sub-variables (Table 3 5 7 2), Regulatory sub-variables 
(Table 3 5 7 3) and Business sub-variables (Table 3 5 7 4 )  was found to be reliable 
as coefficient alpha exceeded 0 7 or was deemed sufficiently close to 0 7 to be 
useful In all cases, the sub-variables were equally weighted into the scale, each 
sub-variable score had a maximum of 1
Table 3 5 7 2 Scale reliability for Quality sub-variables
Cronbach's 
A lpha i f  item  
Deleted
T rainAndDevelop 833
TeamworkHR 839
CustFocus 837
Leadership 836
Com munication 834
QualPlaiming 830
DocQualPols 835
UseStandPracProc 834
ReqM anagement 832
ReviewsAudits 827
Q ualDnvenProcesses 829
Measurem ent 848
ServProvide 844
QualSysInfrastructure 851
SuppherM anage 838
SoftControl 870
LifeCycle 875
Reliability Statistics Cronbach's
Alpha N of Items
849 17
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Table 3 5 7 3 Scale reliability for Regula
Reliability Statistics
Cronbach's 
Alpha if Item 
Deleted
GM Puse 709
DesignDocProv 746
GAM Puse 715
ValDesignedln 756
ValDoc Avail 701
RegCompAuditsProd 786
SourceCode Avail 743
ERES 731
ory items
Cronbach’s
Alpha N of Items
763 8
Table 3 5 7 4 Scale reliability for Regulatory items
Reliability Statistics
Cronbach's 
Alpha if Item 
Deleted
Profit Levelchange5yrPharm a
790
S alesV o IChangeSyrPharma
728
NewProdSalesPharm a2yr
688
M arkets hareRelative 729
Competitiveness 686
Cronbach’s
Alpha N of Items
766 5
Figures 3 5 7 1  to 3 5 7 3  show the distributions of sub-variable scores for the pilot data and 
the corresponding main variable score distributions
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Figure 3 5 71 Boxplot showing scaled range of sub-variable scores and 
corresponding summated main vanable for Quality
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Boxpbt of Regulatory sub-varables and corresponding main vanable
Figure 3 5 7 2 Boxplot showing scaled range of sub-variable scores and 
corresponding summated main variable for Regulatory
Boxpbt of Business sub-vanables and corresponding mam vanable
Figure 3 5 7 3- Boxplot showing scaled range of sub-variable scores and 
corresponding summated main variable for Business.
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As described below, correlation analysis was then used to determine the nature of 
the core relationships and study hypotheses Some non-parametnc difference 
testing was carried out using the background variables to test for potential bias, and 
to check to see whether the correlation findings would be valid across a range of 
scenarios Partial correlation was used to check for spuriousness, intervening and 
moderating variables and where significant important relationships were found, 
regression was carried out to present predictors
3 5 8 Describing the pilot data
For N=29, 82% of responses were from companies who were established more than 
16 years, i e well established Only 1 respondent had been in business for less than 
8 years 65 5% of respondents had been operating in the pharmaceutical market for 
more than 16 years, with 17% operating in that market for less than 8 years These 
percentages might mean some non-response bias might be present in the mam 
study in terms of non-responses from companies not well established or not well 
established in providing for pharmaceutical manufacturers at least
A good spread of company sizes was represented (Table 3 5 8  1) with 200 
employees being the cut off point for ‘large’ companies
 Table 3 5 8 1 Organization size distribution_______
Frequency Percent Valid Percent
Cumulative
Percent
Valid 0-50 7 24 1 24 1 24 1
51-100 6 20 7 20 7 44 8
101 150 3 10 3 103 55 2
151-200 5 172 172 72 4
>200 8 27 6 27 6 100 0
Total 29 100 0 100 0
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Similarly, reasonably flat distributions for product criticality and automation 
complexity were evident from the pilot data (Tables 3 5 8 2 and 3 5 8 3)
Table 3 5 8 2 Criticality of products to end product quality
Frequency Percent Valid Percent
Cumulative
Percent
Valid 0 1 34 34 34
1 1 34 34 69
2 4 138 138 20 7
3 6 20 7 20 7 41 4
4 1 34 34 44 8
5 7 24 1 24 1 69 0
6 9 31 0 31 0 100 0
Total 29 100 0 100 0
(Where a score of 6 represents the highest criticality)
Table 3 5 8 3 Complexity of automation used in products
Frequency Percent Valid Percent
Cumulative
Percent
Valid 1 1 34 34 34
2 2 69 69 10 3
3 8 27 6 27 6 37 9
4 4 138 138 51 7
5 3 10 3 103 62 1
6 11 37 9 37 9 100 0
Total 29 100 0 100 0
(Where a score of 6 represents the highest criticality)
This indicated that sufficient cases would exist in the main study from across the 
range of possible product criticality and automation complexity determinations by 
respondents to ensure that any analysis was relevant across the range That is, 
there were enough responses in the low (1&2), medium (3&4), and high (5&6) 
ranges to carry out a meaningful analysis Hence bias would be unlikely due to 
sufficient representation from companies who produce low complexity automation in
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their products and whose products have little impact on product quality Correlations 
(section 3 5 8 1) would determine any impact on the study variables due to 
complexity and criticality
In order for the study to be externally valid across the range of possible regulatory 
environments it was important to see how the data differed throughout the regulatory 
combinations exhibited by respondents It was possible for companies to work within 
any combination of regulatory environments That is, they could work within none (or 
unknown), one regulatory environment, or many Scores were compared for the 
three main study variables for each regulatory environment and where the 
environment was unknown (Table 3 5 8 4) A non-parametric Mann-Whitney ¿7-test 
was carried out to see whether the differences between scores were statistically 
significant for absence or presence of a given environment Non-parametric tests are 
also more powerful than parametric tests where sample sizes are low [167]
Table 3 5 8 4 Differences in median scores for 3 main study variables for 
presence and absence of admission of regulatory environment (using Mann
Whitney-U)
EM EA Qual FDA Qual ICH Qual PIC/
S
Qual W HO Qual U nknow n Qual
Yes 13 0 Yes 118 Yes 12 5 Yes 12 5 Yes 12 8 Yes 13 1
No 117 N o 13 1 N o 12 2 No 12 2 N o 120 N o 118
Si
Yes
067 Si
Reg*
217 Si:
6 1 Yes
Reg
758 Si
5 1 Yes
Reg
453 Si
Reg
521
6 1 Yes 61
Reg*
Yes 62
Sy;
H IWm
Yes
217
Rei.
3 4
No 4 8 No 3 4 No 5 0 No 4 8 No 4 8 No 5 1
Si
Yes
043 Si
Bus
101 Si
Bus
3 3
107 Si
Yes 2 9 Yes
Bus
254 Si
Bus
042 Si:
Bus
3 0 Yes 2 3 Yes 25 Yes
101
Bus
3 1
No 29 No 3 1 No 29 No 3 0 No 30 No 29
S*i. 237 Sii. 754 Sig 245 Sig 845 .M. 181 Sii 784
Significant at the p= 05 leve (2-tailed)
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In Table 3 5 8 4 there were few statistically significant differences between scores at 
the pilot test stage, however differences in median scores were evident as expected 
Where the main regulatory environments (EMEA, FDA and PICs) were confirmed 
from questionnaires, median regulatory scores were always higher In the case of 
the EMEA this was significant at the p= 05 level As the hypothesis for whether the 
scores would be greater or less was not specified it was non-directional and hence 
two-tailed levels of significance were invoked There was a less clear distinction 
between quality and business scores across the range of regulatory environments
To compare scores between the various regulatory combinations a Kruskal Wallis 
test for N-independent samples (non-parametnc) was performed using the 
regulatory variable as dependent No statistically significant difference was found 
between groups as p=0 145 (Table 3 5 8 5)
Table 3 5  8 5 Results o f Kruskal W allis test for significant differences in regulatory
scores between regulatory groupings
Ranks
| REGCOM P N Mean Rank
Regulatory FD A Only 11 14 00
EM EA and FDA 5 16 40
FD A + PICs 2 13 00
EM EA + FDA + 
PICs
3 24 50
U nknow n 7 10 07
Total 28
Regulatory
Chi Square 6 840
d f 4
Asym p Sig 145
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Figure 3.5.8.1 Box-plots for various regulatory combinations with the 
dependent regulatory variable (pilot).
Although not significant with N=28, the box-plots in figure 3.5.8.1 show that the 
median scores differed. Where the EMEA were involved, median scores tended to 
be higher; however considerable overlap existed across the ranges for ‘FDA only', 
‘EMEA and FDA’, and FDA and PIC/S. Where all three primary regulatory 
environments were involved together, a higher median score and range were 
evident. As expected, where the regulatory environment was unknown by 
respondents, the median score was lower than where it was known. However the 
upper range of the ‘unknown’ box-plot overlapped with the cases where regulatory 
environments were known. This suggested that it was possible to have a 
comparable regulatory score while not knowing what regulatory environment the 
company was producing for. In general though from the pilot data, no significant
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differences existed between regulatory scores and regulatory environment so that 
any findings could not be generalized across the regulatory range
Of the 29 pilot study respondents, 20 reported to be ISO 9001 registered There 
were a very low number of pilot respondents who reported using the other options 
(CMM, Six Sigma and TQM) A Mann-Whitney-U test was carried out to compare the 
non-parametric differences between two groups, those with and without ISO quality 
management systems A significant difference was found in quality scores, however 
no difference existed over the regulatory and business variables for presence or 
absence of an ISO QMS This correlation confirmed what was found elsewhere in 
the literature [92][94][96][97] Table 3 5 8 6 and the box-plot in figure 3 5 8 2 show 
the differences between scores for companies with and without ISO registration
Table 3 5 8 6 M ann W hitney-U test for differences between main study variables for
com panies with and without ISO 9000 9C
Quality Regulatory Business
M ann-W hitney U 
W ilcoxon W 
Z
Asym p Sig (2-tailed) 
Exact Sig [2*(l-tailed  
S ig )]
45 500 
90 500 
-2 098 
036
034(a)
610 0 0  
97 000 
967 
334
354(a)
85 000 
295 000 
-2 3 6  
813
835(a)
01 quality m anagem ent system s
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IS011a
Figure 3.5.8.2: Box-plot for Quality scores for companies with and without ISO
registration.
3.5.8.1 Correlation analysis
Parametric and non-parametric correlation analyses were carried out between the 
main study variables, between all the sub variables and between the main study 
variables and the sub variables. Low and moderate correlations were evident in
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some important areas although statistical significance was not always evident, in 
many cases this was possibly due to the small sample size
Kendall’s tau-b was used as the main correlation test Very similar results were 
achieved using the parametric Pearson’s-r test and the non-parametric Spearman’s 
rho in terms of strength and direction of correlations and statistical significance As 
no direction of relationships was hypothesized for the tests, 2-tailed levels of 
significance were employed Table 3 5 8 1 1 shows Kendall’s tau-b evaluated for the 
mam study variables
Table 3 5 8 1 1 Kendall’s tau-b evaluated for the mam study variables
Correlations
Quality Regulatory Business
Kendall's tau b Quality Correlation 
Coefficient 
Sig (2-tailed)
1 000 2 8 1(*)
036
229
084
N 29 28 29
Regulatory Correlation 
Coefficient 
Sig (2-tailed)
281(*)
036
1000 -0 7 5
579
N 28 28 28
Business Correlation 
Coefficient 
Sig (2-tailed)
229
084
-0 7 5
579
1000
N 29 28 29
* Correlation is significant at the 0 05 level (2-tailed)
There was a low positive correlation between Quality and Regulatory scores This 
was significant at the p=0 05 level There was also a low positive relationship 
between Quality and Business scores, however this was not significant (p= 084) at 
the pilot stage The most striking finding was that there was no direct correlation 
between the Regulatory variable and the Business variable This confirmed the null
154
hypothesis H3o (i e H3 was rejected at this point, albeit only in the pilot study) 
However it was possible to conclude that quality systems might be driven by 
regulatory requirements (as is evident in part from the data) and that regulatory 
factors directly impact business performance Figure 3 5 81  1 gives an overview of 
the pilot correlations
Figure 3 5 81 1 Relationships between mam study variables after pilot testing
(Kendall’s tau-b)
It should be noted however that the quality score was not significantly correlated to 
the business scores for the pilot data, however it was not far from being significant, 
so from an exploratory perspective, the correlation could not be ignored This 
relationship would become clearer when the main study data was analyzed A 
simple linear regression analysis yielded an un-standardized regression equation of
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Coefficient standard error = 0214  
2-tailed significance = 043
Although the errors were potentially large, this did show that regulatory scores could 
be used as a statistically significant predictor of Quality As Quality was not, at this 
point, significantly correlated to business scores, this regression analysis was not 
given much credence as errors were too large to allow reasonable prediction and the 
regression was not itself significant
Other useful significant correlations were evident from the sub-variable analyses (at 
the p= 05, two-tailed level) A low positive correlation was found between the time 
the company was established in the pharmaceutical market and the quality system 
infrastructure score (tau-b = 0 334, N=29) This gave further weight to the possibility 
that regulatory influence may be a cause in part of quality system performance
Organisation size correlated significantly with automation complexity used in 
products (tau-b = 0 368) This suggested that complex automation is related to 
organisation size Importantly, organisation size was not correlated with business 
performance, regulatory performance or business performance scores This meant 
that findings would be equally valid across the range of company sizes This was 
later confirmed using partial correlation Complexity was also correlated positively
EQ1 Quality = 9 819 + 457 Regulatory Constant standard error = 1 07
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and significantly with the software control variable (tau-b = 347) and to whether 
regulatory audits are carried out (tau-b = 0 340) That is, software complexity was 
related to software control (a sub-variable of Quality) and to the extent to which 
regulatory audits take place This was consistent with the requirements of GAMP 
[13] and other software development guidelines [41 ][42][122] where efforts should 
be matched to risk, which increases with complexity Additional complexity might 
also suggest additional functionality, which would leave the software open to the 
requirements of 21 CFR Part 11 and other regulations pertaining to software This 
could explain the pilot study relationship between complexity and the extent which 
regulatory audits are carried out
The cnticahty of end product to end product quality was significantly correlated with a 
number of other variables Notably these were the regulatory variable (tau-b = 0 418) 
and with the sub-variables ‘GMP use’ (tau-b = 0 387), and 'Provision of Design 
Documentation' (tau-b=0 381) and use of GAMP (0 339)
Another significant pilot data correlation (background variables) was between the 
percentage revenue companies acquired from the pharmaceutical market and 
perceived competitiveness in that market (tau-b = 0 353) That is, there seemed to 
be a positive relationship between those companies who relied mostly on the 
pharmaceutical market and their competitiveness
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For the main study variables, a partial correlation test was carried out controlling the 
background variables (Criticality, Complexity, Org size, Established time, 
Established Time in Pharma) Pearson’s r was used in this test as the correlation 
indicator As the Kendall’s tau-b zero order correlations were very close to the 
Pearson’s r values, any diminished correlation due to spuriousness, moderating or 
intervening variables would be evident from this parametric test and useful
Table 3 5 81 2 Partial correlations of all background variables controlled, the 
main study variable relationships compared against zero order correlations
Control Variables Regulatory Business Quality
-none-(a) Regulatory Correlation 1000 -0 0 3 386
Significance (2-tailed) 989 043
d f 0 26 26
Business Correlation -0 0 3 1000 321
Significance (2-tailed) 989 096
df 26 0 26
Quality Correlation 386 321 1000
Significance (2-tailed) 043 096
d f 26 26 0
E stl & PharmEst2 Regulatory Correlation
& OrgSize3 & 1 000 121 339
Com plexity4 &
Criticality8
Significance (2-tailed) 584 113
d f 0 21 21
Business Correlation - 121 1000 300
Significance (2-tailed) 584 164
d f 21 0 21
Quality Correlation 339 300 1000
Significance (2-tailed) 113 164
d f 21 21 0
a Cells contain zero-order (Pearson) correlations
It can be seen from Table 3 5 8 1 2 that the magnitude of the correlation between 
Quality and Regulatory was not much reduced (0 386 to 0 339) and is certainly not 
eliminated So it would hold that there still remained a direct relationship between
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Quality and Regulatory scores and the relationship is not spurious Similarly, the 
correlation between Quality and Business held despite the controlling of the 
background variables The statistical significance for both of these relationships did 
suffer however, it was believed mainly due to the low sample size The Quality 
variable was correlated with Market share (tau-b = 0 320) and Perceived 
Competitiveness (tau-b = 0 285), which were sub-variables of the Business variable 
This again confirmed what the literature indicated
Interestingly the ‘GMP use’ variable was significantly and positively correlated with 
many of the Quality sub-variables These included Training and Development (tau-b 
= 0 486), Teamwork and HR (tau-b = 0 305), Quality Planning (tau-b = 0 354), Use 
of Standards Practices and Procedures (tau-b = 0 373), Reviews and Audits (tau-b = 
0 289), Quality Driven Documented Processes (tau-b = 0 314), Supplier 
Management (tau-b = 0 367), Software Control (tau-b = 0 356), Life Cycle use (tau-b 
= 0 325), and the summated main Quality variable (tau-b = 0 436) These 
correlations were not unexpected as the fundamentals of GMP are to do with 
people, quality systems, reviews and audits, documentation and record keeping and 
software control Many of the quality sub-variables are in fact explicitly detailed as 
requirements in the GMPs [59][70]
Another interesting correlation was that between the ERES variable and software 
control and life cycle use variables (tau-b = 0 454 and 0 458 respectively) As 
compliance with the ERES requirements [23][37] requires software control at
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development stages, and use of life cycle development is conducive to that control 
and development quality, this was an important and expected correlation
3 6 Summary of Pilot study
The mam findings of the pilot study were that the regulatory practices and quality 
practices were correlated and that there is evidence that regulatory practices tend to 
correlate with quality practices Quality practices were correlated with 
competitiveness and market share within the pharmaceutical industry, although not 
significantly correlated with business practices for N=29 Hence H1 would be 
accepted tentatively There was also a positive and significant correlation between 
quality and regulatory practices, meaning that H2 could be accepted for the pilot 
study There was no correlation between regulatory practices and business practices 
and hence H3 could be rejected with confidence (based on the pilot study)
160
Chapter 4: Primary study
The questionnaire was sent to all those potential respondents who had not been 
represented in the pilot study From the sampling population of 647, 219 agreed to 
participate (33 8%) Of the 219 who agreed, 122 or 55 7% responded, including the 
29 pilot study respondents This meant a total response rate of 18 9% and exceeded 
the target of 100 completed questionnaires Three questionnaires were unusable 
because entire sections were incomplete This response rate was considerably 
higher than that typically expected using e-mail surveys [147][148] but lower than the 
70 7% response achieved for the pilot study, although the administration procedure 
used in the pilot study was used in full This lower response rate was possibly due, 
at least in part, to summer administration of the main study Many of the initial e- 
mails for the main study were sent out during the traditional vacation months of July 
and August and there was a noticeable increase in ‘out-of-office’ responses during 
those months Follow ups after the holiday period were carried out as per the normal 
administration procedure, but the response rate although steady, did not approach 
that experienced for the pilot study The rate was however more than sufficient for 
the purposes of this research
Although there was a low rate of missing items, 21 questionnaires had at least one 
missing answer Questionnaire item 9 which asked about the type of organisation 
the respondent worked in (in terms of whether it worked within the customer's sites 
or external from them) was frequently misinterpreted or misunderstood This
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question was deemed unreliable and hence would not be used for any analytical 
purposes Similarly the open question on ‘use of standards’ was generally not 
answered, it provided no useful information
In total 59 items were missing across 119 questionnaires each with 84 questions 
giving a missing rate of 0 59% The distribution of missing answers was evenly 
spread across 38 questionnaire items, so there were no patterns, which might lead 
to concerns over bias
Of the 122 received, 79 (64 8%) were submitted through the use of the web-survey 
form, 3 (2 5%) were submitted by post and 40 (32 8%) were submitted using the MS 
Word™ document as an attachment All questionnaires were printed when received 
The data was input directly into SPSS manually and a data comparison was carried 
out between the data downloaded from the web-survey site and the manual data No 
discrepancies were found, thus validating the manual process
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41 Analysis of main study data
The analytical strategy for the main study was derived mainly from the pilot study 
strategy The larger N for the main study meant that additional tools such as factor 
analysis could be employed A sample size of greater than 100 is generally found to 
be appropriate for such analysis [167] The use of summated scales based on factor 
analysis output meant that small intervals existed within the factor scores meaning 
that it would be appropriate to use parametric as well as non-parametric testing 
[167] In general, because there is some controversy in the use of parametric 
techniques in this type of setting [166][167], non-parametric analyses were 
performed where possible as a check on the results from parametric tests
The strategy was
1 Present and analyse descriptive statistics and data distributions
11 Organisation size distributions
1 2 Time in business distributions
1 3 Regulatory environment distributions
1 4 Quality environment distributions
1 5 Complexity of automated element distributions
1 6 Criticality to user end-product quality distributions
2 Factor Analysis to find underlying dimensions in data related to mam study 
variables
2 1 Exploratory factor analysis
2 2 Principal components analysis
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2 3 Derivation of factors
2 3 1 Retention of components 
2 3 2 Elimination of items 
2 3 3 Resulting factors 
2 3 4 Reliability analysis of summated scales
2 3 5 Distribution of summated scale for study data 
3 Main explorations and hypothesis testing
3 1 Factor correlations 
3 2 Factor regression
3 3 Relationships between background variables and factors
3 31  Categorical differences 
Figure 4 1 1 illustrates the overall data processing strategy
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Figure 4 11 Process flow diagram for data analysis phase
4 2 Descriptive statistics and  distributions
It was important that the distribution of data was obtained from across the spectrum 
of company sizes, length of time in business and operating in the pharmaceutical 
market and also across the regulatory environment and quality system environment 
Other important background considerations, which might theoretically contribute to 
variance in the data, were the criticality of the respondent’s product to the quality of 
the customer’s end product and the complexity of the automation used in the 
respondent’s end product These 6 aspects made up the main background variables 
for the study The distributions needed to be assessed to ensure that no bias could 
be present in the data due to absence of information from particular sectors Once 
valid factors were developed for the data, categorical analysis was then conducted 
to evaluate cross-categorical differences using the background variables It was not 
expected that the background variables would show normal distributions and hence 
care had to be taken when carrying out analyses to ensure that appropriate tests 
were applied
It was important for many of the background variable distributions to show 
responses from across the range of possible options This was necessary to show 
that the study was representative across those ranges, to rule out possible non­
response bias, and to allow evaluation of the results across sub-groups within the 
ranges For all the background variables, acceptable distributions were found
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4.2.1 O rgan iza tion  size d istr ibu tion
From the 119 valid questionnaires, there was an acceptable representation from 
across the range of possible company sizes as represented in figure 4.2.1.1.
Frequency
Valid
Percent
OrgSize 0-50 40 33.6
51-100 21 17.6
101-150 12 10.1
151-200 14 11.8
>200 32 26.9
Total 119 100.0
0J   | ------ 1------ 1------------1------*— 1------- 1------------  1---------------
MO 51-100 »1-1S0 151-W0 >300
Organization Size
Figure 4.2.1.1 Organization size distribution.
Forty small companies were represented and 32 large companies with 47 mid size 
companies making up the remainder as can be seen in figure 4.2.1.2 below.
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Figure 4.2.1.2 Summary of company size distribution.
4.2.2 L ength o f  tim e in business d is tr ib u tio n s
This background variable was divided into two categories, length of time in business 
and length of time operating in the pharmaceutical business. Cases were present for 
the entire range of possibilities as can be seen in figures 4.2.2.1 and 4.2 2.2. It is 
clear that the majority (61.3%) of respondents were established in the 
pharmaceutical market for over 16 years. Overall. 76.5% of the respondents had 
been in business for more than 16 years. Sufficient data existed for all those other 
categories of length of time in business and length of time in the pharmaceutical 
industry to carry out comparative analysis of companies established more and less 
than 16 years. Figures 4.2.2.3 and 4.2.2 4 show the summarized frequencies for 
these categories.
168
C
ou
nt
U m «  In B u sin e « «
Frequency Percent
Time in 
Business
0 to 4 
years 3 2.5
4.1 to 8 
years 7 5.9
81 to 12 
years 7 5.9
12.1 to 16 
years 11 92
>16 years 91 76.5
Total 119 1000
Figure 4.2.2.1 Length ottim e in business distribution.
80 -
60 -
Time established in Pharmaceutical industry
Frequency Percent
Time in 
Pharma
0 to 4 
years 8
6.7
4.1 to 8 
years 12 10.1
8.1 to 12 
years 12 10.1
12.1 to 16 
years 14 11.8
>16 years 73 61.3
Total 119 1000
Figure 4.2.2.2 Length of time in pharmaceutical industry distribution.
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Figure 4.2.2.3 Length of time in business summarized frequencies.
«1er»
PtumuEstabiisted
Figure 4.2.2.4 Length of time in pharmaceutical market summarized
frequencies.
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4 2 3 R egulatory distribution
Of the five possible categories of regulatory environments 9 different permutations 
emerged from the study as can be seen below in figure 4 2 31  and table 4 2 31  
There were 60 of the 118 respondents who produced for FDA regulated 
environments only Only 2 respondents developed systems solely for the EMEA 
market only with 26 others developing for both the EMEA and FDA markets 
(combined with some others such as the PIC/S and the ICH guidelines) The data 
was summarised into three groups to ease understanding and analysis, as can be 
seen in the bar chart m Figure 4 2 3 2 Here the regulatory environment was divided 
into ‘FDA only’, FDA and others’ and ‘Unknown’ 26 respondents reported that they 
did not know their regulatory environments From this it can be seen that those who 
produced for the EMEA market generally produced for the FDA market, but the 
converse is not true
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60-
5 0 -
4 0 -
Regulatory Category
Figure 4.2.3.1 Regulatory environments of respondents. 
Table 4.2.3.1 Regulatory environments of respondents.
Cumulative
Frequency Percent Valid Percent Percent
Valid FDA only 60 504 504 50.4
EMEA only 2 1.7 1.7 52.1
EMEA & FDA 17 14.3 14.3 664
EMEA&FDA&
PIC/S
1 .8 .8 67.2
FDA&PIC/S 3 2.5 2.5 69.7
FDA&ICH 2 1.7 1.7 71 4
EMEA&FDA&I
CH 3 2.5
2.5 73.9
EMEA&FDA&
PIC/S&ICH 5
4.2 4.2 782
Unknown 26 21.8 21.8 1000
Total 119 100.0 100.0
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Summary of Regulatory Category
Frequency Percent
Valid FDA Only 60 50.4
FDA+Othe
rs 31
261
Unknown 26 21.8
Total 117 98.3
Missing System 2 1.7
Total 119 100.0
10-
0J --------- 1------------------   I-------------  I-
FOAOrtj FOA*Of*» LMCC«*
ShortRegCat
Figure 4.2.3.2 Length of time in pharmaceutical industry distribution.
4.2.4 Quality' M anagem ent system  distribution
The distributions for quality system management environment as specified in the
questionnaire are shown in figure 4.2.4.1. The data was then summarised into four 
categories (ISO only, TQM only, Hybrid and No QMS environments), which 
represented 96.7% of the cases in the data. Figure 4.2.4.2 shows the distribution for
the summarised quality categories.
173
F
r»
q
u
»
n
c
y
Quality Category
Frequency Percent
Valid ISO only 75 630
TQM
only 7 5.9
ISO&TQ
M 3 2.5
ISO&6SÌ
gma 1 8
Hybrid 22 18.5
None 11 9.2
Total 119 100.0
QuaRtyCatagory
Figure 4.2.4.1 Quality System Environment distribution.
ShortQualCat
S h o rtQ u a C a t
Frequency Percent
Valid ISO only 75 63.0
TQM
only 7 5.9
Hybrid 22 18.5
None 11 9.2
Total 115 96.6
Missing System 4 3.4
Total 119 100.0
Figure 4.2.4.2 Quality System Environment summarised categories
distribution.
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The array of environments present in the data meant that analysis could be 
performed across the subgroups to test for differences and for comparison with the 
literature.
4.2.5 Com plexity o f  autom ation in end production distribution
C om plexity
5 0 -  
4 0 -
>»
g  3 0 -
3
I
U_ 20-
1 0 -
u I I I
0  1 2 3 4 5 6
C om plexity  R ating
Figure 4.2.5.1 Automation complexity distribution.
As can be seen in figure 4.2.5.1, there was a good spread of respondents from 
those who rated the complexity of the automation making up their products as low, 
to those who rated theirs as high. This was an important background variable and
Frequency
Percen
t
Valid 0 5 4.2
1 5 4.2
2 5 4.2
3 29 24.4
4 13 109
5 20 16.8
6 41 34.5
Total 118 99.2
[ Missing 1 .8
[Total 119 100.0
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sufficient representation was necessary from across the range of complexities. The 
data could be further summarised into low-medium-high categories by considering 0- 
1 as low complexity. 2-4 as medium complexity and 5-6 as high complexity (although 
it could be argued that the data could be handled ordinally also, as was done later in 
the analysis for completeness). Figure 4.2.5.2 below shows the summarised 
complexity frequencies.
Sum m aryC o m p iex lty
IM u n  C ^ rpnty H & C er& m t,
Sum m a ryComptexHy
Frequency Percent
Valid Low
Complexity 10 8.4
Medium
Complexity 47 39.5
High
Complexity 61 51.3
Missing
Total 118 99.2
1 .8
Total 119 100.0
Figure 4.2.5.2 Summary of automation complexity distribution.
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4.2.6 C ritica lity  d istr ibu tion
CrWcaKty to u m t ' i  *nd product quality
0 « 2 I  4 (  •
CfMcatty
Figure 4.2.6.1 Criticality to end user product quality distribution.
Figure 4.2.6.1 above shows the distribution of how critical the respondent’s believed 
their systems to be to the end user’s product quality. Again, a good distribution 
across the range of possible criticality levels was obtained to allow analysis across 
the range for differences in dependent scores. Figure 4.2.6.2 below summarises 
these criticality ratings in terms of low (0-1), medium (2-4) and high (5-6) criticalities 
to allow categorical analysis and ease of understanding of the distribution and its 
effects.
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Summary of Crttcjttty
Frequency Percent
Valid Low 16 13.4
Medium 50 42.0
High 52 43.7
Total 118 99.2
Missing 1 .8
Total 119 100.0
Critical tty
Figure 4.2.6.2 Summary of criticality to end user product quality
distribution.
4.3 Exploratory Factor Analysis
In the development stages of the study a set of constructs were derived from the 
literature that attempted to represent a set of sub-variables, each sub-variable in turn 
then being used as an indicator for Quality Practices, Regulatory Practices and 
Business Performance ‘parent’ variables. The relationships between the sets of 
variables and their ‘parent’ variables were very much hypothetical until sufficient 
data could be collated to test for the presence of underlying or latent concepts that 
would verify the suitability of the sub-variables to represent the main variables. 
Exploratory factor analysis was used to uncover such underlying variables Principal
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Components Analysis (PCA) was used for the factor methodology and is suitable for 
developing empirical summaries of the data set [167][168]
The strategy was to pool all the sub-variable constructs (questionnaire item 
responses) for each parent variable into a factor analysis in SPSS, extract a number 
of components, find ‘meaning’ in the extracted components, and relate the meaning 
to the hypothesised sub-variables The resultant factors were then used to produce 
standard summated scales, whose reliability was tested using Cronbach’s alpha 
Once a reliable series of constructs were produced, they were tested for construct 
validity by checking the resulting items against the initial hypothesised items to 
ensure that important indicators for the main constructs still existed in the summated 
scale data
The result was that 6 factors were extracted to validly represent quality practices 3 
factors were extracted to represent regulatory practices and 2 to represent business 
performance All these factors then formed the basis for reliable sub-scales This 
resulted in using 34 out of the 49 quality questionnaire items, all 16 regulatory 
questionnaire items and all 6 business items (see section 4 3 1) The eleven 
resultant variables were then easy to use to test hypotheses and generally assess 
the data, in that a small number of variables could be used in the analysis
It was expected that extracted factors would correlate with each other, therefore 
oblimin rotation (oblique) was used [167] in extraction Oblique extraction would
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have produced orthogonal (unrelated) factors, which would not have been applicable 
for this analysis Principal components analysis produces an un-rotated pattern 
matrix, which is difficult to interpret Rotation produces a more meaningful final 
solution and shows up clearer distinctions between factors allowing for easier 
extraction of factors Only the rotated pattern matrices are reproduced here
4 3 1 Derivation o f quality practices factors
The 49 questionnaire items (numbers 13-58 and numbers 71,74,75) used as 
indicators of quality were placed in the SPSS factor analysis engine The mean 
communality (= part of variance in common among items) for the questionnaire 
items was 0 56 and there were more than 30 variables, which meant that the 
conditions under which Kaiser’s criteria for the number of factors to extract had not 
been met [168] Hence, a ‘scree’ plot was used to determine the number of 
components to retain This meant that the point of inflection of the scree curve as 
seen below in Figure 4 3 11 could be used as an indicator for how many 
components (factors) to retain to represent the initial data Using Kaiser’s criteria 
would have yielded 11 factors (eigenvalues > 1) Using the scree plot and evaluating 
the additional amounts of variance accounted for by each additional factor, it was 
clear that 6 factors, representing 56 217% of the total variance of the data would be 
appropriate SPSS was then instructed to accept 6 factors The additional 
contributions to the total variance from taking additional factors was negligible, as 
indicated by the scree plot in Figure 4 3 11
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Scree Plot
Figure 4 3 1 1  Scree plot for quality related questionnaire items
The Keiser-Meyer-Olkin (KMO) test for sampling adequacy and Bartlett’s test of 
sphericity are standard tests for proving the suitability of factor analysis The KMO 
test shows sampling adequacy and must be greater than 0 6 [169] Bartlett’s test 
verifies that the correlation matrix between all the items is not an identity matrix 
when it is significant For the quality items, KMO = 0 844 and Bartlett’s test was 
significant (p<0 001) The data selected was hence acceptable for factor analysis as 
can be seen from the results in Table 4 3 11
181
Table 4 3 1 1  KMO and Bartlett's Test for Quality questionnaire items
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy 844
Bartlett's Test of 
Sphericity
Approx Chi-Square 3532 173
Df 1128
Sig 000
The rotated pattern matrix was then analysed to derive meanings from the factors 
and to ensure that unique (although correlated) factors were being extracted Where 
questionnaire items had comparable loadings across several factors, these items 
were dropped In total, 15 items were dropped in this manner It is arguable that 
these could be retained but they would then have to be included in the summated 
scale for each factor By removing those common items it was possible to achieve 
more unique factors whilst not compromising the validity of the derived factors The 
item loading from the derived factors needed to be 0 4 or better for inclusion in the 
final summated scales [167] The pattern matrix is shown below in Table 4 3 12  and 
the excluded (common) items in Table 4 3 13
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Table 4 3 12 Rotated pattern matrix showing extracted components, their
associated items and items / components loadings
1 2 3 4 5 6G
eneral Q
M
S
i
C
ustom
er 
Service 
and 
Leadership
Software 
C
ontrol
Training 
and 
H
R
M
D
esign
D
ocum
entation
Use 
of 
procedures 
policies 
and 
standards
HighEmphasisPersDevI 4 0 765863
LeadersReinforceExcellencel 5 0 640654
EmployeesEm powered 16 0 730266
EmployeesFeelValuedl 7 0 658464
RegQuahtyTraimng19 0 428115
CustomersRateQShighly20 0 542849
Custl nvolvedl mprovement21 0 442159
CustRelationsManaged22 0 582470
Man ExcellentCustl nteract26 0 688158
lssuesQuicklyComm28 0 517519
QualPolsKnownbyStaff32 -0 491298
WorkC!oselyProcedures34 -0 491248
WorkCloselyStandards35 -0 640999
RegularQMSReviews38 0 653194
RegCompAuditsQMS40 0 720581
SuppPerformMeasured43 0 660652
PerformlndicUsedChange44 0 717541
DaytodayWorkPracticesDoc45 0 577700
CustCompSys48 0 551382
FreqCustSatisSurveysSO 0 614402
QMSResponsibility51 0 428776
QualAwareCampaigns53 0 656098
MultiDepartTeams54 0 613871
Qua!PlanFutureObjectives55 0 673568
QualAgreeMainSuppliers56 0 599593
SupplierAudits57 0 490071
lnternalPerfMeasurement58 0 783358
Eval ReqSpecsBeforeCloseout37 -0 528491
Extensivel nfoGatheredDevel41 -0 706511
ExtensivelnfoGatheredTest42 -0 757369
P K r t t Ä W s s s i s a » « » m m n m
RevisionControlSys75 0 790599
CodeSecurityManaged71 0 864097
LifeCycle74 0 799314
n’V" ' y s.1'  ^'■ ' ‘ " . ,  ,Alpha 0 9Ô9 r 0 680 ■ 'v 0807 0 61Ì ~ 0 790 : 0 724
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The reliability coefficients (Cronbach’s Alpha) are also shown for each set of scale 
items that would be created on the basis of the factor analysis In each case but one 
the Alpha value exceeds the 0 7 value normally required to indicate reliable scales
[167] The second factor had an Alpha of 0 680, which was sufficiently close to 0 7 to 
retain Therefore a value of 0 68 is not a major infringement of the requirement For 
the ‘design documentation’ factor there was significant gain in Cronbach’s Alpha if 
item 46 was dropped The item itself had no theoretical basis for inclusion in such a 
group in any case and so was not used in this factor leading to a more reliable, valid 
and focused factor
The common questionnaire items that were common to more than one factor were 
eliminated as discussed, these can be seen in table 4 3 13  below The items that 
had a loading of less than 0 4 by any factor are also shown here Items with a 
loading of 0 4 or less are deemed to have a weak relationship to the factor and are 
hence redundant The remaining items ensure that the factors remain valid None of 
the items in this table were considered further in the study Blank spaces on pattern 
matrices aid clarity in that they indicate that the loadings were less than the 0 4 cut 
off
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Table 4 3 1 3  Rotated pattern matrix showing extracted components, and 
associated items with low or common loading from components
1 2 3 4 5 6G
eneral Q
M
S
C
ustom
er Service 
and 
Leadership
Software 
C
ontrol
T^raining 
and 
H
R
M
Design 
D
ocum
entation
Use 
of procedures 
policies 
and 
standards
i
QMSMaturity52
lndirectAfterSalesTech47
ManlnvolvedDecMaking23
QuallssuesRegDiscussMeet29
PercentT imeDocument49
CompKnowsSupplierQMS31 •~y.' .'-''v .- - .  ' . 'n 1-'
FormalGoalsObjectivesI 8 0 403413 0 454359
ManCommitQuallmprove25 0 484726 -0 43851
QuallssuesRepTopManage24 0 404953 -0 44486
QualVeryWellPlanned30 0 400824 0 406845
QualPo)sWidelyAvail33 0 463612 -0 48118
EvalReqSpecsDuringDesign36 -0 49829 -0 40115
QMSWellKnown27 0 402569 -0 43846
RegGenWorkPracticeReviews39 0 518813 -0 41392
StaffGetJobTrainmg13 0 469497 -0 41792
The factors had then to be categorised in terms of the common ground that they
appeared to cover Table 4 3  14  below explains the rationale in naming the six 
factors as they were
Table 4 3 1 4  Rationale for naming extracted components
Factor
No
Sum m ary
Nam e
Rationale for Sum m ary
1 General QMS This factor was made up of a large number (14) of highly 
correlated items that all surrounded the internal operations 
involved in a quality management system The factor was made 
up of elements involving reviews and audits, use of 
measurement, documentation of work practices, customer 
complaints and feedback mechanisms, clear quality 
responsibilities, quality communication, planned quality and 
supplier management
2 Customer 
Service and 
Leadership
Whereas the General QMS factor had elements that 
represented the Customer management systems, the second 
factor was based on perceived commitment to customer service
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Factor
No.
Sum m ary
Name
Rationale for Summary
and the performance of customer service. It also contained 
elements relating to leadership involvement in quality and the 
overlap between leadership involvement and customer 
sen/ices.
3 Software
Control
This consisted of the 3 questionnaire items directly related to 
software control and it was expected that these items would 
form a distinct factor. This acted as a form of validation for the 
factor analysis effort.
4 Training and 
HRM
The fourth factor grouped 5 items together that represented 
human resources management and training. The five elements 
were essentially motivational and formed an understandable 
factor also.
5 Design
Documentation
The three items correlated to this factor all concerned the 
collection and collation of documented information during the 
design phase.
6 Use of 
procedures 
policies and 
standards
This distinct factor contained elements representing knowledge 
and application of procedures, policies and standards.
As all factors were produced through oblique rotation it was not expected that
orthogonal (unrelated) components would be produced. The verification of this can 
be seen in the correlation matrix in table 4.3.1.6, which shows the correlation 
between the summated scales produced for each factor. These summated scales 
were acquired by summing the item scores for each item present in the 
corresponding factor. Each questionnaire had a score representing each extracted 
factor. Table 4.3.1.6 was then achieved by looking at the correlations between 
scores across the survey data. SPSS also produced a between factor correlation 
matrix which is shown in Table 4.3.1.5. This uses SPSS derived factor scores for the 
survey data rather than summated scales. With the exception of some of the 
software quality correlations, there is a significant correlation between all the 
extracted quality factors, which vindicates their usage as overall quality indicators 
and also validates the use of oblique factor rotation [167][168].
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Table 4 3 1 5  C orrelation  m atrix  for quality factor extracted  com ponents from  SPSS
Component
General
QMS
Customer
Service
Leadership
Software
Control
Training
HRM
Design
Doc
Use
Procedure
Policies
Standards
General
QMS
100 0 077 238 183 -192 359
Customer
Service
Leadership
077 1000 066 276 -216 -197
Software
Control
238 066 1000 130 -169 -096
Training
HRM 183 276 130
1000 -142 - 166
Design
Doc
-192 -216 -169 142 1000 252
Use
Procedure
Policies
Standards
-359 -197 -096 - 166 252 1 000
Extraction Method Principal Component Analysis Rotation Method Oblimin with Kaiser Normalization 
Table 4 3 1 6  Correlation matrix for quality factor sum mated scales
General
QMS
Customer
Service
Leadership
Software
Control
Training
HRM
Design
Doc
Use
Procedure
Policies
Standards
General QMS r 1 00 0 21 0 29 0 34 0 49 0 52
Sig 0 02 0 00 0 00 0 00 0 00
Customer
Service
Leadership r 0 21 1 00 0 15 0 51 0 38 0 42
Sig 0 02 0 00 0 00 0 00
Software
Control r 0 29 0 15 1 00 0 16 0 32 0 21
Sig 0 00 0 09 0 09 0 00 0 02
Training HRM r 0 34 051 0 16 1 00 0 35 0 49
Sig 0 00 0 00 m s m m 0 00 0 00
Design Doc r 0 49 0 38 0 32 0 35 1 00 0 58
Sig 0 00 0 00 0 00 0 00 0 00
Use Procedure
Policies
Standards r 0 52 0 42 021 0 49 0 58 1 00
Sig 0 00 0 00 0 02 0 00 0 00
187
The non-significant and low correlations between software control and some of the 
other factors was not unexpected as software quality is a more specialised aspect of 
quality in general and may not necessarily be mutually inclusive.
It was important to establish construct validity at this point by comparing the 
literature derived indicators of quality to the resultant indicators present in the 
extracted factors. Table 4.3.1.7 shows how this was established.
Table 4.3.1.7: Relationship between literature derived quality indicators, 
representative constructs and extracted factors.
Quality variable Proposed
Item
Used? Variable
represented?
Factor
Training and Development
13
No Yes None
14 Yes Training and HRM
19 Yes Training and HRM
Teamwork and HR
16
Yes Yes Training and HRM
17 Yes Training and HRM
18 No None
Customer Focus 20 Yes Yes Customer Service / Leadership
21 Yes Customer Service /  Leadership
22 Yes Customer Service / Leadership
48 Yes General QMS
50 Yes General QMS
Leadership
15
Yes Yes Training and HRM
23 No None
24 No None
25 No None
26 Yes Customer Service / Leadership
Communication
53
Yes Yes General QMS
54 Yes General QMS
27 No None
28 Ygs Customer Service / Leadership
1 8 8
Quality variable Proposed
Item
Used? Variable
represented?
Factor
29 No None
Quality Planning
55
Yes Yes General QMS
30 No None
Documented Quality 
Policies 32
Yes Yes Use of procedures policies and 
standards
33 No None
Use of standards practices 
and procedures
34
Yes Yes Use of procedures policies and 
standards
35
Yes Use of procedures policies and 
standards
Requirements
management
36
No Yes
-
None
37 Yes Design Documentation
Reviews and Audits
38
Yes Yes General QMS
39 No None
40 Yes General QMS
Quality driven documented 
processes
41
Yes Yes Design Documentation
42 Yes Design Documentation
45 Yes General QMS
49 No None
Measurement
44
Yes Yes General QMS
58 Yes None
Service provision
46
No No None
47 No None
Quality system 
infrastructure
11 No Yes None
51 Yes General QMS
52 No None
Supplier management
31
No Yes None
43 Yes
* -  J General QMS
56 Yes General QMS
57 Yes ttA  - General QMS
Software control
71
Yes Yes Software Control
74 Yes frJ  -  7 Software Control
75 Yes Software Control
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As can be seen from Table 4 31 7, 15 of the 16 indicators of quality (quality criteria) 
derived from the literature in the literature review stage of the study were 
represented by the final quality factors However the value of carrying out factor 
analysis as a basis for detecting underlying latent components in the data is clear 
here, as some of the constructs developed to represent a particular variable actually 
had a higher correlation with a different component and were hence used in the 
summated scale for the more appropriate construct In the pilot study simple 
summated scales were used which may not have been valid (although adequate for 
the purposes of assessing whether it was possible to analyse the pilot survey data) 
However the use of factors and the theoretical relationship between them and the 
literature deduced variables demonstrates the validity of the questionnaire items
4 3 1 1  Distribution of quality factors
Normal distributions were obtained for all the factors This was determined by using 
measures of skewness and kurtosis and by inspecting histograms Values with an 
absolute magnitude less than one represent good normality These were achieved 
as can be seen in Table 4 3 11 1  and in Figures 4 3 11 1  to 4 3 1 1 6 The 
normality, interval size and hence approximation to continuous (interval) data made 
the use of parametric methods more appropriate than if this approximation was not 
there
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Table 4.3.1.1.1: Distributions for quality factors.
General
QMS
Cust
Service
Leadership
Software
Quality
Training
HRM
Design
Doc
Use of 
Procedure« 
Policies and 
Standards
Valid N 119 119 119 119 119 119
Missing N 0 0 0 0 0 0
Mean 2.17 2.94 2.27 2.57 3.18 2.71
Std.
Deviation 0.68 0.52 0.93 0.67 0.65 0.67
Skewness -0.72 -0.11 -0.87 -0.03 -0 34 -0.25
Std. Error 
of
Skewness 022 0.22 0.22 022 0.22 0.22
Kurtosis 043 -0.05 0.09 -0.441 -0.39 0.17
Std. Error 
of
Kurtosis 044 0.44 044 0.44 0.44 0.44
C  u * t < t i p
m • * -  
»
\
ÄI SO 2.00 2*0 IAO I JO  •  OO
Figure 4.3.1.1.1: General QMS Distribution. Figure 4.3.1.1.2: Customer Service
I Leadership distribution.
TrainlngHRM
Figure 4.3.1.1.3: Training and 
HRM distribution.
S  o f t w a r  • Q u a l i t y
O OO 1OO 2.00 3 00 4.00
Figure 4.3.1.1.4: Software Control 
distribution.
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D »»l< jnO oc
Figure 4.3.1.1.5: Use o f Procedures. Figure 4.3.1.1.6: Design
Policies and Standards distribution. Documentation distribution.
4.3.2 D erivation  o f  reg u la to ry  p rac tices fac to rs
The 16 questionnaire items (numbers 59 to 70, 77 and the grouped ERES items 72, 
73 and 76) used as indicators of regulatory practices were placed in the SPSS factor 
analysis engine. The mean communality for the questionnaire items was 0.67 
(sufficiently close to 0.7) and there were less than 30 variables which meant that the 
conditions under which Kaiser’s criteria for the number of factors to extract had been 
met and could be applied to determine the amount of factors or components to retain
[168].
The suitability of the data for factor analysis was assessed. The KMO value was 
0.874 and Bartlett’s test of sphericity was significant meaning that the test was 
appropriate to the data as shown in Table 4.3.2.1.
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Table 4 3 2 1 KMO and Bartlett's Test for regulatory practices variables
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy 874
Bartlett's Test of 
Sphericity
Approx Chi-Square 802 658
df 78
Sig 000
The standard cut off eigenvalue of 1 was used for extraction Also, a ‘scree’ plot was 
used to confirm the number of components to retain This meant that the factor table 
(Table 4 3 2 2) and the point of inflection of the scree curve as seen below in Figure 
4 3 2 1 could be used as an indicator for how many components (factors) to retain to 
represent the initial data Using Kaiser's criteria, 3 factors (eigenvalues > 1) were 
extracted, representing 66% of the total variance in the data
Table 4 3 2 2 Factor table showing cut o ff fo r Eigenvalues above 1 (retained 
______________________ factors) ____________________
Total Variance Explained
Component Initial Eigenvalues
Total
% of
Variance
Cumulative
%
1 5 937266 45 67128 45 67128
2 1 553451 11 94962 57 6209
3 1 085636 8 351043 65 97194
Cut off 4 0 83809 6 446846 72 41879
5 0 758198 5 832291 78 25108
6 0 571003 4 392334 82 64341
7 0 515992 3 969171 86 61258
8 0 439361 3 379698 89 99228
9 0 380168 2 924366 92 91665
10 0 3332271 2 563281 95 47993
11 0 222866 1 71435 97 19428
12 0 202769 1 559761 98 75404
13 0161975 1 24596 100
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Sc re e  P lo t
C o m p o n e n t  N u m b e r
Figure 4 3 21 Scree plot for regulatory practices components
Using oblimin rotation, meaningful factors were then derived for use with summated 
scales Table 4 2 2 3 shows the derived pattern matrix with the interpreted factors 
and their loadings with the individual questionnaire items All the regulatory practice 
questionnaire items were retained for use in the summated scales As all the 
questionnaire items were used the scales could be deemed valid with respect to the 
literature derived variables for regulatory practices It should be noted that the three 
ERES related items (numbers 72, 73 and the five sub-components of number 76) 
formed a sub-scale in itself A factor analysis was carried out to verify that these 
represented a single factor and was successful The Cronbach’s alpha for the sub­
scale was 0 908
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Ta jle 4 3 2 3 Rotated pattern matrix for regulatory practices factors
D
irect R
egulatory 
Involvem
ent
Intrinsic 
R
egulatory 
C
om
pliance
R
egulatory
D
ocum
entation
A
vailability
ERES 0 67
SysDevKnowGMP59 0 69
GAMPused61 0 90
GMPmajorDesignConsider62 0 79
SysDesDevRegCompT rng63 0 58
ExtentGAMPoverStandards64 0 94
FeaturesBuiltlnVal65 0 73
ValConsideredEarlyDesign66 0 83
QMSbasedRegReq67 0 69
DesDocWellDocAnyway60 0 64
RegCompAuditsProd70 0 57
DesignDocAvail68 0 82
ValDocAvail69 0 67
a i & ï ï s î ï f i C f GPf6î
The reliability of the sub-scales is also evident from the values of Cronbach’s alpha 
achieved, which were above 0 7 in all cases The explanation of the regulatory 
factors is detailed in Table 4 3 2 4
Table 4 3 2 4 Meaning of regulatory factors
Factor
No
Sum m ary
Nam e
Rationale for Sum m ary
1 Direct
Regulatory
Involvement
This factor contained questionnaire items that required direct 
regulatory knowledge and application of GAMP, 21 CFR Part 
11, and the GMPs
2 Intrinsic
Regulatory
Compliance
This factor involved inherent components of regulatory 
compliance such as compliance audits, validation, and 
documentation of design work for regulatory purposes
3 Regulatory
Documentation
Availability
This factor contained 2 items that were solely about the extent of 
availability of design and validation documentation
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The correlation between the derived factors and between regulatory scales shows 
that strong cross correlations existed, demonstrating the usefulness of oblimin 
rotation for this data Again, as for the quality factors, SPSS produced a correlation 
matrix using its factor scores The summated scale correlation matrix was acquired 
by summing the items related to each factor Tables 4 3 2 5 and 4 3 2 6 show the 
factor correlations and scale correlations respectively
Table 4 3 2 5 Factor Correlations for regulatory variables
Component
IntnnsicR
egCompli
ance
RegDocA
vailability
DirectReg
Involvem
ent
IntrinsicReg
Compliance 1 00 42 23
RegDocAva
ilabilit
42 1 00 290
DirectRegln
volvement 23 29 1 00
Table 4 3 2 6 Scale Correlations for regulatory variables
IntnnsicRegC
ompliance
RegDocAva 11 
ability
DirectReglnv
olvement
IntrinsicRegCompliance Pearson Correlation 1 47(**) 51(**)
Sig (2-tailed) 000 000
RegDocAva i lability Pearson Correlation 47(**) 1 s i n
Sig (2-tailed) 00 00
DirectReglnvolvement Pearson Correlation 51(**) 51(**) 1
Sig (2-tailed) 000 000
** Correlation is significant at the 0 01 level (2-tailed)
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4.3.2.1 D istribution o f regulatory factors
Normal distributions were obtained for all the regulatory factors. This was 
determined by using measures of skewness and kurtosis and by inspecting 
histograms. Values with an absolute magnitude less than one were achieved again 
represent good normality. These can be seen in Table 4.3.2.1.1. and in Figures
4.3.2.1.1 to 4.3.2.1.3.
Table 4.3.2.1.1: Distributions for regulatory factors.
DirectReglnvol
vement
IntrinsicRegCo
mpliance
RegDocAvailab
ilrty
N Valid 118 118 118
Missing 1 1 1
Mean 22294 22475 2.1186
Skewness -338 -.310 -307
Std. Error of Skewness 223 223 223
Kurt09is -986 -388 -944
Std Error of Kurtosis 442 442 442
h * * » k > R * C t r * * » n c .  I > * d f * g l r v d « m « r <
Figure 4.3.2.1.1: Intrinsic Regulatory Figure 4.3.2.1.2: Direct Regulatory
compliance distribution compliance distribution
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RegDocAvwlabHlty
Figure 4.3.2.1.3 Regulatory documentation 
availability distribution.
4 .3 3  Derivation o f  business perform ance factors
The 6 questionnaire items used as indicators of business performance (number 79 
to 84) were placed in the SPSS factor analysis engine. The mean communality for 
the questionnaire items was 0.68 and there were less than 30 variables which meant 
that the conditions under which Kaiser’s criteria for the number of factors to extract 
had been met and could be again applied to determine the amount of factors or 
components to retain [168].
The suitability of the data for factor analysis was assessed. The KMO value was 
0.684 (above the required 0.6 for sampling adequacy) and Bartlett’s test of sphericity 
was significant meaning that the test was appropriate to the data as shown in Table
4.3.3.1.
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Table 4 3 31 KMO and Bartlett's Test for business performance variables
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy 684
Bartlett's Test of 
Sphericity
Approx Chi-Square 245 374
df 15
Sig 000
Two factors were derived from the data representing 67 9% of the total variance 
using the factor table as shown in table 4 3 3 2 below Again Kaiser's criteria was 
used to retain factors, the goal being to represent the data by the fewest possible 
number of components, which represent an acceptable amount of the total variance
Table 4 3 3 2 Factor table showing cut off for Eigenvalues above 1 (retained
factors)
Total Variance Explained
Component Initial Eigenvalues
Total
% of 
Variance
Cumulative
%
1 2 784047 46 40078 46 40078
2 1 288412 21 47353 67 8743
Cut off 3 0 78521 13 08684 80 96114
4 0 597051 9 950851 90 91199
5 0 352116 5 868603 96 7806
6 0193164 3 219403 100
With only 6 questionnaire items the scree plot was not a very useful indicator as no 
obvious point of inflection was shown The oblimin rotation produced two meaningful 
factors, one related to the items which were clearly surrounding market share and 
competitiveness and the other related to changes in profit and sales Both can be 
seen with their loadings on the questionnaire items in the rotated pattern matrix in 
table 4 3 3 3
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Table 4 3 3 3 Rotated pattern matrix for business performance factorsM
arket Share 
/ 
C
om
petitiveness
Profit and 
S
ales 
Increase
ProfitLevelchange5yrPharma80 0 795857
SalesVolChange5yrPharma81 0 814073
NewProdSalesPharma2yr82 0 816769
MSchange5yrPharma79 0 507938
MarketShareRelative83 0 933486
OverallCompPositionRel84 0 952175
R fc c ' - -
The scale reliabilities for the 2 extracted factors were good, with each 3-item 
summated scale yielding a Cronbach’s alpha of 0 755 All 6 questionnaire items 
were retained for the 2 remaining variables, which was a positive indicator for the 
validity of the scales and factors The first extracted factor related to Market share 
and competitiveness and the second to changes in sales and profitability in relation 
to expectations The factors were hence named ‘Market Share / Competitiveness’ 
and ‘Profit and sales increase’ The factors, using SPSS factor scores, had a 
positive correlation (pearson’s r) of 0 360 and the summated scales had a positive 
correlation of 0 359 significant at the p=0 01 level
4 3 3 1 Distribution of business performance variables
Normal distributions were obtained for both business variables as can be seen from 
the skewness and kurtosis values in table 4 3 31 1 and the histograms in figures 
4 3 3 1 1 and 4 3 3 1 2
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Table 4.3.3.1.1: Distribution of business performance variables.
Market Share / 
Competitiveness
Sales / Profit 
Improvement
N Valid 118 118
Missing 1 1
Mean 3.3418 1.9492
Std. Deviation 1.08994 .54018
Skewness -.421 -.092
Std. Error of Skewness .223 .223
Kurtosis -.219 .271
Std. Error o f Kurtosis .442 .442
n u i> * t ih « i» C o «  p * tu . * n * « i l * l « i  P i o t t f c  p f O i« a  * n t
/
Figure 4.3.3.1.1: Market Share 
I Competitiveness distribution.
Figure 4.3.3.1.2 Profit I Sales 
Improvement distribution.
4.4 Central hypothesis exam ination and explorations
The relationships between the factors were assessed using correlation analysis. 
Parametric tests were used as the criteria under which they could be employed were 
satisfied [167][168]. Stepwise multiple-regression was then used as the multivariate 
technique to assess the unique contribution of independent quality and regulatory
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factors to the dependent business factors The categorical background variables 
were then assessed to check for and to illustrate sub-group differences
4 4.1 Correlations between the quality, regulatory and business factors
Table 4 4  1 1 shows Pearson's r values for the all the quality, regulatory and 
business factors with the significant correlations (p< 05 and p< 01) highlighted The 
inter-correlations within each factor group were expected and have already been 
identified in the factor analysis
Of 18 possible correlation events between the three regulatory factors and the six 
quality factors, 16 had positive significant correlations The two exceptions were 
those between Customer Service and Leadership and Regulatory Documentation 
Availability and between Training and HRM and the same regulatory factor In 
general though it can be said that regulatory practices and quality practices are 
correlated (H2) although no determination of causation could be made
The correlation between business factors and quality factors was not so numerous 
Market Share and Competitiveness had a positive modest correlation with General 
QMS and had a low positive correlation with Training and HRM, and Use of 
Procedures, Policies and Standards Sales and Profit improvement had a low 
positive correlation with General QMS What this meant was that H1 could only be
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partially accepted in that certain aspects of quality practices are correlated to certain 
aspects of business practice
There were low to modest positive correlations between the three regulatory practice 
factors and market share, and between Intrinsic Regulatory involvement and Profit 
and Sales improvement This meant that H3 could also only be partially accepted
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Table 4.4.1.1 Correlation analysis (to 2 significant figures) showing significant
relationships w ithin and between factor groups.
Quality Regulatory Business
■
G
eneralQ
M
S
C
ustS
ervLeadership
œ
3
3
—1
3
5 '
5
(O
I
n
s
D
esignD
oc
U
seP
rocsP
olsS
tandards
0
1
73
<2
3
é
ZO
3
CO
3
IntnnsicR
egC
om
pliance
73
0
1 
è
1
M
arketS
hare
C
om
petitiveness
£
V)
~0
2 ,
ä
3
T>
O
$
3
<D
3
0 2 2GeneralQMS
P e a r s o n
C o rre la tio n 1  0 0 0 2 1 0 2 9 0 3 4 0 4 9 0  5 2 0 2 6 0 6 0 0 2 3 0 .4 1
S *  (2- 
ta iled) 002 000 000 0.00 000 0.00 0.00 001 000 0.02
CustServLeadership
P e a r s o n
C o rre la tio n 0 2 1 1  0 0 0 1 5 0 5 1 0 3 8 0 .4 2 0 .2 8 0 .2 1 0 1 3 0 1 2 0 0 2
S tg  (2- 
ta iied) 0.02 0 0 9 0.00 0.00 000 0.00 0.02 0 1 7 0 2 0 0 8 6
SoftwareControl
P e a r s o n
C o rre la tio n 0 2 9 0 . 1 5 1 0 0 0 1 6 0 .3 2 0 .2 1 0 .4 9 0 4 6 0  2 7 0 . 1 8 0 0 1
S*fl- ( 2 -  
ta iled) 0.00 0 .0 9 0 0 9 0.00 002 000 000 000 0 0 5 0 9 3
TrainingHRM
P e a r s o n
C o r r e c t io n 0 3 4 0 .5 1 0 . 1 6 1 .0 0 0 3 5 0  4 9 0 3 4 0 2 8 0 1 3 0  22 0 .0 9
S *  (2 -  
ta iled) 000 0.00 0 .0 9 0.00 000 000 000 0 1 7 002 0 .3 4
DesignDoc
P e a r s o n
C o rre la tio n 0 4 9 0 3 8 0 3 2 0 .3 5 1 .0 0 0 5 8 0 .2 6 0 .5 1 0  2 4 0 1 6 0 0 2
S*g . (2 -  
ta iled) 0.00 0.00 0.00 0.00 000 0.01 000 0.01 0 .0 9 0 .8 1
UseProcsPolsStandards
P e a r s o n
C o rre la tio n 0  5 2 0 .4 2 0 .2 1 0 4 9 0 5 8 1  0 0 0 3 8 0 5 0 0 2 8 0 .2 9 0 . 1 0
S ig  (2- 
ta iled) 000 000 0.02 000 000 0.00 0.00 UOO 000 0 2 6
DirectRegl nvolvement
P e a r s o n
C o rre ia tio n 0 2 6 0 2 8 0 .4 9 0 .3 4 0  2 6 0 3 8 1 0 0 0 5 1 0  5 1 0 3 1 0 0 2
S *  (2- 
tailed) 000 000 0.00 000 0.01 000 0.00 0.00 0.00 0 8 4
IntrinsicRegCompliance
P e a r s o n
C o rre la tio n 0 6 0 0 2 1 0 4 6 0 2 8 0  5 1 0 .5 0 0 .5 1 1 .0 0 0 4 6 0 3 8 0  2 4
S*fl. (2 -  
ta iied j 000 0.02 000 000 000 000 0.00 000 000 0.01
RegDocAvailability
P e a r s o n
C o rre la tio n 0 2 3 0 . 1 3 0 .2 7 0  1 3 0 .2 4 0 2 8 0 5 1 0  4 6 1 .0 0 0 .2 2 0 0 8
S ig  (2 -
ta .le d ) 0.01 0 . 1 7 0.00 0 . 1 7 0.01 000 000 000 0.02 0 .3 8
MarketShareCompetitiveness
P e a r s o n
C o rre la tio n 0 4 1 0 . 1 2 0 1 8 0  2 2 0  1 6 0 2 9 0  3 1 0 3 8 0 2 2 1 .0 0 0 3 7
s*g (2-
ta .ied ) 000 0 .2 0 0 0 5 0.02 0 .0 9 000 000 000 002 0.00
SalesProfitlmprovement
P e a r s o n
C o rre la tio n 0 .2 2 0  0 2 0 0 1 0 0 9 0 0 2 0 . 1 0 0 0 2 0 2 4 0 0 8 0 3 7 1  0 0
S tg . (2 -  
ta iled) 0.02 0 8 6 0 .9 3 0 3 4 0  8 1 0 2 6 0 8 4 0.01 0 3 8 0.00
Significant at p=.05 level Significant at p=.0 l evel
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4 4 2 Regression analysis
Stepwise multiple-regression was used to determine the unique contribution to each 
business factor from each of the independent correlated quality and regulatory 
factors For the Market share and Competitiveness factor, General QMS, Training 
and HRM, Use of Procedures, Policies and Standards, and the 3 regulatory factors 
were entered in Stepwise regression enters in variables with the highest 
contribution first and so on, eliminating any variable that does not meet criteria for 
inclusion related to that variable’s unique contribution The SPSS regression output 
is shown in table 4 4 2 1 Significance levels were again low, mostly below the 
p=0 01 level
Table 4 4 21 Stepwise Regression coefficients for Market Share and 
Competitiveness factor with all correlated factors applied as independent
variables
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig
B Std Error Beta
1 (Constant) 1 932 308 6 278 000
GeneralQMS 654 136 411 4 829 000
2 (Constant) 1 620 324 4 999 000
GeneralQMS 563 137 353 4 110 000
DirectReglnvol
vement
230 089 222 2 578 O il
a Dependent Variable MarketShareCompetitiveness
Table 4 4 2 1 shows the stepwise entry of General QMS, followed by the combined 
entry of General QMS and Direct Regulatory involvement into the model
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The standardized regression equation that was yielded, showing unique contribution 
to the dependent variable was hence
The two terms deemed by the SPSS procedure to be significant enough to be 
included in the regression equation were General QMS and Direct Regulatory 
Involvement Inclusion of further terms did not increase Market Share sufficiently 
when General QMS and Direct Regulatory involvement were controlled The optimal 
stepwise model was hence produced The adjusted R2 for the equation was 0 201, 
that is 20 1% of the change in Market Share and Competitiveness score could be 
explained by the influence of General Quality Management and Direct Regulatory 
involvement The F ratio for the equation was computed and was significant at the 
p=0 01 level, meaning that the R2 value achieved was unlikely to be zero in the 
population
As standardized coefficients have been employed, the influence of QMS is 0 353 / 
0 222 = 1 6 times (not accounting for error) greater than that of Direct Regulatory 
Involvement In reality this means that increasing efforts in the area of general QMS 
would have a greater influence on market share and competitiveness than
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increasing direct regulatory involvement The influence of direct regulatory 
involvement however was still found to be substantial however It is noted that the 
eliminated independent terms in the equation are partly taken account of in that they 
are all significantly correlated with at least one of the two retained independent 
terms
The resulting Equation 1 was crucial to partially support the hypotheses H1 and H3 
in that one facet of business performance, market share and competitiveness, is 
positively influenced by general quality management systems and direct regulatory 
involvement
For the Profit and Sales improvement factor, the General QMS and Intrinsic 
Regulatory Compliance factors were input as independent variables into the 
stepwise procedure The coefficients for the resulting equation are shown in Table 
4 4 2 2 Again, the model was significant at the p=0 01 level
Table 4 4 2 2 Stepwise Regression coefficients for Sales and Profit
Improvement with all correlated factors ap plied as inde pendent variables
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig
B Std Error Beta
1 (Constant) 1 520 171 8 870 000
IntrinsicRegCo
mphance
191 073 237 2 612 010
a Dependent Variable SalesProfitlmprovement
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The resulting equation was hence
That is the influence on Sales and Profit Improvement by the independent factors 
could be represented adequately by the variation in Intrinsic Regulatory Compliance 
However, the adjusted R2 for this equation is only 0 048 meaning that only 4 8% of 
the Sales and Profit improvement score could be explained by the independent 
factors This was still significant, however, and adds to the evidence for accepting 
H3
4 4 3 Influence of background variables on model
When the background variables (Length of time established, Length of time 
operating in Pharma, Organisation size, Complexity of Automation, Customers look 
for Quality Plans, Customers carry out audits and Criticality of product to end user 
drug quality) were added into the regression equation for the market share and 
competitiveness variable a different, but related regression equation emerged Table 
4 4 3 1 below shows the stepwise output All the other derived quality and regulatory 
factors were also added to the equation in case any of them had an effect on the 
established relationships
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Table 4.4.3.1 Stepwise Regression coefficients fo r Market Share and 
Competitiveness w ith all factors and background variables applied as 
________   independent variables. _________________
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B Std. Error Beta
1 (Constant) 1.899 .309 6.156 .000
G eneralo
MS
.660 .136 .416 4.863 .000
2 (Constant) 1.418 .321 4.416 .000
G eneralo
MS
.577 .131 .363 4.406 .000
Criticality
8 .173 .047 .301
3.654 .000
3 (Constant) 1.862 .372 5.009 .000
G eneralo
MS
.689 .138 .434 4.999 .000
Criticality
8
.182 .047 .317 3.899 .000
Estl -.206 .092 -.195 -2.256 .026
a Dependent Variabfe MarketShareCompetitiveness
The resulting standardized regression equation, showing unique contribution to the 
dependent variable, was therefore:
Regression Equation 3
Market Share and Competitiveness =
1.862 + 0.434 General QMS + 0.317 Criticality -  0.195 Established time + e3. 
where e3 is the error term.
This equation had an R2 of 0.274 meaning that 27.4% of the market share and 
competitiveness score was accounted for. The existence of Established time as a 
moderating term (negative coefficient) in the equation is interesting but as the 
General QMS score has a positive correlation (0.374 significant at the p=.01 level)
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with established time, the total market share and competitiveness should not be 
negated as time increased That is, the net effect of General QMS and Established 
time should be a positive contribution to Market Share as long as General QMS 
increases at an appropriate rate From regression equation 3 it can be seen that the 
contribution of a 2 1 unit change in time is the same as a one unit change in General 
QMS score (standardised), so as long as General QMS increases over time it should 
dominate the length of time established term
The other interesting entry into the equation was the ‘criticality of product to end user 
drug quality’ background variable This replaced the direct regulatory involvement 
term, which has moderate positive correlation (pearson’s r = 0 412, significant at the 
p=0 01 level) with the criticality variable It would seem from this that criticality was a 
greater unique contributor than direct regulatory involvement This is theoretically 
sound as criticality can be said to drive direct regulatory involvement and intrinsic 
regulatory compliance The presence of criticality did not eliminate the significant 
importance of regulatory involvement It revealed that if criticality was held constant, 
then regulatory involvement did not have any significant further influence in the 
Market Share and Competitiveness score
It should be noted that none of the remaining background variables or other factors 
appeared in the regression equation, therefore length of time operating in pharma, 
organisation size, complexity of automation, and the extent to which customers carry 
out audits and look for quality plans were not moderating or intervening variables
2 1 0
The existence of general QMS in regression equation 3 and the theoretical and 
empirical relationship between criticality and regulatory involvement means that the 
original regression equation 1 was not a spurious one with all background variables 
and the remaining factors considered
When the background variables were placed into the stepwise procedure with all 
correlated factors to the Profit and Sales improvement factor, the following 
standardised equation emerged
The SPSS output is shown below in table 4 4 3 2
Table 4 4 3 2 Stepwise Regression coefficients for Profit and Sales 
Improvement with all factors and background variables applied as 
__________________ independent variables ________ ________
Unstandardized
Coefficients
Standardiz
ed
Coefficients t Sig
B
Std
Error Beta
(Constant) 1 611 110 14 622 000
Criticality8 087 026 302 3 373 001
a Dependent Variable SalesProfitlmprovement
Again, the criticality element dominated the equation, and was sufficient to explain 
the changes in Sales and Profit Improvement scores without the requirement for
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/Intrinsic Regulatory compliance as a term Again the positive correlation (Pearson’s r 
= 0 302, significant at the p= 01 level) between these two terms means that although 
criticality would seem to have been the greater determinant, it was also a 
determinant of regulatory compliance and the hypothesised relationships between 
regulatory practices and business performance still held The R2 for the equation 
increased to 9 1% which was a doubling of the contribution offered by the model 
before the background variables were considered
The other background variables did not appear in regression equation 4, which 
indicated that the established relationship was not spurious and that none of the 
background variables could be classed as moderating or intervening variables
4 5 Sub-group differences
To determine differences in scores across the range of categorical and ordinal 
background variables non-parametric difference tests were employed, which made 
no assumptions about the sub-group sizes or distributions Section 4 2 showed that 
the sub group distributions were non-normal, making non-parametric testing 
essential The differences were assessed for each factor in terms of each ordinal 
level of the background variable and for more meaningful summary groups as 
defined in the distribution descriptions (section 4 2) Kruskal-Wallis H-tests were 
used to test for between group differences and Mann-Whitney U-tests were used to 
isolate the differences between pairs of groups when differences existed as 
determined by the Kruskal-Wallis tests The influence of the ordinal sub-groups on
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the hypotheses and the relationships developed had already been tested by means 
of multiple regression, however the information provided by the sub-group difference 
evaluations were a useful output from this research also
4 51  Differences for time established
Table 4 5 11 shows the Kruskal-Wallis H-test for the summary time established 
categories (Established <=16 years, established >16 years) A significant difference 
across categories was found for General QMS and Regulatory Documentation 
Availability scores between the two categories of time established
Table 4 5 1 1  Kruskal-Wallis H-Test for all factors using the Time Established
summary backs round variable as a grou ping variableG
eneralQ
M
S
C
ustS
erv
Leadership
S
oftw
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D
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ent
Intrinsic
R
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vailability
M
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C
om
petitiveness
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Chi-
Square 9 59 0 03 0 19 0 88 1 35 0 65 0 41 1 01 3 84 0 33 1 02
df 1 00 1 00 1 00 1 00 1 00 1 00 1 00 1 00 1 00 1 00 1 00
Asymp
Sig 0 00 0 87 0 67 0 35 0 25 0 42 0 52 0 32 0 05 0 57 0 31
a
Kruskal 
Wallis Test
b Grouping Variable Established (summary)
The difference between companies established up to 16 years, and those in 
business longer was found to be significant using the Mann-Whitney U test (all Mann 
Whitney and Kruskal Wallis significance tests are at the p=0 05 level in this thesis)
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This is illustrated in the boxplot in Figure 4.5.1.1. It was concluded from this that 
companies established more than 16 years had significantly higher General QMS 
scores that those companies established 16 years or less.
< * * 1 6 y r »  > 16y r s
Established
Figure 4.5.1.1 Differences fo r General QMS across the summarised range of
'Time Established’ Categories.
For regulatory documentation availability there was also a significant difference 
between companies who were operating up to 16 years and those operating more. 
The boxplot in figure 4.5.1.2 illustrates this. As shown, regulatory documentation 
availability scores were higher for companies established more than 16 years.
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E s t a b l i s h e d
Figure 4.5.1.2 Differences fo r Regulatory Documentation Availability across 
the summarised range o f 'Time Established’ Categories.
The statistical significant differences in scores across groups and conclusions for the 
time established in pharma background variable were the same as for when total 
time in business was considered. Therefore the above analysis applies and 
reproduction of the results of the analysis was unnecessary. Time established was 
highly correlated with time established in Pharma (pearson’s r = 0.714, significant at 
the p=.05 level).
4.5.2 D ifferences fo r O rgan isa tion  size
The results of the Kruskal-Wallis test for differences in organisation size categories 
is shown in Table 4.5.2.1. Here it can be seen that there was a significant difference 
(at the p=.05 level) in the scores for General QMS and Market Share and
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Competitiveness depending on how large a company was when assessed across 
the 5 ordinal levels as asked on the questionnaire The boxplot in figure 4 5 2 1 
illustrate the differences for General QMS Table 4 5 2  2 shows the differences 
across the groups when using the summarised organisation size categories (Org 
size < 50, 51 to 250 and >250)
Table 4 5 2 1 Kruskal-Wallis H-Test for all factors using the Organisation Size
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Chi-Square 29 51 6 16 3 45 9 39 3 68 2 60 3 37 6 49 5 61 11 55 5 60
df 4 00 4 00 4 00 4 00 4 00 4 00 4 00 4 00 4 00 4 00 4 00
Asymp Sig 0 00 0 19 0 49 0 05 0 45 0 63 0 50 0 17 0 23 0 02 0 23
a Kruskal Wallis Test
b Grouping Variable OrgSize3
Table 4 5 2 2 Kruskal-Wallis H-Test for all factors using the summarised 
Organisation Size background variable as grouping variableG
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Chi-Square 21 55 3 13 0 38 2 43 0 53 0 58 0 07 1 93 2 88 7 97 2 63
df 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00
Asymp Sig 0 00 0 21 0 83 0 30 0 77 0 75 0 96 0 38 0 24 0 02 0 27
a Kruskal Wallis Test
b Grouping Variable OrgCat
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OrgSlzo3
Figure 4.5.2.1 Differences fo r General QMS scores across the 
questionnaire range o f Organisation size categories.
The boxplots indicated increasing levels of General QMS scores up to companies
that had more than 100 employees and a general levelling off after that. This was
confirmed by the Mann-Whitney outcome shown in Table 4.5.2.3 in that there were
significant differences between those companies of 50 or less and those greater
than 100. Also, there were significant differences between the 51-100 group and all
groups with 151 employees or more. However, no differences existed between any
of the groups with greater than 100 employees. This analysis was deemed to be
sufficiently informative, and the summary categories did not need to be employed to
give more information regarding General QMS.
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Table 4.5.2.3: Outcome of Mann-Whitney difference tests fo r pairs o f 
categories showing significant differences o f General QMS scores between 
____________________   groups.____ _______________
Employees 0-50 51-100 101-150 151-200 >200
0-50 . No Yes Yes Yes
51-100 No - No Yes Yes
101-150
4 C 4  o n n
Yes No
V a c
No No
M nl D l - i C U U
>200
Y 6 S
Yes
I  © 5
Yes
IN O
No No
n o
From table 4.5.2 2 it can be seen that using the summary groupings, a significant 
difference existed for Market Share and Competitiveness. This is illustrated in Figure 
45.2.2.
-e
£
S m a l l  (O -B O ) Medium (81-250)
OrgCat
L«'U" (*260)
Figure 4.5.2.2 Differences fo r Market Share and Competitiveness scores 
across the summarised range o f Organisation size categories.
Using Mann-Whitney tests it was found that the differences in scores existed only
between small and medium organisation sizes, the latter being significantly larger.
There was no significant difference found between small and large companies or
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between medium companies and large companies, therefore no conclusive pattern 
was evident
4 5 3 Differences for complexity of automation
Table 4 5 31 Kruskal-Wallis H-Test for all factors using the summarised
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Chi-Square 3 34 1 96 25 44 7 02 6 22 6 19 10 65 6 71 1 35 4 59 0 77
df 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00 2 00
Asymp Sig 0 19 0 37 0 00 0 03 0 04 0 05 0 00 0 03 0 51 0 10 0 68
a Kruskal Wallis Test
b Grouping Variable SummaryComplexity
Using the Kruskal-Wallis results it was evident that significant differences existed 
between Software Control, Training and HRM, Design Documentation provision, Use 
of procedures, policies and standards, direct regulatory involvement and intrinsic 
regulatory compliance scores across the range of summarised complexity levels 
Boxplots for the six factors in relation to complexity levels are shown in figure 4 5 3 1 
to figure 4 5 3 3
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Figure 4.5.3.1. Differences between software control and Training and HRM 
scores across the range o f summary com plexity categories.
t u n  ■ «!»<:«■ pm it)
Figure 4.5.3.2. Differences across Design Documentation provision and Use of 
Procedures, Policies and Standards scores against the range o f summary
com plexity categories.
t  urn a t r f C « «  p i .  >1« i u m m w y C o m p U a l t y
Figure 4.5.3.3. Differences across Direct Regulatory involvement and Intrinsic 
Regulatory Compliance scores against the range of summary com plexity
categories.
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For all the differentiated factors an upward trend was apparent The Mann-Whitney 
summaries for the six factors are shown in Tables 4 5 3 2  to 4 5 3 4
Table 4 5 3 2 Mann-Whitney significant differences between pairs of 
summarised complexity categories for Software Quality and Training and HRM
factors
Low Med High Low Med High
Low — Yes Yes Low — No No
Med Yes — Yes Med No — Yes
High Yes Yes — High No Yes —
Software Control Training and HRM
Table 4 5 3 3 Mann-Whitney significant differences between pairs of 
summarised complexity categories for Design documentation provision and 
_______ use of Procedures, Policies and Standards factors________
Low Med High Low Med High
Low — Yes Yes Low — No No
Med Yes — No Med No — Yes
High Yes No — High No Yes ~
Design Doc provision Use of Procs/Pols/Stds
Table 4 5 3 4 Mann-Whitney significant differences between pairs of 
summarised complexity categories for Direct Regulatory Involvement and 
 _______  Intrinsic Regulatory Compliance ______ ______
LOW Med High LOW Med High
Low — Yes Yes Low — No Yes
Med Yes — Yes Med No — No
High Yes Yes — High Yes No —
Direct Regulatory Involvement Intrinsic Regulatory Compliance
For Software Control, there were significant differences between all three categories 
That is, there were significantly higher Software Control scores for each step up in 
complexity Similarly, Direct Regulatory involvement scores increased significantly 
for each increase in complexity level
Training and HRM scores were higher for high complexity automation environments 
than for medium, but there was no significant difference between low and high
2 2 1
categories, so no distinct pattern emerged here For the provision of design 
documentation significant differences existed between low complexity environments 
and medium and high levels of complexity This indicated that the complexity 
category had a distinct impact on the provision of design documentation In the case 
of Use of Procedures, Policies and Standards, there was a significant difference 
between medium and high complexity levels, but no difference existed between low 
and high or low and medium levels, again yielding no distinct pattern
For intrinsic regulatory environment, there was a significant increase in scores 
between low and high complexity although medium complexity levels did not 
influence scores significantly different from low or high complexity levels
Therefore, complexity had an important and distinctive influence in terms of software 
control, provision of design documentation, direct regulatory involvement and 
intrinsic regulatory compliance
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4.5.4 D ifferences fo r C ritica lity
Table 4.5.4.1 shows the differences across the groups when using the summarised 
criticality categories (Low, Medium and High criticality).
Table 4.5.4.1: Kruskal-Wallis H-Test for all factors using the criticality of 
product to end user drug quality background summarised variable as a
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Chi-Square 6.49 0.84 2.43 5.13 3.63 4.63 1620 14.73 13.46 16.81 15.25
df 2.00 200 200 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00
Asymp. Sig. 0.04 0.66 0.30 0.08 0.16 0.10 0.00 0.00 0.00 0.00 0.00
a Kruskal Wallis Test
b Grouping Variable: CritCat
Boxplots for the six factors with significant difference across groupings in relation to 
complexity levels are shown in figure 4.5.4.1 to figure 4.5.4.3.
CrltCat C i t K l t
Figure 4.5.4.1. Differences across Direct Regulatory involvement and General 
QMS scores against the range of summary criticality categories.
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Figure 4.5.4.2. Differences across Intrinsic Regulatory Compliance scores and 
Regulatory Documentation availability against the range o f summary critica lity
categories.
Figure 4.5.4.3. Differences across Market Share and Competitiveness and 
Sales and Profit Improvement scores against the range o f summary critica lity
categories.
The influence of criticality on the data had already been assessed whilst carrying out 
multiple regression and was again illustrated here for the subgroups. From the 
boxplots an upward trend in median scores and ranges from each increase in 
criticality is generally evident.
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Using Mann-Whitney U-tests, it was only for General QMS that there were significant 
differences between medium and high criticality levels Also, for General QMS, no 
differences existed between the low and high or low and medium levels Hence, no 
distinct determination could be made for this factor
For all five remaining factors the same pattern emerged from the Mann-Whitney U 
test There were no differences between the low and medium cnticalities for any of 
the factors, however there were significant differences between the low and high and 
medium and high levels That is, for the 5 factors, high criticality distributions scored 
significantly higher than medium and low criticality distributions Whilst expected for 
the quality and regulatory factors, this was an interesting finding in terms of the 
business factors This is potentially attributable to higher criticality applications being 
subjected to more rigorous selection by pharmaceutical manufacturers making it 
difficult to be a player in that market, hence increasing market share, 
competitiveness and profitability within that sector for all proven companies
4 5 5 Differences across regulatory groupings
In assessing the categorical differences for the Regulatory Environment background 
variable, the summarised regulatory categories were used, as differences between 
the un-summarised groups were not very meaningful
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The Kruskal-Wallis test is shown in Table 4 5 5 1 and differences were uncovered
for the Software Control and Direct Regulatory Involvement
Table 4 5 51 Kruskal-Wallis H-Test for all factors using the summarised 
regulatory environment background variable as a grouping variable
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Chi-Square 2 40 0 33 6 94 0 06 1 92 0 63 9 84 1 77 3 78 0 04 0 03
df 1 00 1 00 1 00 1 00 1 00 1 00 1 00^ 1 00 1 00 1 00 1 00
Asymp Sig 0 12 0 56 0 01 0 80 0 17 0 43 0 00 0 18 0 05 0 84 0 86
a
Kruskal Wallis 
Test
b Grouping Variable ShortRegCat
The boxplots for Software Control and Direct Regulatory Environment scores are 
shown in Figures 4 5 5 1  to 4 5 5 2
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S h o r tR e g C a t
Figure 4.5.5.1. Differences across Software Control scores against the range 
o f summary regulatory environment categories.
F D A  O nly F D A * O th « f»
ShortRegCat
U n kn o w n
Figure 4.5.5.2. Differences across Direct Regulatory Involvement scores 
against the range o f summary regulatory environment categories.
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For the Software Control factor the scores for the FDA and others categories were 
significantly higher than for both the unknown category and for the FDA only 
category However although it was higher, the FDA only category was not 
significantly higher than the unknown category For the direct regulatory involvement 
factor, the FDA and others category was once again significantly higher than the 
FDA only and unknown categories The FDA only category was also significantly 
higher than the unknown category It was expected that when respondents did not 
know exactly what there regulatory environment was, then their regulatory 
involvement score would be lower
It was not expected that the FDA and others category would be significantly higher 
than for the FDA only category for the software control factor, or that the FDA only 
category would not be significantly higher than the unknown category for the same 
factor Therefore it would seem from the data that companies who worked in FDA 
plus at least one other regulatory environment were better at software quality than 
those who operated solely in FDA environments
4 5 6 Differences across quality system environment groupings
Again for the categorical differences for the Quality System Environment background 
variable, the summarised quality system categories were used, as differences 
between the un-summarised groups were not very meaningful
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The Kruskal-Wallis test is shown in Table 4.5.6.1 and differences were uncovered
for General QMS and Intrinsic Regulatory Compliance factors.
Table 4.5.6.1: Kruskal-Wallis H-Test fo r  all factors using the summarised
quality system background varia ble as a grouping variable.i----------------
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Chi-Square 26.47 5.25 2 81 1 38 7.07 306 2.07 14.67 7.03 2.52 536
df 3.00 300 300 3 00 3 00 300 3.00 3.00 3.00 300 300
Asymp Sig 0.00 0.15 0.42 0.71 0.07 0 38 056 0.00 0.07 0.47 0.15
a Kruskal Wallis Test
b Grouping Variable: ShortQualCat
The boxplots for General QMS and Intrinsic Regulatory Compliance scores are
shown in Figures 4.5.6.1 to 4.5.6.2.
ShortQualCat
Figure 4.5.6.1. Differences across General QMS scores against the range of 
summary quality system environment categories.
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ShortQualCat
Figure 4.5.6.2. Differences across Intrinsic Regulatory compliance scores 
against the range o f summary quality system environment categories.
From the box-plots for both differentiated factors it can be seen that scores for the 
ISO only and TQM only categories were higher than for when there was a hybrid or 
no quality system. The summary tables representing the significant Mann-Whitney 
U-test differences between all pairs of groups for each differentiated factor are 
shown in tables 4.5.6.2 and 4.5.6.3. There were no significant differences between 
ISO only environments and TQM only environments. There were significant 
differences between each of these two groups and the remaining groups with the 
exception of the difference between the ISO only and hybrid groups for the intrinsic 
regulatory compliance factor. The General QMS scores were hence higher when a 
formal quality management approach was in place than when such was absent or 
‘hybrid’. Hybrid systems scored significantly higher than where there was no system.
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Table 4.5.6.2 Mann-Whitney significant differences between pairs of 
summarised quality system environment categories fo r the General QMS
factor scores.
ISO Only TQM Only Hybrid system None
ISO Only — No Yes Yes
TQM Only No — Yes Yes
Hybrid system Yes Yes — Yes
None Yes Yes Yes --
Table 4.5.6.3. Mann-Whitney significant differences between pairs of 
summarised quality system environment categories fo r the in trinsic regulatory 
_____________  com pliance factor scores.
ISO Only TQM Only Hvbrid system None
ISO Only — No No Yes
TQM Only No — Yes Yes
Hybrid system No Yes — Yes
None Yes Yes Yes -
4.6 Summary of Data Analysis
The distributions were evaluated for respondents in terms of the length of time 
companies were established, time established in the pharmaceutical industry, 
organisation size, complexity of the automation used in respondent's products, 
criticality of the respondent's product to end user drug quality, the regulatory 
environment respondent’s products were designed for, and the quality system 
environment of the respondent company. The distributions were assessed using the 
categories from the questionnaire and also using summarised categories that gave 
more meaning to the survey data. It was desirable to have a sufficient number of 
responses across the range of subgroups for each background variable so that the 
presence of any non-response bias could be evaluated. It was found that sufficient
231
data existed across all the groups in a given distribution to allow further analysis and 
to allow generalisation of findings (external validity) The summarisation into a lower 
number of sub-categories contributed to safer generalisation possibilities, as more 
cases were present per category
Factor analysis was then used on the quality, regulatory and business related 
questionnaire items to reduce the data into a smaller number of manageable and 
meaningful factors Principal Component Analysis with Oblique rotation yielded 6 
quality factors, 3 regulatory factors and 2 business factors The factors were used as 
the basis for summated scales, which were all found to be reliable in terms of 
internal consistency using Cronbach’s alpha The summated quality scores were 
found to be positively correlated with the regulatory scores Specified quality scores 
were found to be correlated to the business scores Similarly, specified regulatory 
scores were positively and significantly correlated with one of the two business 
factor scores These relationships meant that the null hypotheses H1o, H2o and H3o 
could not be rejected based on correlation output
Multivariate analysis was then employed to determine predictors and the unique 
variance contributed by individual independent summated scores for each factor 
When all the quality and regulatory variables were input to the stepwise regression 
procedure with the Market Share and Competitiveness factor score as the 
dependent variable it was found that General Quality Management System scores 
and Direct Regulatory Involvement could be used as predictors This model
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accounted for 20 0% of the change in Market Share and Competitiveness Intrinsic 
Regulatory Compliance could be used as a predictor of Profit and Sales increase 
scores, but only 4 8% of the change in this business score could be attributed to the 
model The regression equations showed that the predictors (General QMS, Direct 
Regulatory Involvement and Intrinsic Regulatory compliance) could essentially be 
used to represent all the data in terms of positive effects on business performance 
As the predictors were positively correlated with many other factor scores, this did 
not mean that the other factors were not determinants of business success, merely 
that they could be represented by the predictors The regression equations were 
significant and offered further support to the acceptance of the hypothesis (H1 and 
H3)
Stepwise regression was also used to determine the impact of background variables 
on the established relationships For both regression relationships the regulatory 
component was replaced by criticality, in that criticality could be used to represent 
the regulatory factors For the Market Share and Competitiveness dependent 
variable, General QMS was retained as the dominant predictor but there was a 
moderating effect by the time established in business background variable As 
General QMS was dominant and positively correlated to time established, the 
predictors still showed a significant positive change in the dependent business 
factor The R2 for the equation rose to 0 274 or 27 4% meaning that 27 4% of Market 
Share and Competitiveness scores were accounted for by the predictors, i e 
Criticality could better predict the dependent variable by 7 4% For the Profit and
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Sales improvement factor score R2 increased to 9 1% which was almost a doubling 
in the contribution from the predictors Hence criticality could give a better 
representation than regulatory factors for both business factors Again, this did not 
dimmish the importance of the regulatory scores, it merely showed that another 
predictor could represent them
Sub-group differences were then assessed for each of the background variables 
using both the questionnaire categories and the summarised categories developed 
during the distribution review Sub group behaviour was identified using non- 
parametnc testing between groups For the time established background variable, 
significant differences were found between intrinsic regulatory compliance and 
general QMS scores across groups For the former no useful pattern emerged 
however for the latter it was found that General QMS scores were significantly 
higher for companies in business for longer than 16 years
For organisation size, it was found that General QMS scores were significantly lower 
for small companies when compared to medium and large companies However, 
there were no significant differences between medium sized companies and larger 
ones
Complexity of automation levels yielded significant differences in Software Control, 
Training and HRM, Design documentation Availability, Use of Procedures, Policies 
and Standards and the two regulatory scores For Software Control there was a
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significant increase in scores for each step up in complexity from low to medium to 
high No distinct pattern emerged for Training and HRM or for Use of Procedures, 
Policies and Standards The impact on Design documentation availability was also 
significant in that there were higher scores for high complexity levels than for lower 
complexity levels or medium complexity levels For the regulatory compliance scores 
there were significant score increases between low and high complexity levels but 
medium levels did not differ significantly from either adjacent level
When the criticality background groups (low to medium to high) were assessed, no 
distinct pattern emerged for the General QMS score differences For Direct 
Regulatory Involvement, Intrinsic Regulatory Compliance, Regulatory 
Documentation availability, Market Share and Competitiveness and Sales and Profit 
Improvement, high criticality distributions scored higher than for medium and low 
criticality distributions The differences in business scores were conjectured to be 
due partly to the type of selection process operated by the pharmaceutical 
manufacturing industry
Across the summary regulatory groupings Software Control scores for ‘FDA and 
others’ were higher than for ‘unknown’ and ‘FDA only’ scores The FDA only 
category was not significantly higher than the unknown category, but the range for 
the FDA only category was quite broad
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For the Quality Management environment background variable significant 
differences existed between the ISO only or TQM only categories with when hybrid 
or no QMS was in place, when considered for the General QMS and Intrinsic 
Regulatory Compliance factors
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Chapter 5: Discussion, Conclusions and Outlook
The focus of this research was to ascertain the relationships between quality 
practices and regulatory practices, between quality practices and business 
performance and between regulatory practices and business performance The 
study revealed that significant relationships existed between aspects or factors of 
these three variables These relationships and absence of other relationships could 
be used to determine whether the study hypotheses could be rejected or upheld
5 1 Quality Practices and regulatory practices
Although no evidence could be found of research into the relationships between 
quality practices and regulatory practices, the nature of what are deemed to be 
regulatory practices are essentially quality system manifestations Therefore 
correlations between the quality management, or general quality practices elements 
of the entire quality effort, and the GMP elements of the entire quality effort should 
have existed in a symbiotic way in the findings of this research The correlations 
detailed in this discussion are elaborated on in order to give a general picture of the 
interdependence of GMPs and quality management systems, it is not suggested that 
where two variables or factors are correlated, that this relationship is due to a unique 
contribution, and no other variables or factors are involved No suggestion of 
causation was intended, as the hypotheses, results and the literature imply mutually 
improving influences between quality practices and regulatory practices The Good 
Manufacturing Practice regulations themselves [1][2][3][37][58][59][70] state
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requirements for quality systems implementations and The Orange Guide’ [5] 
defines GMP as being an element of quality assurance Many of the regulatory 
features have a basis, and source, in the quality standards themselves For 
example, the availability of documentation which is required by the regulations is 
also a requirement of the ISO 9001 2000 and ISO 9000-4 2004 under the 
documentation and record management and product realisation sections Validation 
is also a requirement of these standards under the 'Design and development 
planning, review and validation’ sections The GAMP guide [13] heavily leverages a 
series of international quality standards for development and testing of automated 
(software based) systems Regulatory design reviews are essentially an evaluation 
of the development and realisation of software against the quality requirements, 
which is again a quality system requirement of the international quality standards 
(such as the IS09000 series), as is the use of the Software Development Life Cycle 
(SDLC) approach
The details of the requirements set out in the electronic records and electronic 
signatures regulations are once again quality requirements for development and 
control of systems where data integrity is paramount and compliance with other 
standards would yield the same level of software quality Perhaps the only 
requirement that is truly unique is the regulatory requirement for the availability of 
developer source code [51] The regulations in essence then provide a focused set 
of quality requirements for the manufacture of medicinal product and for 
development of systems used in their manufacture Therefore the extent and
238
strength of the correlations found in this work between quality and regulatory 
practices were expected, and the survey was a means of confirmation and validation 
rather than one of discovery for these two variables
However, it needs to be stated that the regulatory factors as extracted in this study 
were distinct That is, for the 'Direct regulatory involvement’ factor, all the elements 
that comprised it had a direct relationship to the GMPs or to GAMP (a means of 
compliance with GMPs) Although a means of achieving high quality, GMPs 
themselves are not completely inherent in a general quality system It is feasible that 
regulatory practices and quality practices could be mutually exclusive However from 
this work and the appraisal of the literature, it is clear that this is not the case in 
practice The positive correlation between the regulatory practices factors and the 
quality practices factors confirms the relationship Andrews [35] states general 
quality management systems such as ISO can contribute to, but don’t completely 
meet the needs of regulatory compliance He also suggests that the quality 
management system outlined by GAMP is appropriate to an environment producing 
automated systems Hence, the mutually beneficial relationships between quality 
management and regulatory compliance are known The two-way relationship is 
illustrated by Margetts [40] who says that in order to achieve regulatory compliance, 
a quality methods approach must be taken for software development As stated by 
Trill [72], the object of GMP and the quality system is the same, assurance of quality 
of the product for the safety and well being of the patient It follows then that a 
company with a higher emphasis on one will have a higher emphasis on the other
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Of the 18 possible inter factor relationships between regulatory and quality practice 
scores, 16 yielded positive significant relationships of varying strength The ‘Intrinsic 
Regulatory Compliance' factor, which represented those activities within companies 
that would result in regulatory compliance, had a Pearson's correlation of 0 60 with 
the ‘General QMS’ factor, which represented the central requirements of most 
quality system standards As many of the intrinsic compliance activities would have 
been in place as a result of direct compliance with quality standards such as 
IS09001 and IS09000-4 it would have been expected that a high correlation 
emerged here Similarly, the ‘Use of procedures, policies and standards’, ‘Software 
Quality’ and ‘Design Documentation' factors had a positive correlations of around 
0 50 with the Intrinsic Regulatory Compliance, for the same reasons as it had such a 
strong correlation with the General QMS That is, by having good quality systems 
practices, the intrinsic regulatory compliance efforts of a company are likely to have 
been positively influenced also Hence, system developers can go a long way to 
achieving compliance with regulatory requirements by adopting international quality 
standards This is supported by Foote [54] who suggests that the CMM requirements 
can be used to provide the same level of quality assurance that following GAMP can 
provide, that is substantively meeting the regulatory requirements through adopting 
a general (non industry specific) standard GAMP itself also alludes to this [13] 
Foote also outlines the comparable sections of the GAMP guidance and how it 
related to the ISO 9000 series, again recognising the correlation The significant 
moderate positive correlations between the Software Quality and regulatory
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compliance factors also show this relationship That is, software quality is correlated 
with the regulatory compliance scores, which is the goal of those regulatory 
compliance practices Sharp [5] identifies GMP activities as being the focus of a 
greater QA effort, therefore the compliance factors should have a direct correlation 
with one or more facets of ‘pure’ quality assurance The extent of the existence of 
positive correlations between the group of quality practices factors and regulatory 
compliance factors in this work supports, and is supported by Sharp’s assertions 
Glennon [7] also points out the closeness of general good engineering practices to 
the practices required by the regulators, in that the following through specific 
requirements of established standards, the regulatory requirements can be fulfilled in 
the main
The relationship between quality practices and direct regulatory practices and 
knowledge may in part be due to the cultural legacy of being ‘good at quality’, or may 
be in part due to having to realise a top class quality system as a result of regulatory 
requirements Further support is given to the interdependence of quality practices 
and regulatory practices by Coady and de Claire [77] whose approach to overall 
compliance to process control system validation requirements adopts a joint quality 
system and direct regulatory compliance strategy The level of correlation between 
general QMS was much higher when matched with intrinsic regulatory compliance 
than with direct regulatory involvement (r=0 60 and 0 26 respectively at the p=0 01 
level) Intrinsic compliance means the practical realisation of the requirements 
through the quality system, whereas the direct regulatory involvement factor was
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more concerned with direct knowledge and application of the GMPs (including Part 
11) and use of GAMP
The dependence of regulatory compliance on sound quality systems for software is 
emphasised in the literature [13][25][35][39] This dependence was confirmed by 
these results, in that moderate positive correlations were found between the 
software control factor and both the direct regulatory involvement and intrinsic 
regulatory compliance factors Similarly, the moderate positive correlation between 
provision of design documentation and intrinsic regulatory compliance enhanced this 
finding Provision of design and test documentation as part of the software lifecycle 
and control elements of a quality system is advocated by GAMP [13], and by the 
literature in general when discussing development of systems [8][35][55]
In this study a positive correlation was found between software control and 
availability of regulatory documentation, which suggests that companies who employ 
a more formal software control system during development are better at keeping 
validation and design documentation The direction of this relationship is unknown 
although it can be stated that those who have better software control score better 
with regards to record and test script retention, and those who focus more highly on 
such retention have better software control This mutuality is inherent in analysing 
the quality / regulatory practices relationships Again this is consistent with the body 
of literature, which always states that regulatory requirements can be complied with 
by means of quality system manifestations, but that these manifestations cannot be
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effective without good regulatory practices The sound appreciation of the 
regulations is necessary to have a quality system capable of compliance [51] 
Hence, the positive correlations between regulatory practice scores and quality 
practice scores from this work make sense in this context, in that better 
interpretation of the regulations can lead to better quality systems and better quality 
systems may enhance the compliance effort
The ‘soft skills' side of the quality practices scores consisting of leadership, customer 
service, training and human resource management all had a positive correlation with 
direct regulatory involvement and intrinsic regulatory compliance The positive 
influence of these aspects of quality management on business performance as 
stated in the wider body of literature seems to influence the regulatory practices 
element also (although it is not suggested that this could be the case in the absence 
of other factors) In general, the influence of these quality system elements on 
regulatory practice is positive, although correlations are generally low in magnitude 
However, their influence through other aspects where they are more highly 
correlated such as the general quality management system, the use of practices, 
procedures and standards, and provision of design documentation may have a 
knock on positive influence It has to be stated though that as training is a regulatory 
requirement that the direction of influence could as easily be from the regulatory side 
to the quality system rather than the other way around In any case, the mutual 
benefits were clear once again when looking at the scores for regulatory practices 
and the customer service and leadership / training and HRM scores As the net
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effect of these aspects is to increase overall knowledge, proficiency, customer 
involvement and motivation regardless of the source (i e quality system or 
regulatory pressures), the benefits are clearly positive in terms of regulatory 
compliance and quality
The moderate positive correlations between the software control factor and the 
direct regulatory involvement factors was expected as the constituents of the direct 
regulatory compliance scale consisted of some items that were based on use of 
GAMP, which uses lifecycle development for software and advocates software 
controls Similarly for the intrinsic regulatory compliance factor, testing and 
development documentation help make up the scale As a good software 
development environment would consist of good software control and testing 
methodology (whether required by regulatory authorities or not), the strong 
correlation was expected here also The correlation between general quality 
management system scores and intrinsic regulatory compliance scores (pearson’s r 
= 0 60 at the p= 01 level) was considerably higher than for that between general 
QMS and direct regulatory involvement (pearson’s r=0 26 at the p=0 01 level) This 
was because many of the items contributing to the intrinsic regulatory compliance 
scale were quality system manifestations of regulatory compliance requirements, 
such as validation, audits and documentation and record keeping Hence a good 
quality system should mean better de facto compliance Similarly, by applying the 
requirements of the regulations in practice, the quality practices of an organisation 
should be improved This mutuality is confirmed through this research
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The moderate correlation between the provision of design documentation and 
intrinsic regulatory compliance was higher (Pearson's r = 0 51 at the p=0 01 level) 
than for that between provision of design documentation and regulatory 
documentation availability (Pearson’s r=0 24 at the p=0 01 level) The high 
correlation with the former was due to the common elements of validation and 
regulatory required design documentation provision, with the design and validation 
activities that make up intrinsic regulatory compliance The low correlation with the 
latter factor was possibly due to the availability term That is, although developers 
document their development and testing, they do not necessarily make it available to 
end-users For lower risk and less complex systems this can be acceptable to drug 
manufacturers (as per GAMP categorisations for example), however for higher risk 
or more complex automated solutions, manufacturers would request better levels of 
design documentation from suppliers Although low, the positive significant 
correlation here was still important to show that provision of design documentation 
can contribute positively to intrinsic regulatory compliance
The ‘Availability of regulatory documentation’ factor was a more specific requirement 
than the two compliance factors in the regulatory grouping It was not correlated 
significantly with the ‘Customer service and leadership’ or 'Training and HRM’ 
factors However, the more general quality practices factor of ‘provision of design 
documentation’ did have a positive correlation with this regulatory documentation 
factor The lack of correlation here was possibly due to the more specific nature of
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the factor Regulatory documentation availability itself had a low correlation with the 
quality practices variables It is reasonable to say that the largest practical difference 
for almost all suppliers of systems to the pharmaceutical industry has been the 
additional work (in terms of creating that documentation, and making it available to 
the standard required by pharmaceutical customers) required for validation and 
validation protocol scripting and execution This goes beyond the test script 
requirements for non industry-specific software testing, so therefore does not tie in 
that closely to the normal requirements of a quality system This could explain the 
lack of strength in the correlation between this factor and the quality factors It is an 
important regulatory consideration however, and is moderately correlated with both 
the direct regulatory involvement score and the intrinsic regulatory compliance score 
(Pearson’s r= 0 51 and 0 46 respectively at the p=0 01 level)
The use of procedures, policies and standards had a higher correlation with intrinsic 
regulatory compliance (Pearson’s r = 0 50 at the p=0 01 level) than with the other 
two regulatory practices scores Again this is because of the nature of the intrinsic 
regulatory compliance factor which involves quality system manifestation as 
opposed to the more abstract ‘knowledge based' nature of direct regulatory 
involvement (Pearson’s r = 0 38 at the p=0 01 level) and the more specific nature of 
availability of regulatory documentation (Pearson's r = 0 24 at the p=0 01 level) Use 
of procedures and policies in particular are paramount to both regulatory compliance 
and to a successful quality system, so the r=0 50 correlation here was not 
unexpected
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The aim of this section of the research was to show that where high quality practice 
scores existed, then high regulatory practice scores would also exist No causal 
exploration was required From the analysis and discussion it can be seen that 
regulatory factors and quality factors were indeed positively correlated, with some 
factors more highly correlated than others The general finding that quality and 
regulatory practices are mutually beneficial concurs with the inferences in the wider 
literature, although as stated previously, no research other than this exists to uphold 
it Therefore it can be stated that H2 in this work cannot be rejected, as 16 out of 18 
possible relationships between quality practices and regulatory practices factors 
were positively and significantly correlated All regulatory factors were correlated 
with at least two quality factors and wee versa
5 2 Quality Practices, Regulatory practices and Business Perform ance
The general finding from the literature was of a weak positive correlation between 
quality management practices and business performance, whether as part of a TQM 
effort, ISO 9001 environment or as practices in some hybrid quality structure The 
purpose of this section of the research was to ascertain whether the same 
relationships could be determined empirically when the added dimension of 
regulatory practices was considered This extra dimension had to be considered in 
the sector of interest, developers of automated solutions for the pharmaceutical 
industry The models developed showed that when the quality and regulatory
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variables were considered, weak to moderate relationships were found between 
aspects of quality management, regulatory involvement and compliance, and 
aspects of business performance This was consistent with the findings from the 
literature as discussed below The two aspects of business performance, profit and 
sales improvement and market share were positively correlated with several quality 
and regulatory practice factors to differing degrees which did much to uphold the 
study hypotheses although no ‘simple’ relationship could be extracted from the set of 
results It would not have been justified to say for example that all the quality 
practices outlined in this work contributed to business performance improvements 
directly, as some of the extracted factors had no direct correlation and did not figure 
in the stepwise regression models
Although in the stepwise regression models the general quality management 
system, direct regulatory involvement and intrinsic regulatory compliance factors 
played extremely important roles as determinants of business performance 
improvements, their existence in the regression equations was more representative 
than absolute (market share was partly determined by general quality management 
system scores and by direct regulatory involvement (Equation 1 ) and profit and sales 
improvement was partly determined by intrinsic regulatory compliance (Equation 2)) 
The purpose of stepwise regression is to establish unique representative 
contributions, however, the roles of the other factors, although only directly and 
indirectly correlated, were also important The fact that a given company had a good 
general quality management system and knew the regulations well would not in all
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likelihood bring success if that company did not for example make regulatory 
documentation, such as validation documentation, available to their customers 
Regulatory documentation provision was correlated significantly to market share 
Hence the models developed were representative and not mutually exclusive to the 
factors eliminated by the stepwise model
When considering the regression equations, the independent entries could be 
considered to be representative of the quality or regulatory cultures within an 
organisation To get a truer overall picture of the roles of quality and regulatory 
practices, the correlations plus the regression models needed to be considered In 
this regard, the factors that were correlated with Market share and Competitiveness 
which was a non financial measure with financial effects, were general quality 
management, training and human resource management, use of policies, practices 
and procedures and the three regulatory factors Sales and profit improvement, a 
financial measure, was correlated to General QMS and intrinsic regulatory 
compliance
Software quality, customer service and leadership and design documentation 
provision were not correlated with any of the business factors but they were all 
correlated to the general quality management system factor and to most of the 
regulatory factors, which in turn were correlated to both business performance 
factors It was not reasonable then to discount the impact of these factors on 
business performance, in fact as these are co-correlated to some of the same quality
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and regulatory practice factors, and they are all indicators of a combined quality / 
regulatory culture (which are correlated in any case), it can be stated by inference 
that these were positive contributors to business performance in the pharmaceutical 
market
Consider again the regression models
Regression Equation 1
Market Share and Competitiveness =
1 932 + 0 353 General QMS + 0 222 Direct Regulatory Involvement + e1 
Regression Equation 2 
Sales and Profit Improvement =
1 520 + 0 237 Intrinsic Regulatory Compliance + e2
The influences of both quality and regulatory practices were clear There was no 
doubt that the mam predictors of market share and competitiveness and profit and 
sales improvement were not quality and regulatory performance, but more likely to 
be related to the product offering, marketing, pricing and competitive strategies of 
the company However the influence of quality and regulatory practices was 
significant The influence on Market Share and Competitiveness in the 
pharmaceutical industry was particularly interesting (R2 for equation 1 was 20 1%) 
This was quite a large increase in market share and competitiveness above 
expectations from employing higher levels of quality and regulatory practices, with 
General QMS being represented as having the highest unique contribution to the
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model The lower R2 for equation 2 of 4 8% meant that intrinsic regulatory 
compliance did not have such a large effect on profit and sales improvement, but a 
4 8% improvement may be considered to be quite large depending on company 
expectations
The combined effects that can be seen from both models show two things Firstly 
that improvements in market share, competitiveness and sales and profits above 
expectations within the pharmaceutical industry could be achieved through higher 
levels of quality and regulatory performance and secondly that there was no 
substitute for the other aspects of business strategy for maximising gain Armitage 
and Chai [170] and Sadikoglu [171] agree with the assertion that strong financial 
performance is mainly based on superior competitive practices and internal 
efficiencies In the case of market share and competitiveness the contribution of 
quality management alone in the stepwise model (first step) had an adjusted R2 
value of 16 1% So regulatory practices added a further 4% to the total contribution 
to market share and competitiveness This showed that for this sector that quality 
practices had the greater effect on business, but that direct regulatory involvement 
(representing the regulatory effort) was also important
The importance of the regression equations was to establish the strength and 
direction of relationships and to assess the unique contribution of the set of factors, 
rather than as a predictive tool It should be therefore viewed qualitatively rather than 
quantitatively So qualitatively speaking, both quality practices and regulatory
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practice had a positive influence on business performance giving support to the 
study hypotheses H1 and H3 To contrast the case of the pharmaceutical sector 
against other sectors, this research confirmed that the relationships established 
between quality and business performance for other sectors were similar to the 
automated pharmaceutical systems sector as explored later in this section There 
was however the added aspect of regulatory involvement and compliance and its 
symbiotic relationship with quality practices, which added a unique contribution to 
business performance coupled with the indirect mutually beneficial effects on quality 
practices by regulatory practices, quality practices in turn offering a unique 
contribution to business performance as determined by the regression models As 
regulatory practices and quality practices both contribute to an overall quality effort, 
then the case for the pharmaceutical market of interest must be that it is the entire 
combined effort of quality practices coupled with regulatory practices that contributes 
to business success, and that one should not be considered without the other In the 
case of the regression equation for profit and sales improvement, the independent 
quality and regulatory practices variables could all be represented by the intrinsic 
regulatory compliance factor The representation reinforced the fundamental 
importance of the application of the regulations but once again it was crucial not to 
ignore the effects of the other mutually beneficial quality and regulatory factors which 
were inter-correlated as previously described
There has been much work carried out into the relationship between quality 
practices and business practices in other industries, where regulations were not
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considered The research is broadly divided into that which evaluates either quality 
management or product quality against organisation performance, which may or 
may not include financial measures Ismail and Hashmi [28] found that companies 
with lower levels of quality management practices were more susceptible to poor 
performance than those with higher levels of quality practices for the Irish 
manufacturing industry In that study market share was used as a performance 
indicator and the features that made up TQM and IS09001 quality management 
were used to form the basis of the independent variable A general index was used 
for performance and practice scores and a correlation of 0 69 was found between 
practice and performance The strength of correlation found by Ismail and Hashmi 
was higher than elsewhere in the literature and 20% higher than the highest 
correlation found in this study between any quality practice factor and any business 
performance factor The direction of correlation was positive however and still 
moderate, which is comparable Lee et al [82] found by using technical measures of 
quality performance in manufacturing that there was a weak positive relationship 
between quality and performance, when return on assets and sales growth were 
used to measure organisational performance There was undoubtedly a difference in 
the type of measure used here as the focus was on end product quality However 
the goal of quality management and assurance was end product quality and it was 
interesting and important to establish that the knock on effects on business 
performance were also positive The weak positive contribution of product quality 
was not directly comparable to the findings in this work owing to the difference in 
measures Forker [80] also established a similar relationship between product and
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process quality measures and business performance, whilst looking at the furniture 
industry
Sharma and Gadenne [30] established that in businesses with top level commitment 
to quality management programmes, greater emphasis on QM approaches are 
positively associated with organisation performance, which according to Adam et al
[85] is natural and expected Quality management's goal is to eliminate waste and 
reduce defects Adam et al also recognised the general trend from the literature was 
of a weak positive influence of quality on financial performance Their use of hard 
measures of performance such as net profit, return on assets and sales growth, with 
a combination of quality management and product quality measures yielded a weak 
positive correlation also Similar to this work, their factor analysis extracted 
components, which included customers, knowledge, employee involvement and 
employee satisfaction Hence this research agreed with the work of Adam et al in 
terms of findings and the representative indicators of quality The preliminary work of 
Agus [83] into the structural linkages between TQM, product quality performance 
and business performance in electronics companies which, although it could not 
confirm structural linkages, did establish correlations that were comparable with this 
work The independent practices of leadership, customer focus, supplier relations, 
training, employee focus and quality measurement were all found to have positive 
correlations to the business performance index which included revenue growth, 
sales growth, market share and profits as business performance indicators The 
individual correlations were not stated, just the scale correlations With the exception
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of measurement, which was highly correlated, all the correlations were in the low to 
moderate region
The relationships between quality and business may not be constant over time and 
caution would need to be exercised when making generalisations from this work 
Tsekouras et al [84] in a study of 134 Greek firms implementing IS09000, found that 
the effects of implementation on business performance may not become clear in the 
first 5 to 6 years but their evidence suggested that benefits are more long term That 
study used hard financial performance measures In order to ascertain whether 
those findings were similar for the pharmaceutical industry, a longitudinal study 
would be required Adam and Flores [85] showed that the generalisation of the 
relationship was not always reliable in their comparison of quality practices and 
financial performance between the US and Mexico It was found that in the US that 
employee involvement, leadership and emphasis on design and conformance 
contributed directly to financial performance (return on assets and net profit), 
whereas the same could not be said for the Mexican case However, not all research 
concurred with this work Zhang [172] used a dichotomous perceptive measure to 
establish whether quality practices resulted in improvements in business 
performance Respondents were asked to answer yes or no to whether increased 
levels of quality practices resulted in market share increase Only 20% of IS09000  
companies said that market share was increased whereas 60% of TQM companies 
said that it increased This was possibly as a result of the type of measure employed 
by the research in that there were no in between options that could assess whether
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the sustenance (lack of increase) of market share was deemed to be expected and 
hence a positive outcome of the heightened quality application, and the singular 
option was probably not a very effective means of establishing performance This 
was an exception however as the findings from this work for the automated systems 
developers in the pharmaceutical industry were generally consistent with the findings 
from other industries when quality practices and business performance was 
considered Lemak and Reed [86] for instance also found that an increase in profit 
margin could be expected after the adoption of TQM practices Therefore in the 
context of the literature it was deemed that although there is a special case for 
pharmaceuticals in terms of the added influence of the regulations, the generally 
established relationship between quality practices and business performance was 
upheld
5 3 Background considerations and generalisations
The purpose of looking at the background variables was to assess whether the 
primary relationships established between quality practices and business 
performance and between regulatory practices and business performance held up 
under controlled background conditions, to evaluate differences between companies 
with different characteristics and as a qualification for the generalizations from this 
research The applicability of the study across the various company sizes, time 
established in business and in the pharmaceutical industry, regulatory and quality 
system environments, the complexity of the software used in the respondent’s
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products and the criticality of those products to the drugs manufactured by their 
customers were important considerations for this work
When looking at the regulatory groupings it was interesting to find that 91 out of 119 
or 76% of respondents developed their systems to FDA guidelines 26 respondents 
did not know what their regulatory environments were which was unexpected This 
was probably down to the person responding rather than the organisation not 
knowing as the vast majority of respondents' websites have references to the FDA in 
particular Another fact that makes this seem erroneous on behalf of many 
respondents is that although the question was often answered as unknown, the 
regulatory questions in the questionnaire were considered and answered Maybe the 
way the question was asked posed some difficulty although no comments from 
respondents or from the pilot study indicated this The high number of FDA 
companies in the study (compared to just 2 for example who claimed to develop to 
EMEA standards and none who claimed to be from just PIC/S developers) is 
probably due to several factors Firstly the world pharmaceutical market is heavily 
dominated by US companies Of the top 20 producers of medicines in 2003, 13 or 
65% were American owned [173] and 50% of world consumption is by North 
America [174] Hence there is a massive requirement for drugs and hence 
manufacturing systems to be manufactured within, and for, the FDA market 
Secondly the FDA regulations themselves are more prescriptive, specific and it 
might be said restrictive, than the EMEA / PIC/S equivalents Compare for example 
the extensive requirements of the 21 CFR Part 11 rule for electronic signatures with
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the closest equivalent in Europe, EU Volume 4 Annex 11 The former is extensive 
and in its requirements, and better in terms of providing industry with direction for 
compliance, whereas the latter is more general and shorter Although the actual 
expectations by regulators may not be much different in either environment in terms 
of compliance requirements the FDA rules are of a higher standard Part 11 was an 
FDA response to industry for guidance on the use of electronic record and electronic 
signature systems No such extensive guidance exists from the European 
regulators This highlights the general trend of the FDA being world leaders in terms 
of proscribing requirements for automated / computerised systems used in drug 
manufacture Hence developers would be shrewd to observe FDA regulations when 
bringing new products to the market 28 respondents or 23 5% said that they worked 
to EMEA regulations Therefore sufficient representation existed from this sector, 
however as only 2 of those respondents did not also work in an FDA environment it 
was not possible to compare scores between the FDA and the European regulator
The most meaningful analysis that could be done therefore was to look at the data in 
terms of those companies who operated to FDA regulations only, those who 
operated in FDA and other environments (including EMEA / PIC/S and ICH), and 
those who operated in self-proclaimed ‘unknown’ environments Looking at the 
regulatory groupings differences were found in terms of software quality and direct 
regulatory involvement For software control if was found that where respondents 
gave attention to FDA and at least one other set of regulations that they had 
significantly higher scores than when just FDA regulations were followed and when
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the regulatory environment was unknown It is suggested that the lack of a 
significant difference in scores between those companies who operated in FDA only 
environments and those who did not know their regulatory environments may be 
down to the high range of scores from respondents in the ‘unknown’ category That 
is, the lower quartile for the FDA only category only goes as low as 1 6 whereas for 
the unknown category the range extended below one It is expected that if more 
accurate answers were achieved for this question then the FDA only category would 
have resulted in a significantly higher score than the unknown category
What was important to extract from the analysis was that companies with a broader 
perspective on international regulations scored better in terms of software quality 
This was perhaps due to a compliance culture that existed in terms of organisations 
that aim for best practice in software quality being more adept at using and 
complying with the regulations
In the case of direct regulatory involvement, differences were expected and found 
between those respondents who knew their regulatory environments and those who 
did not Both the ‘FDA only’ and ‘FDA and others’ categories scored higher than the 
unknown category If the respondent did not know their environment (as 26 
respondents claimed) it is unlikely that they would be adept at complying with the 
regulations What was noticeable though again was that the FDA and others 
category scored significantly higher again than for FDA only companies This 
suggested that an international view of the regulations was more likely to yield better
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application of the regulations than just an FDA focus This could be attributable to 
their greater experience in assessing, applying and complying with varied 
regulations and implementing quality systems based on the combined knowledge of 
several sets of regulations However this seemed to be as far as it went with regards 
to superiority, as there were no significant differences in any of the other factors with 
respect to regulatory grouping Therefore the actualisation of quality practices such 
as general QMS or intrinsic regulatory compliance was not significantly different 
between any of the regulatory sub-groups Whereas no differences were anticipated 
between the ‘FDA only’ and 'FDA and others’ categories it might be expected that 
differences would exist between each of these groups and the ‘unknown’ category 
However other factors such as the quality management system employed would 
seem to have played a larger role here
Out of the 119 valid responses, 75 or 63% had ISO registration and no other quality 
system installed Another 3 respondents had TQM also whilst 7 had only TQM 22 
(18 5%) reported having Hybrid systems and 11(9 2%) reported having none Those 
categories deemed large enough for differential analysis were those companies with 
ISO only, TQM only, Hybrid systems and no quality systems In total only 10 (8%) of 
respondents had TQM, which indicates that this quality philosophy was not widely 
used in this sector The high number of respondents who either had a hybrid quality 
system or no quality system might in part reflect the industry itself Pharmaceutical 
companies tend to use proprietary quality systems designed to meet regulatory 
requirements directly rather than ISO based systems Possibly many of the
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developers of automated systems for the pharmaceutical companies follow suit 
However pharmaceutical companies expect their suppliers to have formal quality 
management systems and it is normally part of their selection criteria, so having a 
formal system such as IS09001 is advantageous Differences were revealed 
between sub-categories for the two dominant quality implementation factors in the 
quality and regulatory factor groupings -  the general quality management system 
factor and the intrinsic regulatory compliance factor No differences existed between 
the ISO only and TQM only categories for either factor In the case of the general 
QMS factor, both quality system types scored significantly higher than for companies 
with hybrid or no quality systems As the application of a formal system requires 
many of the components comprising this factor, then it is reasonable that general 
QMS scores would be higher for companies with formal systems established The 
same pattern emerged in the case of intrinsic regulatory compliance with the 
exception that ISO systems did not score significantly higher than TQM only 
systems This supports the previously stated possibility that vendors might be 
adapting hybrid quality systems reflecting those used by pharmaceutical 
manufacturers focused on regulatory requirements, hence resulting in higher 
intrinsic compliance scores Companies with hybrid systems scored significantly 
higher than those with no system in the case of both general QMS and intrinsic 
regulatory compliance, which again showed the relative superiority of having a 
formal system not aligned with established systems as opposed to none at all None 
of the remaining quality or regulatory factors had differentiated scores with respect to 
the sub-categories examined, demonstrating that the implementation of a formal
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system has most effect on the central quality system implementation than on sub­
systems that go to make up the greater quality effort
No significant differences were found in terms of business performance between 
ISO only and TQM only environments Zhang [173] found TQM had better overall 
effects on business than IS09000 from a general review of the literature in a pan- 
sector study It was not clear from that work whether the differences uncovered were 
statistically significant however The generalisation cannot be extended to this sector 
though, as regulatory influences would seem to have a greater impact on companies 
than TQM With regards to quality performance, Sohail and Hoong [95] found that 
both IS09000 and TQM practices result in significantly better organisation (and 
quality) performance, compared to companies without them, which is consistent with 
this work Ismail and Hashmi [28] found that mean organisation performance was 
significantly higher for companies with ISO only than for those with TQM only when 
looking at Irish manufacturing This shows that the implementation of TQM and ISO 
does not seem to yield similar results across all sectors, and care should be taken 
when making generalisations
Sohail and Hoong [95] found that there were significant differences in quality 
performance between those companies operating less than 10 years and those 
operating more than 10 years Tsekouras et al [84] found that the effectiveness of 
ISO 9000 quality schemes was not significant in the first 5 to 6 years after adoption 
This work discovered differences in scores for general QMS, provision of design
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documentation, intrinsic regulatory compliance and regulatory documentation 
depending on the length of time a company was established (and depending on the 
time they were established in the pharmaceutical industry, which was highly 
correlated with total time established) In the case of the general quality 
management system and provision of design documentation scores, those 
companies established for between 4 1 and 8 years exhibited significantly lower 
scores than for any other category, including the 0 to 4 years established category It 
is not understood why this difference existed but possibly very new companies have 
a very high emphasis on quality management due to newer initiatives such as 
GAMP 4 and 21 CFR Part 11 and the general direction of quality management, with 
companies older than 8 years having mature quality systems exposing a gap in the 
4 1 to 8 year category It was probably more meaningful to examine the summary 
categories, which showed that the general QMS score was significantly higher for 
companies established longer than 16 years than those not established as long 
There was no significant difference in the provision of design documentation score 
The difference in general QMS scores was likely to be attributable to maturity in 
accordance with Crosby [78], Sohail and Hoong [95] and Tsekouras et al [84]
For provision of regulatory documentation a significant difference did exist between 
those operating less than 16 years and those operating more, so maturity seemed to 
be a factor here too From the sub-category differential analysis it would seem then 
that time established did not have significant categorical influence on the other 
factors in the study which shows for example that software quality, direct regulatory
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involvement and business performance scores were not necessarily influenced by 
time, and that comparable results for these factors were established across the 
range of time established categories
Sadikoglu [171] found that TQM performance was not dependent on company size 
This study found differences in scores for general QMS and market share and 
competitiveness for the questionnaire categories of organisation size, and for 
general QMS and market share and competitiveness for the corresponding summary 
categories For general QMS there was a difference between small companies with 
less than 50 employees and those with greater than 100 No differences were 
established between the 0-50 employees category and those with between 51 and 
100 employees or between those with 51-100 employees and greater than 200, 
however there was a difference between those with 51-100 and 151-200 No 
difference existed between those with 101-150, 151-200 or those with greater than 
200 Therefore there seemed to be an increase in general QMS scores with 
organisation size up to a point where it then levelled off With small companies in 
particular it is often difficult to have individuals dedicated purely to quality and the 
resources required are often unavailable to fulfil many quality functions As the 
company sizes increase resources become available and as the complexity of 
operations increase in sympathy with size companies tend to have dedicated quality 
staff and more extensive quality systems However it would appear from this study 
that this is the case up to a company size of 100 employees, beyond which quality 
systems don’t score any higher for this sector
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For market share and competitiveness, using the summary organisation size 
categories, there were significant differences found between small and medium 
companies, but none between small and large or medium and large companies, so a 
linear increase was not observed It was hence found that medium sized 
organisations in this sector tended to have a higher market share than smaller ones, 
but smaller companies did not have significantly smaller market share and 
competitiveness improvement scores than large companies Small companies often 
operate on a niche basis, providing flexible systems and products for their market 
which can have dramatic effects on market share and competitiveness 
improvements that might not be as marked in large companies with staple products 
and services, which have similar size competitors The influence on market share 
and competitiveness is of course based on many other more complex factors 
including marketing, new product introductions, competitor practices, product 
patents and so on so the influence of organisation size should not be overstated
The complexity of the software employed in respondent’s products showed 
significant categorical differences with respect to software control, training and HRM, 
provision of design documentation, use of procedures, policies and procedures and 
both direct regulatory involvement and intrinsic regulatory compliance Whilst 
complexity did not show up any sub-category differences in terms of the main quality 
management system, many of the related subsystems were very much affected by 
complexity levels The software control factor showed an upward step change for
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each increase in complexity level, therefore controls on software development and 
maintenance seemed to increase in line with complexity Interestingly, direct 
regulatory involvement also exhibited the same pattern There are many factors that 
are likely to influence the software control finding As complexity increases the scope 
for errors and the difficulty in debugging systems increases, so it makes sound 
business sense for the developer to employ stringent controls over the development 
Also, for more complex systems, the number of developers involved is usually 
greater so that employing a formal means of control can be part of a greater project 
management effort in terms of avoidance of errors, and coordination of modular 
activities
For the direct regulatory compliance consideration, more complex systems are likely 
to be larger systems such as manufacturing control systems, manufacturing 
execution systems, quality documentation management systems, building 
management systems, SCADAs, distributed control systems, inventory management 
systems etc which very often can have considerable impact on product quality 
Therefore to be competitive in the market, developers need to be in tune with the 
regulations This is illustrated by GAMP [13], which imposes requirements that 
increase in line with complexity and risk In the case of intrinsic regulatory 
compliance a difference in scores was detected between the low and medium 
complexity categories but no difference was detected between the low and high, or 
medium and high categories so no pattern of any use emerged
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When provision of design documentation was considered differences existed 
between low and both medium and high complexity levels illustrating that provision 
of design documentation for low complexity systems would not be seen with the 
same priority as for higher levels of complexity This was also consistent with the 
GAMP [13] guidance, which has lesser requirements in this regard for systems with 
a lower complexity rating For training and HRM and use of procedures, policies and 
standards there were differences between the low and medium levels of complexity 
and the high complexity levels For higher levels of complexity it would be expected 
that the use of standards in particular would increase, particularly when the system 
in question must be able to interface with other systems The quality expectations in 
general would also be higher from a regulatory standpoint with regard to procedures 
and policies used in general for more complex systems, again as required by GAMP
[13], but also by the European and US regulations directly [59][70] These 
requirements also extend to training, which scored higher for the higher level of 
complexity Thus, from this study it appears that companies operating with differing 
levels of complexity score differently in terms of quality and regulatory practices
It was important to ensure that the primary relationships were not spurious across 
the range of possible company backgrounds The stepwise regression results 
showed that the relationships were upheld when all the background variables were 
entered into the model, but that criticality of the respondent’s product to the drug 
quality of their customers played a major role when determining business 
performance From regression equation 3 it was shown that criticality could be used
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to represent direct regulatory compliance in the model, showing that this factor had a 
substantial influence on many of the other quality and regulatory factors in the 
model That model meant that market share and competitiveness were primarily 
dependent (amongst the study variables) on the general quality management 
system and on criticality Also for regression equation 4 where profit and sales 
improvement was the dependent item, criticality could be used as a factor that 
determined the improvement in that business factor Hence criticality can be viewed 
as playing an important part in the extent of direct regulatory involvement and 
intrinsic regulatory compliance, that is, for the developers developing products for 
critical use the regulatory practice scores are strongly linked to the criticality 
Besides the salient role the criticality background variable played with regard to the 
main relationships established in the study, there were also categorical differences 
found for general QMS, direct regulatory involvement, intrinsic regulatory 
compliance, availability of regulatory documentation, market share and 
competitiveness, and sales and profit improvement This further illustrated the 
impact that the criticality of the product on customer’s drug quality had (see below)
When the summary categories of criticality were assessed for general QMS high 
levels of criticality scored higher than for medium levels but no difference existed 
between low and medium or low and high, i e the finding was inconclusive As there 
were significant increases between low and high, and medium and high scores for 
the other five differentiated factors the influence of high criticality could be clearly 
observed High criticality resulted in significantly higher scores for the three
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regulatory factors and the two business factors The step increase in regulatory 
practices is probably attributable to the two way relationship between manufacturers 
and their suppliers, in that in order to be effective in the market developers must be 
prepared to meet customer’s requirements in terms of compliance, and also that 
manufacturers demand criticality dependent levels of quality and regulatory practices 
from their suppliers, that is based on the risk to their processes The business 
performance scores step increase can be attributed to the selection processes 
operated by manufacturers, which is based on many things including GMP risk (as 
outlined in GAMP [13]) That is, many manufacturers will require the quality systems 
of their suppliers to be of a standard that matches the risk to the product or to their 
compliance effort, i e the GMP criticality of the automated system Following this, 
those suppliers with greater regulatory emphasis can expect to have significantly 
better business performance in the pharmaceutical market than those with lesser 
emphasis From this work it was clear that developers supplying the higher risk 
products did in fact have this greater regulatory emphasis and the corresponding 
knock on benefits in terms of business performance
The benefits from employing hard subjective measures rather than using a direct 
organizational metrics (such as balanced scorecards [175][176]) approach to 
assessing business performance proved justified in that a broader picture of the 
performance of suppliers was possible Without this, analysis of the main Market 
Share and Competitiveness factor might not have been possible
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5 4 Conclusions
The hypotheses of this research were upheld That is, it can be said that high levels 
of quality practices result in better business performance (H1), that firms with higher 
general quality implementation levels have a better regulatory focus (H2) and that 
high levels of regulatory practices results in improved business performance (H3) 
The relationship between quality practices and business performance for providers 
of automated systems for use in a pharmaceutical manufacturing environment was 
consistent with the results found for other sectors, but regulatory factors provided 
additional business advantages These advantages were particularly marked when 
the developer was producing systems that posed high risk to the drug product, in 
terms of in market share and competitiveness, and profit and sales improvements 
above expectations
The general quality management system employed by a company, and its practices 
relating to direct regulatory involvement, and actual regulatory compliance had a 
greater influence than other factors in terms of the improvements in business 
performance observed Regulatory practices and quality practices are closely related 
and comprise the overall quality focus in terms of a regulatory market Although 
there was a very real and positive influence by both regulatory and quality practices 
on business performance, business performance is primarily determined by other 
factors related to the developers business and technical practices and the 
manufacturer’s requirements, market niches, product quality etc The symbiotic
270
relationship between quality and regulatory practices meant that suppliers who adopt 
regulatory practices are likely to have better quality systems, so that the general 
quality system and the software quality practices are generally superior for 
organisations with a regulatory focus
The regulatory environment in which respondents operate has an influence on 
software quality in particular, and an international regulatory focus tends to result in 
better software quality practices Broadly similar results were found in this research 
for TQM and ISO quality systems implementations for the sector of interest This 
differed from other work, which found differentiated results for these quality systems 
However, consistent with other work it was found that operating a formal, recognised 
quality system results in higher levels of quality practices In addition to this, 
regulatory compliance levels tend to be higher when a recognised quality system is 
in place Although not as effective as recognised quality systems, hybrid systems 
were significantly more effective than no quality system at all
The length of time a company is established has an influence on certain elements of 
quality practices and regulatory practices, particularly the general quality 
management system where a maturation factor seems to exist Organisation size 
was also found to have an influence on the general quality management system 
performance, which increases until companies get larger than 100 employees after 
which there appears to be no significant change in practices scores
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The complexity of the automation of a product influences quality and regulatory 
practices also, particularly in relation to software quality practices In summary, 
quality practices, regulatory practices and business performance have a degree of 
interdependence for developers of automated systems for use by the 
pharmaceutical manufacturing industry Other important drivers of these three 
aspects though include complexity of automation and the criticality of the developer’s 
systems to the manufacturer’s drug quality Quality and regulatory practices are also 
determined somewhat by the regulatory focus of a company, the quality system 
employed, organisation size and the length of time the company has been 
established
5 5 Recom m endations
To maximise business benefits in the pharmaceutical market, developers of 
automated systems for use in a manufacturing environment should ensure that
1 They have direct knowledge and implementation of regulatory requirements 
and guidance
2 In order to maximise market share and profit and sales improvements that 
focus on quality is high
3 The level of quality and regulatory practices should be matched to the risk that 
their systems can pose to the manufacturer’s drug quality
4 The level of quality and regulatory practices should be matched to the 
complexity of the automation used in their products
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5 The quality and regulatory emphasis is placed on the general quality 
management practices as required by recognised quality standards such as 
IS09001 and TQM, and on effective practices which ensure actual regulatory 
compliance Care should be taken to ensure all the other quality and regulatory 
practices are emphasised also as they are related to the general quality 
management system and intrinsic regulatory compliance
6 They have sound knowledge of international regulatory requirements and 
guidance
5 6 Lim itations o f this research and recom m endations for further research
This work only considered developers of automated systems, which were operating 
external to the pharmaceutical manufacturing environment Many automated 
systems are developed and built by the manufacturers themselves in-house This 
research did not look into those areas Further to that, it would be a useful body of 
work to evaluate the relationships between general GMP practices (i e not limited to 
those concerned with automated systems) for manufacturers and their business 
performance, however, gathering sufficient data from differing companies might 
prove difficult It would also be useful to compare the quality and business scores 
between companies who operated in regulated and non-regulated markets
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Another limitation of this work is that the focus was on quality and regulatory 
systems rather than on the quality of the end product itself Further research would 
be necessary to establish the relationships that product quality has on business 
performance, and its relationship to regulatory practices This work looked 
specifically at pharmaceutical manufacturing There are other areas related to this 
which were not within the scope of this work which could be included in future 
research such as the medical devices industry, medical diagnostics and also 
pharmaceutical clinical trials Furthermore, longitudinal studies could be carried out 
into how the quality practices, regulatory practices and the relationships with 
business performance change over time, as regulatory practices in particular change 
over time in accordance with regulatory ‘creep’ or ‘spiral’
With regards to the methodology employed herein, survey research was carried out 
as the sole method for acquiring information Supplemental activities could have 
included direct interviews with respondents in order to confirm the questionnaire 
findings with face-to-face perceptions Assessment of other indicators of business 
success such as stock growth or drug manufacturer perceptions might also have 
been carried out The quality questions used in this research were adapted from 
variables used in other work It is standard practice in survey research to use 
questionnaires and questions unaltered from validated instruments It would perhaps 
have been better to follow this practice for this research, rather than substantially 
changing the questions to create a new instrument This would have allowed a more 
complete comparison with other work in the literature than was possible by using a
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new set of questions It was felt that the questionnaires available in the literature did 
not match the requirements of this study, in that they had too many sections that 
were not relevant It was also difficult to find a complete validated and relevant 
questionnaire in common usage Therefore, selective adaptation was appropriate
5 7 Thesis Contribution
The contribution made by this thesis includes
1 The creation of a robust and reliable modular survey instrument for assessing 
any combination of general quality practices, regulatory practices, software 
quality and perceptive business performance measures for administration by 
Internet web host, electronic mail or by postal delivery The survey instrument 
could be applied to in-house pharmaceutical system development, medical 
device suppliers and clinical trial environments with some small modifications
2 The creation of a methodology for administering electronic surveys based on 
best practices extracted, evaluated and refined from the existing research on 
survey analysis achieving substantially higher response rates than achieved in 
the literature
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3 The formulation of a first set of variables derived from themes in the non- 
academic literature to attempt to evaluate pharmaceutical regulatory practices by 
bodies external to the industry itself (i e suppliers)
4 The collation of all the regulations pertaining to development of automated 
systems in the pharmaceutical industry from a European / PIC/S, and US 
perspective into a single academic body of work
5 A comparison of the interaction between pharmaceutical regulatory practices, 
software quality practices and general quality practices
6 The creation of a set of principal components analyzed factors for assessing 
quality practices, regulatory practices and business practices which could be 
used as a theoretical base for further research
5 8 Research Contribution
The contribution made by this research includes
1 The relationships between quality and business performance in the wider body of 
literature were compared with the case for the pharmaceutical industry It was 
found to be generally comparable Pharmaceutical regulatory practices also
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played a role as part of the greater quality effort of an organisation, which did not 
compare to other sectors
2 The first body of research aimed at evaluating the relationships between
pharmaceutical regulatory practices and quality practices was performed
3 The first body of research aimed at evaluating the relationships between
pharmaceutical regulatory practices and their impact on business performance
for those subjected to them was performed
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Appendix A 1 Initial e-mail templates 
A 1 1 Initial contact mail
Subject Assistance (For the attention of the manager responsible for quality)
Hi there,
Hello to everyone at <COMPANY NAME>
I am looking from some assistance from your Quality manager / Engineering 
manager I am a PhD student at Dublin City University in Ireland and I am currently 
carrying out research into the quality and regulatory practices 
of companies that produce automated/software systems for the Pharmaceutical 
manufacturing sectors
This involves the collection of data from companies using a simple questionnaire 
Firstly I need to establish contact with your Quality manager or the person 
responsible for quality to get agreement to send the questionnaire Your 
completed questionnaire is completely confidential
Due to the limited number of companies like yourselves, your response is extremely 
valuable to the study In order to reward respondents I will supply the full results of 
my research The data and conclusions will show 
what the best and optimal quality and regulatory practices are for best business 
performance in the pharmaceutical manufacturing sectors
So if you could forward this mail to your Quality manager it would be really 
appreciated If your company has several Quality managers within sub-companies, 
please forward to each Quality manager If you could confirm 
with me that you have forwarded the mail and who you have contacted this would 
also be hugely helpful Please do not hesitate to contact me with any questions or 
concerns
Thanking you in advance,
Diarmuid P Meagher BSc (Hons) MEng MIEI 
Department of Mechanical and Manufacturing Engineering, 
Dublin City University,
Dublin 9 
Ireland
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Subject Thank you 
That's fantastic <NAME>
The questionnaire is not difficult, intrusive or time consuming It is currently 
being validated and I hope to send it out in the next six weeks Every respondent 
I get is worth their weight in gold to me
Thanks again,
Diarmuid
A 1 2 Thank you mail
Appendix A 2 Non- response e-mail templates
A 2 1 No response mail
Subject Product Quality 
Hi,
I contacted <COMPANY NAME> a few weeks ago looking for information from the 
person responsible for the quality of your end-products I received no response 
The Quality Manager or Engineering Manager would probably be able to provide 
me with the information I need I would be obliged if you could pass this 
mail on to someone relevant or maybe if you could provide me with a more 
appropriate e-mail address to use
Thanking you, 
Diarmuid Meagher
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Subject Re Product Quality 
Hi <NAME>,
Thank you for your prompt response I am a PhD student in Ireland (Dublin City 
University) and I am researching the quality aspects of the manufacture of systems 
and equipment used in Pharmaceuticals I have a survey questionnaire that is not in 
any way intrusive and easy to complete which asks about your quality system and 
regulatory awareness
I am currently in the process of gathering together a list of companies like 
<COMPANY NAME> who are willing to participate It is completely confidential and 
the findings will be made available to your company which may have business 
advantages Is there any way you can help? It would really be hugely appreciated
Regards,
Diarmuid
A 2 2 Response to answered ‘no-response mails’
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Appendix A 3 Pre-test instructions
Pre test instructions
Your assistance with pre-testing my questionnaire is massively appreciated Below 
you will see instructions for the pre-test Please feel free to comment on any aspects 
of the pre-test, the instructions for completing the questionnaire, and the 
questionnaire itself
The purpose of the questionnaire is to gather data relating to 1) Quality practices, 2) 
Regulatory Practices and 3) Business Performance for manufacturers of automated / 
software systems for use in all areas of pharmaceutical manufacturing
Data relating to the study variables will be collected as well as data for some 
background variables as seen in appendix 1 to these pre-test instructions
Instructions
1 Please complete the questionnaire as it is according to the Questionnaire 
Completion Instructions Place as many comments on the questionnaire as 
you like
2 Suggest any additions to the questionnaire
3 Discuss aspects of the existing questionnaire that might need to be changed
4 Suggest any changes to the completion instructions and the method of 
administration
Please indicate how you felt about the following aspects of the questionnaire 
(You can just type below the following questions if you like)
a) Was it simple to understand?
b) Was it clear?
c) Was it difficult to answer?
d) Was it ambiguous?
e) Were the questions specific enough?
f) Did the questionnaire take too long to complete?
g) Were the concepts mentioned commonly known in your opinion? Should 
there be more background information?
h) Did the questions adequately relate to the variables in appendix 1 in your 
opinion?
i) How did you feel about answering the business performance questions?
Please collate your comments and return a copy of the completed and annotated 
questionnaire when you are ready 
Again, thank you so much 
Diarmuid
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Appendix 1(to pre-test instructions) Study and Background Variables
Study vanables 
QUALITY
22 Training and development
23 Cost of quality
24 Customer focus and feedback
25 Quality system infrastructure
26 Leadership
27 Communication 
26 Quality planning
29 Supplier Management
30 Software lifecycle approach
31 Measurement
32 Documented quality policies and responsibilities
33 Use of standards, practices and procedures
34 Requirements management and evaluation
35 Reviews and audits
36 Software control
37 Testing management
38 Teamwork, human resource management and employee involvement 
motivation
39 Quality driven documented processes
40 Preparation for delivery / approval for release and product realization
41 Service provision
42 Risk management
REGULATORY
1 Extent of use of the GAMP guidelines
2 Extent to which validation features are designed into products
3 Extent to which other regulatory requirements are designed into the software
4 Extent of direct use of GMPs in design
5 Extent of regulatory training for system developers
6 Knowledge and application of rules for electronic records and electronic 
signatures
7 Availability of source code to manufacturers
8 Extent of provision of design documentation
9 Extent of provision of validation documentation
10 Extent of planning of regulatory activities into design
11 Extent of regulatory design reviews
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BUSINESS PERFORMANCE
1 Market Share
2 Growth in market share
3 Net profit as a percent of sales
4 Profit growth
5 Sales growth
6 Average past 3 years sales growth
7 Order book growth
8 Workforce growth
9 Increase in product range
10 Percent sales from new products
Background vanables
12 Length of time in business
13 Length of time serving pharmaceutical industry
14 Company size
15 Complexity of automation used in products
16 Regulatory environments
17 End price trends due to regulatory changes
18 End price trends due to quality changes
19 Criticality of product to drug quality
20 Applicability of company quality system to development environment
21 Organisation type
22 Quality system independence from client
23 Quality management environment
Appendix B 1 The survey questionnaire
(The formatting here does not match the formatting of the actual questionnaire 
document exactly due to page set-up differences)
Survey of quality practices, regulatory practices and business 
performance for developers of automated systems for use in 
pharmaceutical manufacturing
This questionnaire is part of a study into the relationships between business performance and quality 
practices /  regulatory practices for developers of automated systems into the life science and 
pharmaceutical manufacturing industries Due to the relatively limited amount of suppliers to the 
pharmaceutical industry a high response rate is imperative, therefore your responses are extremely
valuable
Please answer all the questions below in full Some of your answers may require input from other 
departments Your responses are completely confidential and the findings of the study will be 
made available to all respondents who request them 
_________ Please feel free to make as many comments as you like to clarify your answers_________
Section I Background questions
In each case put an 'x' in the box that best represents you and your company.
1 How long has your company been established?
0 to 4 years 4 1 to 8 years 8 1 to 12 years 12 1 to 16 years >16years
[ ] [ ] [ ] [ ] [ ]
2 How long have your company been supplying pharmaceutical manufacturers?
0 to 4 years 4 1 to 8 years 8 1 to 12 years 12 1 to 16 years >16years
[ ] [ ] [ ] [ ] [ ]
1 many people are employed within your organisation?
0-50 51-100 101-150 151-200 >200
[ ] [ ] [ ] [ ] [ ]
4. How would you rate the maximum complexity of the automation/software that makes 
up your end products?
Not very complex Very complex automation/ software
(i e development time (i e development time takes
takes or took of a few months) or took many months/years)
0 1 2 3 4 5 6
[ ] [ ] [ ] [ ] [ ] [ ] [ ]
5 For which regulatory manufacturing environments do you produce
automated systems (put an ‘x’ in each box that applies)?
EMEA FDA PIC/S ICH WHO Not Known
[ ] [ ] [ ] [ ] [ ] [ ]
Other(s) _________________________
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6. To what extent do customers look for a quality plan from your company?
Never [ ] Rarely [ ] Often [ ] Very Often [ ] Always [ ]
7. What percentage of your clients would you say carry out audits of your 
quality system?
0-20% 21-40% 41-60% 61-80% 81-100%
[ ] [ ] [ ] I )  M
8. How critical would you say that your most critical product is to the quality of the drugs 
produced by your customers?
Not at all critical Fairly critical Highly critical to drug quality
0 1 2 3 4 5 6
[ ] [ 3 [ 1 [ ] [ 1 [ ] [ ]
9. Which describes your company best:
Pre-develops products away from the drug manufacturer's site [ ]A
Production facility engineering (Design /  Build /  Validation) [ ]B
Other:___________________________
10. (O nly answ er i f  B is  selected above).
To what extent are your quality systems independent from the quality system used 
by your clients?
Clients quality system used completely [ ]
Mostly the client's quality system is used[ ]
Mostly our quality system is used [ ]
Our own quality system is used alone [ ]
11. What is your company's quality management environment? (Select all that apply)
ISO [ ] ( )TQM [ ] CMM [ ] Six Sigma [ ] Hybrid [ ]
(state which ISO(s))
Others):____________________________
12. What formal engineering or software standards do you use (please list)? None [ ]
Section 11: Organizational Management
The following section describes specific organizational management characteristics.
Please indicate the extent of your organisations adherence to those characteristics by placing an Y  in 
the box below on the scale of 0 to 4, where: 4 = To a very great extent, 3 = To a great extent, 
2 = To some extent, 1 = To a very little extent, 0 = Not at all.
Please answer honestly and remember that all data is completely confidential.
To what extent do you agree it can be said of your company that: _____
0 1 2 3 ( 4
13. Staff receive thorough training for their job functions
14. There is a high emphasis on personal development of staff.
15. Leaders reinforce a culture of excellence.
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16. Employees in general are heavily empowered.
17. Employees feel valued, recognized and rewarded.
18. Employees have formal goals and objectives.
Section 111 : Q uality M anagem ent System s
The following section describes specific regulatory quality management characteristics.
Please indicate the extent of your organisations adherence to those characteristics by placing an Y  in 
the box below on the scale of 0 to 4, where: 4  = To a very great extent, 3 = To a great extent, 
2 = To some extent, 1 = To a very little extent, 0 = Not at all.
Please answer honestly and remember that all data is completely confidential.
To what extent do you agree it can be said of your company that:
0 1 2 3 4
19. Regular training is provided in quality techniques.
20. Customers rate our customer service very highly.
21. Customers are involved in the improvement of systems, products 
and procedures.
22. Customer relationships are well managed and nurtured
0 1 2 3 4
23. Senior management are involved in decision making processes 
related to quality.
24. Quality issues are reported to top management.
25. Management are very committed to improving quality
26. Management have excellent interaction with customers.
27. The quality system is well known throughout the company.
28. Issues, problems and changes are communicated very quickly 
within the company.
29. Quality issues are regularly discussed at meetings.
30. Quality is very well planned.
31. The company is very knowledgeable of its supplier's quality 
management practices.
32. Quality policies are well known by staff.
33. The quality policies are widely available.
34. People work very closely to pre-scribed procedures.
35. People work very closely to industry standards.
36. Product requirements are evaluated against specifications during 
design projects.
37. Product requirements are evaluated against specifications before 
project dose out.
38. Reviews of the quality system are regularly carried out.
39. Reviews of qeneral work practices are regularly carried out.
40. Compliance audits are regularly carried out.
41. Information is extensively gathered and retained during product 
design -develop -  build phases
42. Information is extensively gathered and retained during product 
testing.
43. Supplier performance is measured.
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44 Performance indicators are used as a key driver for change
45 Day to day work practices are thoroughly documented
46 Direct after sales technical service is available to customers
47 Third party after sales technical service is available to customers
48. It  can be said of your customer complaints system that it:
Doesn't really exist [ ]
Is informal [ ]
Is forma! but not that developed [ ]
Formal system, well developed [ ]
49 What percentage of your company's time in design, development, build and testing 
phases would you say is spent carrying out documentation?
0-20% 21-40% 41-60% 61-80% 81-100%
[ ] [ ] [ ] U  [ ]
50 I t  can be said of your company that customer satisfaction surveys
Are never performed 
Are rarely performed 
Are often performed 
Are very often performed 
Are extensively performed
51. I t  can be said of your quality management system that:
No one in particular is responsible for quality 
There are many people responsible for quality 
There is one person responsible for quality (not a Quality Manager)
There is someone working part time as a Quality Manager 
There is at least one dedicated full time quality manager
52. Which would you say applies to your company (Place an 'x' in each box that applies)1
Quality is a purely a manufacturing /engineering responsibility [ ]
The company has a strong quality leader who works as part of Engineering/manufacturing
[ ]
The quality department reports to top management, where the Quality Manager has a role in 
company management [ ]
The Quality Manager is a senior person in your company and gets directly involved with 
customers [ ]
There is a Quality Manager on the board of directors Quality is a major 'thought leader' [ ]
53 I t  can be said of your company that quality awareness campaigns are run
Never [ ]
Rarely [ ]
Often [ ]
Very Often [ ]
54. It  can be said of your company that established multi-departmental teams.
Do not exist [ ]
Exist but rarely meet [ ]
Exist and often meet [ ]
Exist, meet often and are effective [ ]
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55 It  can be said of your company that a quality plan stating future objectives1
Does not exist [ ]
Exists but is not really adhered to [ ]
Exists and is mainly adhered to [ ]
Exists and is completely adhered to [ ]
56. I t  can be said of your company that quality agreements with main suppliers1
Are not in place [ ]
Are maintained informally [ ]
Are formally maintained for some main suppliers [ ]
Are formally maintained for all main suppliers [ ]
Not Applicable [ ]
57. It  can be said of your company that supplier audits are carried out1
Never [ ]
Rarely [ ]
Often (randomly) [ ]
Routinely [ ]
Not Applicable [ ]
58. It  can be said of your company that for internal performance measurement1
No system exists [ ]
An informal system exists [ ]
A formal system exists which is not always up to date and accurate [ ]
A formal up to date and accurate system exists [ ]
Section IV. Regulatory related practices
The following section describes specific regulatory practice characteristics Please indicate the extent 
of your organisations adherence to those characteristics by placing an Y  in the box below on the 
scale of 0 to 4, where 4 = To a very great extent, 3 = To a great extent, 2 = To some 
extent, 1 = To a very little extent, 0 = Not at all
To what extent do you agree that it can be said of your company that
0 1 2 3 4
59 System developers are knowledgeable of GMP
60 Design work is well documented whether or not a customer 
requests it i
61 GAMP guidelines are used
62 The GMP regulations are a major design consideration for your 
company's products
63 System designers and developers receive regulatory compliance 
training
64 To what extent does your company use GAMP rather than other industry standards
Mostly industry Mostly GAMP
standards used Used equally used
0 1 2 3 4 5 6 Neither used
t ] [ ] t ] t ] t ] [ ] t ] n
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65 Features are but ft into your products to aid validation*
Not really at all [ ]
Few Features [ ]
Many features [ ]
Extensively [ ]
66. Validation is considered as early as product design
Not really at all [ ]
Rarely [ ]
Usually [ ]
Always [ ]
67 The Quality Management System is based on regulatory requirements1
Regulatory requirements not really considered in system structure [ ]
Regulatory requirements considered in a small way in system structure [ ]
Many elements of system structure based on regulatory requirements [ ]
The system was built to ensure complete regulatory compliance [ ]
68 Design documentation for your company's products1
Does not really exist [ ]
Exists but is not available to customers [ ]
Exists and is made available to customers as a standard package [ ]
Exists and is tailored to meet customer requirements [ ]
69 Validation documentation for your company's products:
Does not really exist [ ]
Exists but is not available to customers [ ]
Exists and is made available to customers as a standard package [ ]
Exists and is tailored to meet customer requirements [ ]
70 Regulatory compliance audits of all your products and systems are carried out1
Never 
Rarely 
Often
Very often and randomly 
Often and routinely
Section V Software quality related practices
(RELEVANT TO ALL COMPANIES THAT HAVE CODE PRESENT IN PRODUCTS IN ANY FORM 
e g. PLC code, software, firmware, SCADAs etc)
The following section describes specific software quality related practice characteristics Please 
indicate the extent of your company's adherence to those characteristics by placing an Y  in the box 
below on the scale of 0 to 4, where 4 = To a very great extent, 3 = To a great extent, 2 = To 
some extent, 1 = To a very little extent, 0 = Not at all
To what extent do you agree it can be said of your company thaï■ ■
0 1 2 3 4
71 Security of code is managed during development
72 There is a high knowledge of 21 CFR Part 11
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73 Training is provided on 21 CFR Part 11 related matters
Not at all [
Rarely [
Often [
Very Often [
Extensively [
74 How would you categorise the process under which firmware/software is/has been
developed for your company
No real life-cycle model used [ ]
Informal life-cycle model used [ ]
Formal m-house life-cycle model used [ ]
Formal recognised life-cycle model used [ ]
75 Your company's system for revision control of software1
Does not really exist [ ]
Exists informally [ ]
Is formal and fairly effective [ ]
Is formal and very effective [ ]
76 Products and systems are designed  to be compliant to standards for.
Not
really
Not
needed
Partly By
practice
By
design
A Electronic records7
B Electronic signatures7
C Audit Trail7
D Privacy of the individual citizen7
E Security7
77 Source code is made available to drug manufacturers1
Not at all [ ]
In very limited circumstances [ ]
Where required using 3rd party agreements [ ]
Where required using direct agreements with clients [ ]
Section VI Business performance
The purpose of the section is to get an overall view of your organisations business performance It 
may require input from other departments Please provide as much information as possible and 
provide your closest estimate to the following questions
78 What percentage of your annual revenue is derived from sales to the pharmaceutical 
industry7
0-20% 21*40% 41-60% 61-80% 81-100%
[ ] [ ] [ ] [ ] [ ]
79. During the past 5 years, your market-share in the pharmaceutical industry
Has reduced significantly [ ]
Has reduced by a small amount [ ]
Has remained the same [ ]
Has increased by a small amount [ ]
Has increased significantly [ ]
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80 For your products that are sold into the pharmaceutical industry overall profit levels 
for the last 5 years have Been considerably below expectations [ ]
Been below expectations [ ]
Met expectations [ ]
Exceeded expectations [ ]
Greatly exceeded expectation [ ]
81 For your products that are sold into the pharmaceutical industry sales volumes for 
the last 5 years have Been considerably below expectations [ ]
Been below expectations [ ]
Met expectations [ ]
Exceeded expectations [ ]
Greatly exceeded expectation [ ]
82. For your products that are sold into the pharmaceutical industry percentage sales 
from new products in the last two years have
Been considerably below expectations [ ]
Been below expectations [ ]
Met expectations [ ]
Exceeded expectations [ ]
Greatly exceeded expectation [ ]
For products sold into the pharmaceutical industry, indicate your company's performance 
in relation to competitors in terms of.
83 Market Share LowO 1 2 3 4 5 6High
[ ] [ ] [ ] [ ] [ ] [ ] [ ]
84 Overall competitive position LowO 1 2 3 4 5 6High
[ ] [ ] [ ] [ ] [ ] [ ] [ ]
Thank you for your valued time The value of your contribution to this study cannot be
underestimated
PLEASE SAVE THIS COMPLETED QUESTIONNAIRE AND RETURN BY E-MAIL TO
diarmuid.meaaher3@mail.dcu.ie or alternatively olease Dost bv normal mail to
Diarmuid Meagher, or Diarmuid Meagher,
12 Foxpark, c/o Professor M S J Hashmi,
Finnstown Abbey, Dept of Mechanical and Manufacturing Engineering,
Lucan, Dublin City University,
Co Dublin Dublin 9
Republic of Ireland Republic of Ireland
Please feel free to comment as desired on any aspects of the questionnaire
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Appendix B 2 Questionnaire instructions
Instructions
Please answer the questionnaire for your software / automated system development 
environment as best you can
There are 3 easy ways to complete the questionnaire
1 Online using the secure online questionnaire
https //fs19 formsite com/diarmuid/Diarmuid/secure index html
(You can save your questionnaire and return to it at any time if you have to
leave it for any reason)
2 Use the attached MS Word questionnaire This can be completed on your PC 
and returned by e-mail For this just save the document under whatever name 
you wish, complete and return to diarmuid meagher3@mail dcu le
3 Alternatively you can print the questionnaire, complete it by hand and return it
by post to the address on the end of the questionnaire
If you wish to identify yourself on the questionnaire you can, but this is completely up 
to you It would be appreciated though if you are using the online questionnaire or 
returning the questionnaire by post that you inform me by e-mail that you have 
completed a questionnaire
Again, thank you very much for your invaluable assistance Results of the study will 
be made available to ail participants
STATEMENT OF CONFIDENTIALITY, ANONYMITY AND NON-DISCLOSURE 
Any data or information supplied through the questionnaire answers or by e-mail is 
completely confidential and will not be disclosed to any parties within or external to 
Dublin City University No e-mails or respondent details will be disclosed to third 
parties Any further assurances required are available on request in whatever way 
required by respondents Once the data from questionnaires is entered onto the 
study database it will no longer be possible to link respondents to their supplied 
data E-mails will be destroyed securely
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Appendix C 1 Reliability analysis for Pilot study data (N=29)
Only variables with two or more associated questionnaire items were considered for 
this analysis The items dropped for the purpose of reliable pilot analysis were not 
necessarily dropped for the main study data Some of the sub-variables used to 
make up the pilot study main variables are not considered below as they only have 
one questionnaire item associated with them, meaning that no analysis was 
necessary
Variable Items
Training and
Development 13 14 19 
Teamwork and
HR
Customer
focus
Leadership
16,17 18
48, 50, 20, 
21, 22
15, 23, 24, 
25 26
Cronbach's Items Revised 
Alpha Removed Alpha
0 712!
Justification
53, 54, 27 
Communication 28, 29
Quality
Planning 30,55
Documented
quality
practices 32,33
Use of 
standards, 
practices and 
procedures 34 35
Requirements 
Management 36 37
Reviews and
Audits 38 39, 40
Quality driven 
documented
processes 41 42,45,49
0 795
0 702
0 729!
0 469 53,54
0 333
Removed items 53 and 54 to 
allow a reliable representation 
of Communication using the 
three Likert scaled items 27 to 
29 The three remaining items 
focused directly on the 
variable The 'tools' questions 
0 663 were dropped
As these items did not vary 
together, the quality planning 
variable was assessed through 
the single item which assessed 
directly whether quality was 
1 planned well
309
Variable Items
Measurement 44, 58
Quality system 11 a-e, 51, 
infrastructure 52
Supplier 31, 43, 56, 
management 57
Extent of use of 59, 62 63, 
GMPs 67
Extent of 
provision of 
design
documentation 60 68
Extent of use of 
GAMP 61 64
Extent to which 
validation 
features are 
designed into 
products
Software
control
65, 66
71, 75
Knowledge and 
application of 
rules for 
electronic 
records and 
signatures
Competitive 
strength 
relative to 
competitors
72 73 76
83, 84
Cronbach's Items Revised 
Alpha Removed Alpha
0 434
0 185
0 878 (0 899 
for scale 
making up 
question 76)
Question 44 removed (how 
performance indicators are 
used) Single question used to 
assess extent of 
44 1 measurement
Reliability far from ideal for this 
variable Corrected to 0 548 by 
omitting item 51, which asked 
about QMS responsibility 
Variable represented by 
presence of a QMS and 
51 0 548 maturity of QMS
Justification
The single question regarding 
availability of design 
documentation was asked 
This question directly 
1 represented the variable
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Appendix D -  Collated quality practices criteria
Q uality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Source9 Sourcel 0
Average 
percent items 
defective
Adam et 
al
Cost of quality
Adam et 
al Crosby
Customer 
focus and 
satisfaction
Adam et 
al
Yee
Tsang Rao McAdam Parzinger MBNQA ISO EQA
Teamwork,
human
resource
management
and employee
involvement /
motivation
Yee
Tsang Rao McAdam EQA Parzinger MBNQA ISO
Continuous
quality
improvement
Yee
Tsang EQA Parzinger MBNQA ISO Crosby
Top
management 
leadership, 
commitment 
and recognition 
of quality
Yee
Tsang Radding Rao McAdam EQA Parzinger MBNQA ISO CMM Crosby
Training and
employee
development
Yee
Tsang McAdam EQA Parzinger ISO CMM
IEEE
730 Rao MBNQA
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Quality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Source9 Sourcel 0
Sound quality
system
infrastructure
Yee
Tsang Rao EQA CMM Crosby ISO MBNQA Radding
The role of
supervisory
leadership
Yee
Tsang EQA MBNQA
Communication 
within the 
company
Yee
Tsang EQA ISO CMM Crosby MBNQA
Supplier 
partnership and 
supplier 
management
Yee
Tsang Rao McAdam EQA MBNQA ISO
IEEE
730
Measurement 
and feedback
Yee
Tsang Radding Rao EQA Parzinger MBNQA ISO CMM Crosby McAdam
Cultural
change
Yee
Tsang Crosby
Creation of a 
common 
quality 
language Radding
Quality as a 
design function Radding
Building 
testability into 
development Radding
Automated 
software quality 
products Radding
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Q u ality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Source9 Sourcel 0
Strategic 
quality planning Rao McAdam EQA MBNQA ISO
IEEE
12207.0
Explicit
organizationally 
linked policies Rubey McAdam EQA ISO IEEE 730
Quality
assurance
plans Rubey
IEEE
12207.0 IEEE 730 Rao MBNQA ISO
Use of 
standards, 
practices, 
procedures and 
conventions Rubey
IEEE
12207.0 IEEE 730 ISO
Requirements
evaluation Rubey ISO CMM
IEEE
12207.0 IEEE 730
Design
evaluation Rubey ISO IEEE 730
Test evaluation Rubey ISO IEEE 730 Radding
Reviews and 
audits Rubey ISO CMM IEEE 730 MBNQA
Evaluation of 
software 
development 
processes Rubey ISO
Software library 
control Rubey ISO
Configuration
management Rubey CMM
IEEE
12207.0 IEEE 730 ISO
Subcontractor
control Rubey CMM
313
Q uality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Sourced Sourcel 0
Non-
developmental, 
non-deliverable 
and customer 
supplied items 
evaluation Rubey
Problem 
reporting and 
corrective 
action Rubey ISO Crosby
IEEE
12207.0 IEEE 730
Preparation for 
delivery / 
approval for 
release and 
product 
realization Rubey ISO
Quality records Rubey ISO
Audit of SQA Rubey ISO
Stated rights 
and
responsibilities 
of customer 
and contracting 
organization Rubey
Obtain data
about
customers McAdam MBNQA ISO EQA
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Quality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Source9 Sourcel 0
Formation of 
short term 
problem 
solving teams McAdam
Documented 
and systematic 
processes McAdam EQA MBNQA ISO CMM
IEEE 
12207 0 Crosby Parzinger Radding
Information and
knowledge
management EQA MBNQA
Financial, 
building and 
equipment 
management EQA ISO
Use of quality 
tools Parzinger
IEEE
730
Cycle time 
reduction Parzinger
Customer
feedback
driven
improvement Parzinger EQA MBNQA Rao ISO
Organizational 
and personal 
learning MBNQA McAdam
Capacity for 
rapid change 
and flexibility MBNQA
Focus on the 
future MBNQA EQA
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Q uality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Source9 Sourcel 0
Managing for 
innovation MBNQA
Social
responsibility MBNQA
Quality manual ISO
Defined roles 
and
responsibilities ISO
Management 
review of 
processes ISO MBNQA
Infrastructure ISO
Change 
management 
and control ISO CMM IEEE 730
Service
provision ISO
IEEE
12207.0
Project 
management 
tracking and 
oversight CMM
Requirements
management CMM ISO
Defect
prevention CMM Crosby Parzinger
Lifecycle
approach
IEEE
12207.0
IEEE
730 ISO
Validation and 
testing plans IEEE 730 ISO
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Quality
criteria Sourcel Source 2 Source3 Source4 Source5 Source6 Source7 Source8 Source9 Sourcel 0
Risk
management IEEE 730 ISO
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